miltefosine has been researched along with phosphorylcholine in 978 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (1.43) | 18.7374 |
| 1990's | 130 (13.29) | 18.2507 |
| 2000's | 258 (26.38) | 29.6817 |
| 2010's | 452 (46.22) | 24.3611 |
| 2020's | 124 (12.68) | 2.80 |
| Authors | Studies |
|---|---|
| Eibl, H; Liersch, T; Unger, C; Vehmeyer, K | 1 |
| Amelung, F; Berger, MR; Heyl, P; Reinhardt, M | 1 |
| Geilen, CC; Reutter, W; Wieder, T | 2 |
| Planting, A; Stoter, G; van der Burg, M; Verweij, J | 1 |
| Eibl, H; Kuhlencord, A; Maniera, T; Unger, C | 1 |
| Chial, HJ; Hendrickson, EK; Hendrickson, HS; Johnson, JL; Khan, TH | 1 |
| Eibl, H; Unger, C; Vehmeyer, K | 1 |
| Altmann, A; Berger, MR; Dimitrakopoulou, A; Haberkorn, U; Oberdorfer, F; Reinhardt, M; Strauss, LG; van Kaick, G; Wallich, R | 1 |
| Eibl, H; Engel, J | 1 |
| Harleman, JH; Hilgard, P; Stekar, J; Voegeli, R | 1 |
| Eibl, H; Kaufmann-Kolle, P; Unger, C | 1 |
| Eibl, H; Kötting, J; Marschner, NW; Neumüller, W; Unger, C | 1 |
| Eibl, H; Kötting, J; Reitz, RC; Unger, C | 1 |
| Eibl, H; Engel, J; Hilgard, P; Peukert, M; Sindermann, H; Unger, C | 1 |
| Becker, J; Burg, G; Dummer, R; Hefner, H; Röger, J; Sindermann, H; Vogt, T | 1 |
| Berkovic, D; Eibl, H; Fleer, EA; Unger, C | 3 |
| Fleer, EA; Kaufmann-Kolle, P | 1 |
| Eibl, H; Kötting, J; Marschner, NW; Unger, C | 1 |
| Doenecke, D; Eibl, H; Hochhuth, C; Unger, C | 1 |
| Breiser, A; Eibl, H; Fenneberg, K; Fleer, EA; Ries, UJ; Stekar, J; Unger, C | 1 |
| Becker, M; Büttner, B; Fichtner, I; Görlich, M; Naundorf, H; Rewasowa, EC | 1 |
| Bishop, FE; Dive, C; Freeman, S; Gescher, A | 1 |
| Eibl, H; Kötting, J; Marschner, N; Unger, C | 1 |
| Berger, MR; Sobottka, SB | 1 |
| Eibl, H; Fleer, EA; Ries, UJ | 1 |
| Eibl, H; Hochhuth, CH; Unger, C; Vehmeyer, K | 1 |
| Berger, MR; Eibl, H; Kötting, J; Unger, C | 1 |
| Berkovic, D; Doenecke, D; Eibl, H; Hochhuth, C; Unger, C | 1 |
| Buchner, K; Geilen, CC; Haase, R; Hucho, F; Reutter, W; Wieder, T | 1 |
| Arndt, D; Fichtner, I; Jungmann, S; Zeisig, R | 1 |
| Eibl, H; Unger, C | 3 |
| Demuth, L; Grunicke, HH; Maly, K; Oberhuber, H; Uberall, F; Zaknun, J | 1 |
| Geilen, CC; Haase, R; Reutter, W; Wieder, T | 1 |
| Hilgard, P; Kampherm, E; Nolan, L; Pohl, J; Reissmann, T | 1 |
| Eibl, H; Scheurich, P; Unger, C; Vehmeyer, K | 1 |
| Berger, MR; Reinhardt, M; Schmähl, D; Yanapirut, P | 1 |
| Eibl, H; Lenzen, S; Rustenbeck, I | 1 |
| Kotsinas, A; Maurer, HR; Patsilinacos, P; Spandidos, DA; Zoumpourlis, V | 1 |
| Eibl, H; Fleer, EA; Kuo, JF; Raynor, RL; Shoji, M; Vogler, WR | 1 |
| Hilgard, P | 1 |
| Berger, MR; Eibl, H; Richter, H; Schmähl, D; Seelig, MH | 1 |
| Bauer, S; Remmele, T; Stricker, H; Sturm, V; Wowra, B; Zeller, WJ | 1 |
| Eibl, H; Hilgard, P; Nagel, G; Peukert, M; Sindermann, H; Unger, C | 1 |
| Angres, G; Scherf, HR; Schmähl, D | 1 |
| Lenzen, S; Rustenbeck, I | 1 |
| Eibl, H; Kim, DJ; Nagel, GA; Unger, C; Vehmeyer, K | 1 |
| Breiser, A; Damenz, W; Eibl, H; Engel, J; Fleer, EA; Hilgard, P; Kim, DJ; Nagel, G; Unger, C | 1 |
| Breiser, A; Eibl, H; Engel, J; Hilgard, P; Nagel, GA; Peukert, M; Sindermann, H; Unger, C; von Heyden, HW | 1 |
| Berger, MR; Eibl, H; Engel, J; Hilgard, P; Schumacher, W; Stekar, J; Unger, C; Voegeli, R | 1 |
| Fleer, EA | 1 |
| Berger, MR; Eibl, HJ; Muschiol, C; Schmähl, D | 1 |
| Berger, M; Breiser, A; Damenz, W; Drube, A; Eibl, H; Fleer, EA; Kim, DJ; Nagel, GA; Unger, C | 1 |
| Berger, MR; Scherf, HR; Schmähl, D; Schuler, B | 1 |
| Berger, MR; Eibl, HJ; Garzon, FT; Muschiol, C; Scherf, HR; Schmähl, D; Schuler, B; Unger, C; Zeller, WJ | 1 |
| de Haas, GH; Maki, AH; Mao, SY | 2 |
| Ikeda, K; Samejima, Y; Sano, S; Teshima, K | 1 |
| Hayashi, K; Ikeda, K; Kawauchi, S; Samejima, Y; Teshima, K | 1 |
| Hamaguchi, K; Hayashi, K; Ikeda, K; Teshima, K | 1 |
| Böhm, M; Derer, W; Dettlaff, S; Fritzsche, U; Fusenig, NE; Harms, U; Hülsen, A; Schiebel, H; Schulz, J | 1 |
| Geilen, CC; Haase, A; Orfanos, CE; Wieder, T | 1 |
| Bruyneel, EA; Mareel, MM; Steelant, WF; Van den Eeckhout, EG | 1 |
| Hilgard, P; Klenner, T; Stekar, J | 1 |
| Arndt, D; Eue, I; Zeisig, R | 1 |
| Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J | 1 |
| Beckers, T; Hilgard, P; Voegeli, R | 1 |
| Arndt, D; Asongwe, G; Bibby, MC; Double, JA; Fichtner, I; Jungmann, S; Naundorf, H; Zeisig, R | 1 |
| Goppelt-Struebe, M; Winter, I | 1 |
| Arndt, D; Eue, I; Rudolf, M; Zeisig, R | 1 |
| Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J | 1 |
| Berkovic, D; Berkovic, K; Eibl, H; Fleer, EA; Unger, C | 1 |
| Bock, TK; Müller, BW | 1 |
| Berger, MR; Drevs, J; Eibl, H; Kaufmann-Kolle, P; Kötting, J; Marschner, N; Unger, C | 1 |
| Geilen, CC; Haase, A; Morré, DJ; Morré, DM; Reutter, W; Wieder, T | 1 |
| Detmar, M; Geilen, CC; Orfanos, CE; Reutter, W; Wieder, T | 1 |
| Burg, G; Dummer, R; Krasovec, M; Röger, J; Sindermann, H | 1 |
| Engel, J; Hilgard, P; Kutscher, B; Maurer, HR; Nössner, G; Schumacher, W; Stekar, J; Voegeli, R | 1 |
| Bruyneel, EA; Hilgard, P; Mareel, MM; Schallier, DC; Storme, GA; Van den Berge, DL | 1 |
| Colombo, DT; Reitz, RC; Tran, LK | 1 |
| Amtmann, E; Berger, MR; Betsch, B; Gebelein, M; Heyl, P; Scherf, HR | 1 |
| Bernhardt, G; Engel, J; Schönenberger, H; Spruss, T | 1 |
| Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J | 1 |
| Lowenstein, JM; Pawelczyk, T | 1 |
| Planting, AS; Stoter, G; Verweij, J | 1 |
| Armand, JP; Gandia, D; Planting, AS; Stoter, G; Verweij, J | 1 |
| Becher, R; Bornfeld, N; Kellner, U; Theischen, M; Wessing, A | 1 |
| Hilgard, P; Klenner, T; Stekar, J; Unger, C | 1 |
| Campenot, RB; Posse de Chaves, E; Vance, DE; Vance, JE | 1 |
| Berkovic, D; Fleer, EA; Grunwald, U; Hiddemann, W; Menzel, W; Unger, C | 1 |
| Cabot, MC; Geilen, CC; Giuliano, AE; Orfanos, CE; Wieder, T; Zhang, Z | 1 |
| Arndt, D; Eue, I; Fichtner, I; Kosch, M; Zeisig, R | 1 |
| Berkovic, D; Fleer, EA; Grunwald, U; Hiddemann, W | 1 |
| Brachwitz, H; Grunicke, HH; Kindler, E; Maly, K; Schubert, C; Stekar, J; Uberall, F | 1 |
| Arndt, D; Hirota, S; Shimada, K; Zeisig, R | 1 |
| Geilen, CC; Hakyi, N; Hoffmann, M; Orfanos, CE; Reutter, W; Schön, M; Schön, MP | 1 |
| Croft, SL; Snowdon, D; Yardley, V | 1 |
| van Heugten, HG; Verdonck, LF | 1 |
| Clive, S; Leonard, RC | 1 |
| Berger, MR; Brun, R; Kaminsky, R; Konstantinov, SM; Zillmann, U | 1 |
| Almond-Roesler, B; Blume-Peytavi, U; Geilen, CC; Orfanos, CE; Sommer, C | 1 |
| Engel, J; Hilgard, P; Klenner, T; Kutscher, B; Nössner, B; Stekar, J | 1 |
| Berger, MR; Eibl, H; Kaufmann-Kolle, P; Unger, C | 1 |
| Beckers, T; Holtmann, H; Klenner, T; Nooter, K | 1 |
| Bollmann, G; Bothe, E; Gademann, G; Paukisch, H; Strate, W | 1 |
| Arndt, D; Eue, I; Fichtner, I; Sternberg, B; Zeisig, R | 1 |
| Engel, J; Hilgard, P; Klenner, T; Kutscher, B; Nössner, G; Stekar, J | 1 |
| Bibby, MC; Parkin, SM; Safa, O | 1 |
| Berkovic, D; Fleer, EA; Goeckenjan, M; Hiddemann, W; Lüders, S | 2 |
| Colombo, DT; Reitz, RC; Speck, JJ; Tran, LK | 1 |
| Hou, L; Liu, XY; Wang, YZ; Wu, LJ; Xu, QS; Zhang, YB | 1 |
| Berkovic, D; Fleer, EA; Haase, D; Hiddemann, W | 1 |
| Boggs, K; Jackowski, S; Rock, CO | 1 |
| Chaimovich, H; da Costa, MH | 1 |
| Berkovic, D; Fleer, EA; Hiddemann, W; Kuduz, J | 1 |
| Arthur, G; Bittman, R | 1 |
| Ferrua, B; Grousson, D; Kubar, J; Le Fichoux, Y; Lelièvre, A; Rousseau, D; Ruette, S | 1 |
| de Vries, EG; Meijer, C; Mulder, NH; Oosterhuis, JW; Timmer-Bosscha, H | 1 |
| Dittrich, N; Haftendorn, R; Ulbrich-Hofmann, R | 1 |
| Geilen, CC; Orfanos, CE; Wieder, T | 1 |
| Gellerich, FN; Ulbrich-Hofmann, R; Vagina, O | 1 |
| Bergmann, J; Brachwitz, H; Langen, P; Thomas, Y | 1 |
| Civoli, F; Daniel, LW | 1 |
| Berkovic, D | 1 |
| Arndt, D; Fichtner, I; Stahn, R; Zeisig, R | 1 |
| Grosman, N | 1 |
| Goyal, AK; Hilgard, P; Makharia, MK; Mandal, AK; Murray, HW; Rosenkaimer, F; Sundar, S; Voss, A | 1 |
| Chang, YB; Fu, D; Wang, YZ; Xing, C | 1 |
| Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM | 1 |
| Bartelink, H; Ruiter, GA; van Blitterswijk, WJ; Verheij, M; Zerp, SF | 2 |
| Brochez, V; De Potter, CR; Diniz, JA; Van den Eeckhout, EG; Van Heuverswyn, D | 1 |
| Garnier, JM; Gire, C; Minodier, P; Nicaise, C | 1 |
| Bierer, DE; Dener, JM; Dubenko, LG; Flores, M; Gerber, RE; Litvak, J; Lu, Q; Phuan, PW; Truong, T; Ubillas, RP; Ye, Z; Zhou, Y | 1 |
| Fu, D; Shi, Z; Wang, Y | 1 |
| Berger, MR; Eibl, H; Konstantinov, SM | 1 |
| Bachmann, P; Berman, J; Fischer, C; Jha, TK; Karbwang, J; Sundar, S; Thakur, CP; Voss, A | 1 |
| Herwaldt, BL | 1 |
| Clive, S; Gardiner, J; Leonard, RC | 1 |
| Arndt, D; Fahr, A; Fichtner, I; Teppke, AD; Zeisig, R | 1 |
| Delph-Etienne, S; Murray, HW | 1 |
| Engel, J; Gupta, LB; Makharia, MK; Murray, HW; Rosenkaimer, F; Singh, MK; Sundar, S; Voss, A | 1 |
| de Castro, SL; Meirelles, MN; Santa-Rita, RM; Santos Barbosa, H | 1 |
| Eibl, H | 1 |
| Sherwood, JA | 1 |
| Fuji, N; Hariya, Y; Kohama, G; Yokosawa, N; Yonekura, N | 1 |
| Murray, HW | 5 |
| Agrawal, G; Bachmann, P; Fischer, C; Makharia, A; More, DK; Murray, HW; Sundar, S; Voss, A | 1 |
| Hart, D; Heise, N; Klenner, T; Lux, H; Opperdoes, FR | 1 |
| Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J | 1 |
| Ruiter, GA; van Blitterswijk, WJ; Verheij, M; Zerp, SF | 1 |
| Murray , HW | 1 |
| Adamo, S; Coletti, D; Molinaro, M; Palleschi, S; Silvestroni, L; Tomei, F | 1 |
| Ermakova, NA; Moĭseenko, VM; Orlova, RV; Protsenko, SA | 1 |
| Bensch, M; Berkovic, D; Bertram, J; Binder, C; Fleer, EA; Haase, D; Wille, T | 1 |
| Eue, I | 1 |
| Duchêne, M; Eibl, H; Hottkowitz, T; Kollaritsch, H; Scheiner, O; Seifert, K; Wernsdorfer, WH; Wiedermann, G | 1 |
| Hernández-Alcoceba, R; Lacal, JC; Lucas, L; Penalva, V | 1 |
| Croft, SL; Escobar, P; Yardley, V | 1 |
| Grunicke, H; Hofmann, J; Liu, R; Lu, P; Pietro, AD; Rybczynska, M; Sharom, FJ; Spitaler, M; Steinfels, E | 1 |
| Castanys, S; Gamarro, F; Jiménez, IA; Parodi-Talice, A; Pérez-Victoria, FJ; Pérez-Victoria, JM; Ravelo, AG | 1 |
| Berman, J; Engel, J; Fischer, C; Gutierrez, P; Nicholls, RS; Padilla, J; Soto, J; Toledo, J; Voss, A | 1 |
| Boeck, G; Grunicke, H; Hofmann, J; Knebel, NG; Rybczynska, M; Spitaler, M | 1 |
| David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G | 1 |
| Sundar, S | 1 |
| Engel, J; Fischer, C; Voss, A | 1 |
| Arana, B; Diaz, A; Rizzo, N | 1 |
| Croft, SL; Escobar, P; Marques, C; Matu, S | 1 |
| Aspöck, H; Duchêne, M; Eibl, H; Hottkowitz, T; Obwaller, A; Seifert, K; Walochnik, J; Wiedermann, G | 1 |
| Kaminsky, R | 1 |
| Desai, S; Klein, RR; Thakker, DR; Troutman, MD; Ward, PD | 1 |
| Fritz, JS; Hasebe, K; Hu, W; Tanaka, K | 1 |
| Marty, P; Rosenthal, E | 2 |
| Paterson, R | 1 |
| Boelaert, M; Bryceson, AD; Croft, SL; Desjeux, P; Guerin, PJ; Olliaro, P; Sundar, S; Wasunna, MK | 1 |
| Kumar, P; Pai, K; Pandey, HP; Sundar, S; Tripathi, K | 1 |
| Carrasco, MP; Jiménez-López, JM; Marco, C; Segovia, JL | 4 |
| Bozza, MT; Freire-De-Lima, CG; Gibaldi, D; Heise, N; Mendonça-Previato, L; Previato, JO; Saraiva, VB | 1 |
| Jacobs, S | 1 |
| Berman, J; Bryceson, A; Engel, J; Fischer, C; Jha, TK; Junge, K; Sindermann, H; Sundar, S; Thakur, CP | 1 |
| Ouyang, H; Thakker, DR; Ward, PD | 1 |
| Bryceson, AD; Engel, J; Olliaro, PL; Ridley, RG; Sindermann, H | 1 |
| Agarwal, PK | 1 |
| Roca, B | 1 |
| Croft, SL; Duchêne, M; Seifert, K | 1 |
| Carter, KC; Mullen, AB; Pereira, OC; Spickett, C; Sundar, S | 1 |
| Lobovská, A; Nohýnková, E | 1 |
| Bachmann, P; Berman, J; Jha, TK; Junge, K; Sindermann, H; Sundar, S | 1 |
| Birchmore, JL; Hanson, PK; Malone, L; Nichols, JW | 1 |
| Castanys, S; Gamarro, F; Pérez-Victoria, FJ | 1 |
| Berman, J | 3 |
| Bommer, W; Croft, SL; Eibl, HJ; Engel, J; Engel, KR; Sindermann, H; Unger, C | 1 |
| Castanys, S; Gamarro, F; Ouellette, M; Pérez-Victoria, FJ | 1 |
| Castanys, S; Croft, SL; Gamarro, F; Javier Pérez-Victoria, F; Matu, S; Seifert, K | 1 |
| Thakur, BB | 1 |
| Dwivedi, S; Koirala, S; Rijal, S; Sangraula, H; Sharma, KK | 1 |
| Agresta, M; D'Arrigo, P; Fasoli, E; Losi, D; Pedrocchi-Fantoni, G; Riva, S; Servi, S; Tessaro, D | 1 |
| Bock, D; Braun, S; Meyer, O; Roch, O; Rooke, R; Settelen, N | 1 |
| Berman, JD; Bhattacharya, SK; Bryceson, AD; Engel, J; Jha, TK; Junge, K; Karbwang, J; Sindermann, H; Sundar, S; Thakur, CP | 1 |
| Bories, C; Bréard, J; Loiseau, PM; Paris, C | 1 |
| Loiseau, PM; Rakotomanga, M; Saint-Pierre-Chazalet, M | 2 |
| Garnier, JM; Minodier, P; Retornaz, K; Robert, S | 1 |
| Danhier, S; Plantin, P; Schoenlaub, P; Vilque, JP; Viseux, V | 1 |
| Jaiswal, BP; Kumar, R; Prasad, R; Singh, UK | 2 |
| Arana, BA; Arboleda, M; Berman, JD; Diaz, A; Engel, J; Gutierrez, P; Junge, K; Luz, M; Rizzo, N; Sindermann, H; Soto, J; Toledo, J; Vega, JC | 1 |
| Duijsings, D; Houweling, M; Vaandrager, AB; van der Sanden, MH; van Golde, LM | 1 |
| Dey, CS; Verma, NK | 2 |
| Barbosa, HS; de Castro, SL; Henriques-Pons, A; Santa-Rita, RM | 1 |
| Desjeux, P | 1 |
| Duijsings, D; Houweling, M; Mol, JA; Teerds, KJ; Vaandrager, AB | 1 |
| Seal, D | 1 |
| Hepburn, NC | 1 |
| Dube, A; Singh, N | 1 |
| Bommer, W; Engel, KR; Fischer, C; Sindermann, H | 1 |
| Conde, O; Dynarowicz-Łatka, P; Miñones, J; Rey Gómez-Serranillos, I | 1 |
| Singh, S; Sivakumar, R | 1 |
| Azzouz, S; Garcia, RG; Maache, M; Osuna, A | 1 |
| Bommer, W; Eibl, HJ; Engel, KR; Kuhlencord, A; Sindermann, H; Sundar, S; Zappel, H | 1 |
| Henriquez, FL; Ingram, PR; McBride, J; Roberts, CW | 1 |
| Casas, M; Dynarowicz-Łatka, P; Gómez-Serranillos, IR; Iribarnegaray, E; Miñones, J | 1 |
| Arya, KR; Dube, A; Kapil, A; Maurya, R; Mishra, PK; Singh, N | 1 |
| Dynarowicz-łatka, P; Gómez-Serranillos, IR; Iribarnegaray, E; Miñiones, J; Miñones, J | 1 |
| Balkay, L; Krasznai, Z; Krasznai, ZT; Márián, T; Szabó-Péli, J; Trón, L | 1 |
| Barbosa, HS; de Castro, SL; Lira, R; Santa-Rita, RM; Urbina, JA | 1 |
| Bandyopadhyay, S; Chatterjee, M; Dutta, A; Mandal, C | 1 |
| Dube, A; Singh, N; Sundar, S | 1 |
| Buscaylet, S; Dales, JP; Grob, JJ; Lagrassa, S; Mahieu-Renard, L; Richard, MA | 1 |
| Gupta, S; Ramesh, SC; Srivastava, VM | 1 |
| Baumann, D; Burg, G; Faeh, A; Grimm, F; Günthard, HF; Hasse, B; Hasse, U; Mathis, A; Schraner, C; Weber, R | 1 |
| Murray, HW; Sundar, S | 1 |
| Kumar, A; Sundar, S | 1 |
| Berger, M; Karaivanova, M; Konstantinov, S; Martinova, Y; Petkova, S; Topashka-Ancheva, M | 1 |
| Chappuis, F; Croft, SL; De Doncker, S; Dujardin, JC; Koirala, S; Llanos-Cuentas, A; Miranda, C; Rijal, S; Yardley, V | 1 |
| Mravljak, J; Pecar, S; Zeisig, R | 1 |
| Djureen-Mårtensson, E; Hansson, J; Månsson-Brahme, E; Ragnarsson-Olding, B | 1 |
| Demetzos, C; Dimas, K; Hatziantoniou, S; Papagiannaros, A; Papaioannou, GT | 1 |
| Bange, FC; Rihl, M; Schmidt, RE; Stoll, M; Ulbricht, K | 1 |
| Bandyopadhyay, S; Chatterjee, M; Ganguly, S; Sarkar, A | 1 |
| Bories, C; Demetzos, C; Loiseau, PM; Papagiannaros, A | 1 |
| Agrawal, D; Agrawal, S; Chakravarty, J; Chhabra, A; Kumar, K; Singh, V; Sundar, S | 1 |
| Barratt, G; Buyse, M; Chacun, H; Farinotti, R; Menez, C | 1 |
| Aspöck, H; Blaha, C; Duchêne, M; Walochnik, J | 1 |
| Croft, SL; Seifert, K | 1 |
| Ellis, DH; Ganendren, R; Handke, R; Obando, D; Sorrell, TC; Widmer, F; Wright, LC | 1 |
| Berman, JD | 1 |
| Soto, J; Soto, P | 2 |
| Asafa, Y; Belay, AD; Davidson, RN; Mesure, J | 1 |
| de Vries, PJ; Dinant, HJ; Faber, WR; Godfried, MH; Schallig, HD; van der Meide, WF | 1 |
| Kayser, O; Lemke, A | 1 |
| Bhattacharya, SK; Jha, TK; Rai, M; Sundar, S; Thakur, CP | 1 |
| Gutteridge, WE | 1 |
| Engel, J; Sindermann, H | 1 |
| Berman, J; Bryceson, AD; Croft, S; Engel, J; Gutteridge, W; Karbwang, J; Sindermann, H; Soto, J; Sundar, S; Urbina, JA | 1 |
| Bhattacharya, SK; Karbwang, J; Sur, D | 1 |
| Jha, TK | 1 |
| Croft, SL; Seifert, K; Yardley, V | 1 |
| Ballet, JJ; Benichou, J; Brasseur, G; Duclos, C; Favennec, L; François, A; Gargala, G; Hellot, MF; Muraine, M; Vasseneix, C | 1 |
| Castanys, S; Gamarro, F; Pérez-Victoria, FJ; Sánchez-Cañete, MP | 1 |
| Blanco, B; Convit, J; Engel, J; Kannee, C; Sindermann, H; Ulrich, M; Zerpa, O | 1 |
| Conde, O; Dynarowicz-Łatka, P; Miñones Trillo, J; Miñones, J; Rey Gómez-Serranillos, I | 1 |
| Assefa, Y; Boots, G; Davidson, RN; Dejenie, A; den Boer, M; Hundie, TB; Mesure, J; Ritmeijer, K | 1 |
| Acuña, AU; Amat-Guerri, F; Andreu, D; de la Torre, BG; Hornillos, V; Rivas, L; Saugar, JM | 1 |
| Croft, SL; Engel, J | 1 |
| Berman, J; Soto, J | 1 |
| Barron, D; Bavchvarov, BI; Castanys, S; Cortés-Selva, F; Costi, MP; Di Pietro, A; Gamarro, F; Maitrejean, M; Muñoz-Martínez, F; Parodi-Talice, A; Pérez-Victoria, FJ; Pérez-Victoria, JM | 1 |
| Barratt, G; Besnard, M; Buyse, M; Farinotti, R; Loiseau, PM; Ménez, C | 1 |
| Bérard, F; Coiffier, B; Dumontet, C; Gimonet, JF; Thomas, L | 1 |
| Bandyopadhyay, U; Choubey, V; Guha, M; Kumar, S; Maity, P; Puri, SK; Srivastava, K | 1 |
| Azzouz, S; Dos Santos, MF; Maache, M; Osuna, A; Petavy, AF; Sarciron, ME | 1 |
| Dey, CS; Singh, G; Verma, NK | 1 |
| Calvopina, M; Cooper, PJ; Gomez, EA; Hashiguchi, Y; Sindermann, H | 1 |
| Soto, J; Toledo, JT | 1 |
| Beijnen, JH; de Vries, PJ; Dorlo, TP; Eggelte, TA | 2 |
| Jayswal, BP; Mishra, OP; Prasad, R; Singh, UK | 1 |
| Anders, G; Ardiles, J; Balderrama, M; Berman, J; Engel, J; Fuentelsaz, C; Gomez, A; Molleda, F; Parra, R; Rea, I; Sindermann, H; Soto, J; Soto, P; Toledo, J; Valda, L | 1 |
| Blanc, S; Chaminade, P; Gaudin, K; Loiseau, PM; Rakotomanga, M | 1 |
| Barratt, G; Buyse, M; Dugave, C; Farinotti, R; Ménez, C | 1 |
| Luque-Ortega, JR; Rivas, L | 1 |
| Boelaert, M; Diap, G; Gerstl, S; Guerin, PJ; Meheus, F; Van der Stuyft, P; Vanlerberghe, V | 1 |
| Anwar, M; Bashir, S; Bukhari, I; Iqbal, J; Jamshid, M; Masoom Yasinzai, M | 1 |
| Bertoglio, J; Bréard, J; Paris, C | 1 |
| García, E; Llull, D; Rivas, L | 1 |
| González, LM; Vélez, ID | 1 |
| Chen, SC; Guse, Z; Halliday, C; Jolliffe, KA; Kong, F; Lee, OC; Sorrell, TC; Tong, Z; Widmer, F; Wright, LC | 1 |
| Mumtaz, N; Rahman, SB; ul Bari, A | 1 |
| Barratt, G; Buyse, M; Farinotti, R; Ménez, C | 1 |
| Avila, A; Blanco, B; Convit, J; Matos, N; Mendoza, I; Polegre, M; Pratlong, F; Ravel, C; Ulrich, M; Zerpa, O | 1 |
| Davidson, RN; Junghanss, T; Krause, E; Stojkovic, M | 1 |
| Adderley, U; Smith, R | 1 |
| Sunderkötter, C; von Stebut, E | 1 |
| Ruiz-Villaverde, R; Sánchez-Cano, D; Villaverde-Gutierrez, C | 1 |
| Minodier, P; Parola, P | 1 |
| Mishra, J; Saxena, A; Singh, S | 1 |
| Amato, VS; Tuon, FF | 1 |
| Blanc, P; Garnier, JM; Minodier, P; Noël, G; Retornaz, K; Uters, M | 1 |
| Alder-Baerens, N; Castanys, S; Castanys-Muñoz, E; Gamarro, F; Pomorski, T | 1 |
| Hölzle, F; Loeffelbein, D; Ramadan, H; Sommerer, F; Wolff, KD; Wysluch, A | 1 |
| Akhoundi, B; Fotouhi, A; Hooshmand, B; Kabir, MJ; Mohebali, M; Nadim, A; Rahnema, A; Razaghian, AR; Zarei, Z | 1 |
| Boucher, P; Hadighi, R; Khamesipour, A; Meamar, AR; Mohebali, M; Ouellette, M; Roy, G | 1 |
| Anders, G; Bhattacharya, SK; Das, VR; Ganguly, NK; Jha, TK; Kumar, N; Lal, C; Pandey, K; Ranjan, A; Sindermann, H; Singh, VP; Sinha, PK; Sundar, S; Thakur, CP; Verma, N; Verma, RB | 1 |
| Castanys, S; Croft, SL; Gamarro, F; Pérez-Victoria, FJ; Sánchez-Cañete, MP; Seifert, K; Stettler, M | 1 |
| Thakker, DR; Tippin, TK | 1 |
| Bhattacharya, SK; Bimal, S; Das, P; Das, VN; Kumar, N; Lal, CS; Pandey, K; Singh, D; Sinha, PK; Topno, RK; Verma, N; Verma, RB | 1 |
| Casquero, A; Fernández-Guerrero, ML; Górgolas, M; Refoyo, E; Troya, J | 1 |
| Acquaviva, V; Antinori, S; Bestetti, G; Corbellino, M; Foschi, A; Longhi, E; Meroni, L; Parravicini, C; Piolini, R; Trovati, S | 1 |
| Bhattacharya, SK; Das, P; Das, VN; Kumar, N; Lal, CS; Pandey, K; Sinha, PK; Topno, RK; Verma, N | 1 |
| Kumar, A; Mitra, G; Thakur, CP; Thakur, M; Thakur, S | 1 |
| Acuña, AU; Amat-Guerri, F; Delgado, J; Hornillos, V; Luque-Ortega, JR; Rivas, L; Saugar, JM | 1 |
| Ansari, NA; Jain, RK; Ramesh, V; Salotra, P | 1 |
| Aichelburg, A; Aspöck, H; Assadian, O; Steuer, A; Vetter, N; Visvesvara, G; Walochnik, J | 1 |
| Eibl, H; Hiddemann, W; Hossann, M; Issels, RD; Lindner, LH; Teichert, N; Vogeser, M; Wachholz, K | 1 |
| Azzouz, S; Maache, M; Osuna, A; Petavy, AF; Sánchez-Moreno, M | 1 |
| Auer, H; Geusau, A; Schnedl, J; Stingl, G; Walochnik, J; Wöhrl, S | 1 |
| Bradel-Tretheway, B; Chugh, P; Dewhurst, S; Kim, B; Maggirwar, SB; Monteiro-Filho, CM; Planelles, V | 1 |
| Balderrama, M; Berman, JD; Rea, J; Soto, J; Soto, P; Toledo, J; Valda, L | 1 |
| Bimal, S; Das, P; Das, VN; Kumar, N; Lal, CS; Pandey, K; Sinha, PK; Topno, RK; Verma, N | 1 |
| Beijnen, JH; de Vries, PJ; Dorlo, TP; Eggelte, TA; Hillebrand, MJ; Rosing, H | 1 |
| Chavan, HD; Dey, CS; Singh, G | 1 |
| Choudhury, K; Clos, J; Kube, M; Reinhardt, R; Zander, D | 1 |
| Bouchaud, O; Izri, A | 1 |
| Amon, U; Krahl, D; Neub, A; Stich, A | 1 |
| Beijnen, JH; de Vries, HJ; de Vries, PJ; Dorlo, TP; Huitema, AD; Keizer, RJ; van Thiel, PP | 1 |
| Bonnet-Delpon, D; Bories, C; Chollet, C; Crousse, B; Loiseau, PM | 1 |
| Palumbo, E | 2 |
| Ayres, DC; Giorgio, S; Pinto, LA | 1 |
| Coelho, F; Marques, N; Meliço-Silvestre, A; Oliveira, J; Sá, R; Saraiva Da Cunha, J | 1 |
| Ansari, NA; Ramesh, V; Salotra, P | 1 |
| Castanys, S; Castanys-Muñoz, E; Gamarro, F; Pérez-Victoria, JM | 1 |
| Alzate, JF; Arias, A; de la Iglesia-Vicente, J; Jiménez-Ruiz, A; Mollinedo, F; Rico, E | 1 |
| Le Pape, P | 1 |
| Del Prado, G; Gracia, M; Huelves, L; Ponte, C; Rodríguez-Cerrato, V | 1 |
| Koul, N; Sen, E; Sharma, V; Tewari, R | 1 |
| Farmen, S; Kaul, DR; Khaled, YA; Lowe, L; Visvesvara, GS; Yanik, GA | 1 |
| Berman, JJ | 1 |
| Im, KI; Jung, SY; Kim, JH; Kim, K; Kwon, D; Lee, YJ; Park, S; Shin, HJ; Song, KJ | 1 |
| Artuc, M; dos Santos, RV; Friedrichson, T; Guhl, S; Jennings, G; Maurer, M; Sünder, C; Weller, K; Zuberbier, T | 1 |
| Agarwal, D; Agrawal, N; Chakravarty, J; Murray, HW; Olliaro, P; Rai, M; Sundar, S; Vaillant, M | 1 |
| Alborzi, A; Fakhar, M; Hatam, GR; Kadivar, MR; Motazedian, MH; Pouladfar, GR | 1 |
| Cabrera-Serra, MG; Piñero, JE; Valladares, B | 1 |
| Gravino, AE; Manna, L; Neglia, G; Picillo, E; Reale, S; Vescio, F; Vitale, F | 1 |
| Gravino, AE; Manna, L; Picillo, E; Reale, S; Vitale, F | 1 |
| Bestetti, A; Bossolasco, S; Cernuschi, M; Cinque, P; De Bona, A; Gaiera, G; Gianotti, N; Lazzarin, A; Maillard, M | 1 |
| Aichelburg, AC; Aspöck, H; Assadian, O; Perneczky, G; Prosch, H; Steuer, A; Vetter, N; Visvesvara, GS; Walochnik, J | 1 |
| Bossolasco, S; Ceserani, N; Cinque, P; Gaiera, G; Gianotti, N; Guffanti, M; Lazzarin, A; Ratti, D; Salmaso, F | 1 |
| Caruso-Neves, C; Gomes-Quintana, E; Heise, N; Saraiva, VB; Wengert, M | 1 |
| Acuña, AU; Amat-Guerri, F; Carrillo, E; Hornillos, V; Rivas, L | 1 |
| Kulshrestha, A; Kumar, D; Salotra, P; Singh, R | 1 |
| Chakrabandhu, K; Huault, S; Hueber, AO | 1 |
| Chocholova, E; Faber, WR; Jensema, AJ; Kager, PA; Wonders, J | 1 |
| Carrasco, MP; Jiménez-López, JM; Marco, C; Ríos-Marco, P; Segovia, JL | 3 |
| Caccin, P; Montecucco, C; Rossetto, O | 1 |
| Buonavoglia, C; Decaro, N; Gravino, AE; Manna, L; Picillo, E | 1 |
| Olliaro, P; Sundar, S | 1 |
| Beck, JC; Berman, J; Davidson, C; Mings, S; Ondo, AL; Shanler, SD | 1 |
| Carvalho, L; Castanys, S; Gamarro, F; Pérez-Victoria, FJ; Sánchez-Cañete, MP | 1 |
| Davidson, RN; Killingley, B; Lamb, LE | 1 |
| Bianciardi, P; Mateo, M; Maynard, L; Miró, G; Vischer, C | 1 |
| Bimal, S; Das, P; Das, VN; Lal, CS; Pandey, K; Siddiqui, NA; Singh, D; Topno, RK; Verma, N; Verma, RB | 1 |
| Meenakshi Thakur, AK; Thakur, CP; Thakur, S | 1 |
| Bellemore, MC; Ellis, DH; Kesson, AM; O'Mara, TJ; Sorrell, TC | 1 |
| Eun, HM; Maynard, L; Sanquer, A; Woerly, V | 1 |
| Hirayama, K; Kaneko, O; Pandey, BD; Pandey, K; Yanagi, T | 1 |
| Chatterjee, M; Mandal, G; Sarkar, A; Singh, N; Sundar, S | 1 |
| Barratt, G; Loiseau, PM; Saint-Pierre-Chazalet, M | 1 |
| Agarwal, R; Kamat, V; Maiti, M; Martin, S; Saha, B; Wadhone, P | 1 |
| Clement, JG; Gershkovich, P; Thornton, SJ; Tidwell, RR; Wasan, EK; Wasan, KM; Werbovetz, KA; Zhu, X | 1 |
| Cos, P; da Luz, RI; Maes, L; Timmermans, JP; Toté, K; Vermeersch, M | 1 |
| Auer, H; Duchêne, M; Gruber, F; Mildner, M; Obwaller, A; Suchomel, M; Tschachler, E; Walochnik, J | 1 |
| Darley, S; Laxminarayan, R; Olliaro, P; Sundar, S | 1 |
| Collini, P; Greig, J; Lockwood, D; Premchand, N | 1 |
| Aresu, L; Bianciardi, P; Brovida, C; Castagnaro, M; Cavicchioli, L; Giroud, L; Valente, M; Vischer, C | 1 |
| Ardiles, J; Berman, J; Rea, J; Soto, J; Toledo, J; Valda, L; Valderrama, M | 1 |
| Ben Brahim, M; Bories, C; Le Moyec, L; Loiseau, PM; Rakotomanga, M; Saint-Pierre-Chazalet, M | 1 |
| Cos, P; da Luz, RI; Dujardin, JC; Maes, L; Vermeersch, M | 1 |
| Figueroa, RA; Miranda, MC; Prager, M; Zea, DF | 1 |
| Bukovský, M; Devínsky, F; Karlovská, J; Lacko, I; Lukác, M; Mojzis, J; Mojzisová, G; Mrva, M; Ondriska, F; Valentová, J | 1 |
| Belloni, B; Brockow, K; Eben, R; Hartmann, B; Hartmann, K; Maurer, M; Ruëff, F; Schoepke, N; Siebenhaar, F; Staubach, P; Weber, A | 1 |
| Benaim, G; De Lucca, M; Martinez, JC; Mendoza-León, A; Payares, G; Serrano-Martín, X | 1 |
| Bukovský, M; Devínsky, F; Fischer-Fodor, E; Lacko, I; Lukác, M; Miklásová, N; Mrva, M; Ondriska, F | 1 |
| Aguiar, MG; Fernandes, AP; Ferreira, LA; Nunan, EA; Nunan, FA; Silva, DL | 1 |
| Bäumer, W; Jennings, G; Rundfeldt, C; Wlaź, P | 1 |
| Bart, A; de Vries, HJ; de Vries, PJ; Faber, WR; Kager, PA; Leenstra, T; Schallig, HD; van der Meide, WF; van der Sluis, A; van Gool, T; van Thiel, PP; van Vugt, M; Zeegelaar, JE | 1 |
| Eichhorn, A; Gazeau, C; Griewank, K; von Stebut, E | 1 |
| Kumar, D; Ramam, M; Ramesh, V; Salotra, P; Verma, S | 1 |
| Müller, A; Stich, A; Tappe, D | 1 |
| Bianciardi, P; Cañavate, C; Cruz, I; Miró, G; Mortarino, M; Oliva, G; Vischer, C | 1 |
| Alvar, J; Balasegaram, M; Boelaert, M; Lynen, L; Meheus, F; van Griensven, J | 1 |
| Bhatt, AP; Bhende, PM; Damania, B; Dittmer, DP; Roy, D; Sin, SH | 1 |
| Dölle, S; Hoser, D; Loddenkemper, C; Maurer, M; Rasche, C; Worm, M; Zuberbier, T | 1 |
| Liarte, DB; Murta, SM | 1 |
| Devínsky, F; Lacko, I; Lukác, M; Pisárcik, M | 1 |
| Duncan, RC; Kumar, D; Nakhasi, HL; Salotra, P; Singh, R | 1 |
| Croft, SL; Escobar, P; Hernández, IP; Luna, KP; Rueda, CM; Zorro, MM | 1 |
| Gupta, S; Haq, W; Sane, SA; Shakya, N | 2 |
| Humayun, KN; Jehan, F; Khalid, U; Saleem, T; Soofi, S | 1 |
| Chaturvedi, P; Khaitan, BK; Khandpur, S; Kumar, U; Samantaray, JC; Sharma, VK | 1 |
| Badaro, R; Chang, KP; Day, J; Mehta, SR; Schooley, RT; Spina, C; Zhang, XQ | 1 |
| Bravo, F; Cabello, AM; Gotuzzo, E; Legua, P; Martínez, DY; Ramos, C; Seas, C | 1 |
| Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D | 1 |
| Falk, SP; Noah, JW; Weisblum, B | 1 |
| López, L; Mestra, L; Rodríguez, E; Rojas, C; Sánchez, X; Vélez, I | 1 |
| Ali, N; Bhattacharya, P; Mondal, S | 1 |
| Aguiar, MG; Fernandes, AP; Ferreira, LA; Pereira, AM | 1 |
| Calogeropoulou, T; Georgikopoulou, K; Kolocouris, N; Papanastasiou, I; Pavlidis, T; Prousis, KC; Scoulica, E | 1 |
| Balasegaram, M; Boelaert, M; Faiz, MA; Meheus, F; Olliaro, P; Rijal, S; Sundar, S | 1 |
| Gupta, S; Sane, SA; Shakya, N | 2 |
| Olliaro, PL | 1 |
| Amer, EI; Baddour, NM; Eissa, MM; El-Azzouni, MZ | 1 |
| Bart, A; de Vries, HJ; de Vries, PJ; Faber, WR; Kager, PA; Krull, AC; Leenstra, T; Schallig, HD; van der Meide, WF; van der Sluis, A; van Gool, T; van Thiel, PP; van Vugt, M; Zeegelaar, JE | 1 |
| Alam, S; Arana, B; Berman, J; Chakravarty, J; Ghalib, H; Kumar, N; Kumari, P; Pandey, K; Ravidas, V; Sinha, PK; Sundar, S; Verma, DK; Verma, N | 1 |
| Chatterjee, M; Das, P; Das, S; Goswami, RP; Kumar, D; Mandal, G; Mukhopadhyay, D; Roy, S; Saha, B; Saha, P; Sarkar, A; Singh, SK | 1 |
| Ferner, R; Figueroa, BA; Ghalib, H; Kshirsagar, N; Lazdin, J | 1 |
| Ampuero, J; Carvalho, EM; Guimarães, LH; Machado, PR; Penna, G; Rocha, AT; Schriefer, A; Sousa, RS; Talhari, A; Villasboas, L | 1 |
| Fedorko, DP; Mahanty, S; Nash, TE; Ramanathan, R; Talaat, KR | 1 |
| Alam, S; Arora, R; Balasegaram, M; Chakravarty, J; Das, P; Ellis, S; Kumari, P; Lal, CS; Modabber, F; Nawin, K; Olliaro, P; Pandey, K; Rai, M; Sharma, B; Sinha, PK; Strub-Wourgaft, N; Sundar, S; Vaillant, M; Verma, DK; Verma, N | 1 |
| Boelaert, M; van Griensven, J | 1 |
| Chrusciak Talhari, C; Chrusciak-Talhari, A; da Silva, RM; de Oliveira Penna, G; Dietze, R; Gadelha Yamashita, EP; Lima Machado, PR; Talhari, S | 1 |
| Katubulushi, M; Kelly, P; Obwaller, A; Sianongo, S; Sinkala, E | 1 |
| Alvar, J; Arana, B; Battacharya, S; Das, P; Kroeger, A; Matlashewski, G; Mondal, D; Rijal, S; Sinha, PK; Sundar, S; Zilberstein, D | 1 |
| Auer, H; Mooseder, G; Poeppl, W; Pustelnik, T; Walochnik, J | 1 |
| Gharavi, MJ; Khademvatan, S; Rahim, F; Saki, J | 1 |
| Hanus, I; Harms, G; Häussinger, D; Löscher, T; Richter, J | 1 |
| Garajová, M; Lukáč, M; Mrva, M; Ondriska, F | 1 |
| Gupta, S; Haq, W; Sane, SA; Shakya, N; Vishwakarma, P | 1 |
| Katara, GK; Ramesh, V; Salotra, P; Verma, S | 1 |
| Allard, JL; Allen, GB; Gross, MJ; Hogan, DA; Leclair, LW; Lundblad, LK; Rajamani, S; Vasil, ML; Wargo, MJ | 1 |
| Eissa, MM; El Bardicy, S; Tadros, M | 1 |
| Baquedano, Y; Font, M; Jiménez-Ruiz, A; Moreno-Mateos, D; Palop, JA; Plano, D; Sanmartín, C | 1 |
| Bijosono Oei, J; Desmarini, D; Djordjevic, JT; Jolliffe, KA; Schibeci, SD; Sorrell, TC; Zuo, X | 1 |
| Amorim, AC; Andrade, HM; Bartchewsky, W; Brandão, RM; Castro, JA; Dumont, K; Guimarães, TM; Monte, SJ; Oliveira, NC; Pinheiro, MB; Ribeiro, ML; Silva, AS; Silva, RN; Toledo, VP; Yoko, M | 1 |
| Bavchvarov, BI; Campillo, M; Castanys, S; Gamarro, F; López-Martín, C; Martínez-García, M; Pérez-Victoria, JM; Torrecillas, IR | 1 |
| Bajpai, P; Gupta, S; Sane, SA; Shakya, N; Vishwakarma, P | 1 |
| Abuzaid, AA; Alexander, N; Balasegaram, M; Dorlo, TP; Edwards, T; Ellis, S; Khalil, EA; Kinoti, D; Kirigi, G; Musa, AM; Njoroge, N; Omollo, R; Wasunna, M; Younis, BM | 1 |
| Ahmad, Z; Ahmed, BN; Arana, B; Bangali, AM; Berman, J; Chowdhury, MZ; Faiz, MA; Hossain, M; Islam, MN; Islam, QT; Mascie-Taylor, CG; Rahman, M; Rahman, MR; Sayeedur, R | 1 |
| Damasceno, QS; Galuppo, MK; Morais-Teixeira, Ed; Rabello, A; Romanha, AJ | 1 |
| Bellio, M; Branquinha, MH; d'Avila-Levy, CM; Gonçalves, KC; Marinho, Fde A; Oliveira, AC; Oliveira, SS; Santos, AL | 1 |
| Obwaller, A; Polat, ZA; Vural, A; Walochnik, J | 1 |
| Click, J; Gee, SN; Hsu, MY; Rothschild, B; Saavedra, A; Sheth, V | 1 |
| De Doncker, S; Decuypere, S; Dujardin, JC; Maes, L; Rijal, S; Vanaerschot, M | 1 |
| Das, P; Kumar, N; Lal, CS; Pandey, K; Ranjan, A; Sinha, PK; Verma, N; Verma, RB | 1 |
| Leprohon, P; Moreira, W; Ouellette, M | 1 |
| Ferrua, B; Lang, T; Lemichez, E; Maddugoda, MP; Marty, P; Michel, G; Munro, P; Pomares, C | 1 |
| Barbhuiya, JN; Chatterjee, M; Das, NK; Kundu, S; Mukhopadhyay, D; Roy, S | 1 |
| Gupta, S; Sane, SA; Shakya, N; Shankar, S | 1 |
| Harms, G; Reiter-Owona, I; Richter, J; Scherbaum, H; Stich, A | 1 |
| Abreu, S; Chaminade, P; Imbert, L; Libong, D; Loiseau, PM; Ramos, RG | 1 |
| Baudouin, R; Bories, C; Campos Vieira, N; Figadère, B; Fournet, A; Loiseau, PM; Séon-Méniel, B; Vacus, J | 1 |
| Baharia, RK; Dube, A; Gupta, R; Jaiswal, AK; Kushawaha, PK; Samant, M | 1 |
| Beijnen, JH; de Vries, PJ; Dorlo, TP; Schoone, GJ; Stienstra, Y; van Thiel, PP; van Vugt, M | 1 |
| Bertão, HG; da Silva, RA; de Azevedo Albuquerque, MC; Padilha, RJ; Rádis-Baptista, G | 1 |
| Badino, P; Farca, AM; Ferroglio, E; Miniscalco, B; Monticelli, P; Odore, R; Trisciuoglio, A | 1 |
| de Souza, W; Godinho, JL; Rodrigues, JC; Silva, R; Simas-Rodrigues, C; Ürmenyi, TP | 1 |
| Garcerant, D; Gore Saravia, N; Miranda, MC; Montero, LM; Muvdi Arenas, S; Nicholls, RS; Osorio, L; Pérez, M; Prager, M; Rodríguez-Barraquer, I; Rojas, MX; Rubiano, LC | 1 |
| Machado, PR; Penna, G | 1 |
| Bart, A; de Vries, HJ; Faber, WR; Hoekzema, R; Zeegelaar, JE | 1 |
| Debache, K; Hemphill, A | 1 |
| Gedamu, L; Getachew, F | 1 |
| Boisvert, S; Coelho, AC; Corbeil, J; Leprohon, P; Mukherjee, A; Ouellette, M | 1 |
| Adhikari, A; Bhattacharyya Majumdar, S; Gupta, G; Kar Mahapatra, S; Majumdar, S; Majumder, S; Mukherjee, AK | 1 |
| Magerl, M; Maurer, M; Metz, M; Siebenhaar, F; Weller, K | 1 |
| Chatterjee, M; Ghosh, S; Pakrashi, S; Roy, D; Sarkar, A; Sen, S | 1 |
| Benaim, B; Garcia, CR | 1 |
| Alves, EA; Kückelhaus, Cdos S; Kückelhaus, SA; Muniz-Junqueira, MI; Ponte, CB; Sampaio, RN; Urdapilleta, AA | 1 |
| Bories, C; Cojean, S; Haouchine, D; Houzé, S; Hubert, V; Huteau, F; Lariven, S; Le Bras, J; Loiseau, PM; Matheron, S; Michard, F; Pratlong, F | 1 |
| Bøhler, E | 1 |
| Castillo, H; Diaz-Toro, Y; Fernández, O; Ovalle, C; Perez, M; Saravia, NG; Valderrama, L; Valderrama, M | 1 |
| Abreu, S; Chaminade, P; Gaudin, M; Imbert, L; Laprévote, O; Libong, D; Loiseau, PM; Touboul, D | 1 |
| Bastien, P; Bendix, K; Christensen, M; d'Amore, F; Hellberg, YK; Larsen, CS; Petersen, E; Ravel, C; Schaumburg, H; Vase, MØ | 1 |
| Boelaert, M; Chakravarty, J; Dujardin, JC; Ostyn, B; Prajapati, VK; Rai, M; Singh, A; Singh, AK; Sundar, S | 1 |
| Kumar, M; Singh, N; Singh, RK | 1 |
| Balasegaram, M; Beijnen, JH; de Vries, PJ; Dorlo, TP; Huitema, AD; Lima, MA | 1 |
| Beijnen, JH; de Vries, PJ; Dorlo, TP; Huitema, AD | 1 |
| Bhutani, KK; Brahmbhatt, KG; Gohil, VM; Loiseau, PM | 1 |
| Acuña, AU; Amat-Guerri, F; Andreu, D; Bart, JM; de la Torre, BG; Hornillos, V; Luque-Ortega, JR; Navarro, M; Rivas, L; Rueda, C | 1 |
| Gupta, S; Sane, SA; Shakya, N; Vishwakarma, P | 1 |
| Bhandari, V; Deep, DK; Dujardin, JC; Kulshrestha, A; Prajapati, VK; Ramesh, V; Salotra, P; Schonian, G; Stark, O; Sundar, S | 1 |
| Andrade, Ida S; Catta-Preta, CM; Cavalcanti, DP; de Freitas-Junior, PR; de Souza, W; Einicker-Lamas, M; Motta, MC | 1 |
| Beijnen, JH; de Vries, PJ; Dorlo, TP; Eggelte, TA; Schoone, GJ | 1 |
| Bilbao-Ramos, P; Bolás-Fernández, F; Dea-Ayuela, MA; Galiana-Roselló, C; González-Alvarez, M; González-Rosende, ME; Pérez-Serrano, J; Rolón, M; Vega, C | 1 |
| Acuña, AU; Alonso, A; Alonso, L; Berardi, M; Ito, AS; Marquezin, CA; Mendanha, SA | 1 |
| Garg, R; Tremblay, MJ | 1 |
| Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA | 1 |
| Ghosal, S; Sahi, S; Tewatia, P | 1 |
| Das, P; Das, S; Pandey, K; Rabidas, VN; Rani, M; Sahoo, GC; Singh, D | 1 |
| Amer, EI; Eissa, MM | 1 |
| Balasegaram, M; Beijnen, JH; de Vries, PJ; Dorlo, TP | 1 |
| Ernst, W; Florian, C; Hanses, F; Ritter, U; Schleicher, U; Schmid, M; Wege, AK; Zimara, N | 1 |
| Bilbao, J; Duplisea, K; Guiot, MC; Kolyvas, G; Qvarnstrom, Y; Umar, I; Visvesvara, GS; Webster, D | 1 |
| Gonzaga dos Santos, M; Kemmer, G; Müller, FD; Pomorski, TG; Schiller, J; Weingärtner, A; Zampieri, RA | 1 |
| Azizan, A; Kyle, DE; Srivastava, A; Sweat, JM; Vesely, B | 1 |
| Gomes, MS; Gomes, P; Matos, J; Moreira, R; Tomás, A; Vale, N; Vale-Costa, S | 1 |
| Bieber, T; Biedermann, T; Brasch, J; Dominicus, R; Hunzelmann, N; Jakob, T; Magerl, M; Mahler, V; Maurer, M; Popp, G; Rother, M; Schäkel, K; Schlingensiepen, R; Schmitt, J; Siebenhaar, F; Simon, JC; Staubach, P; Wedi, B; Weidner, C | 1 |
| Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A | 1 |
| Brown, E; Castanys-Muñoz, E; Coombs, GH; Mottram, JC | 1 |
| Calogeropoulou, T; de Souza, W; Ishida, K; Prousis, K; Rozental, S; Vila, TV | 1 |
| Boelaert, M; Picado, A; Rijal, S; Sundar, S | 1 |
| Gupta, S; Kumar, S; Mittal, M; Suryawanshi, SN; Tiwari, A; Vishwakarma, P | 1 |
| Carreras, L; Costa, A; López, C; Rotger, C; Sanna, E; Vega, M | 1 |
| Arana, B; Berman, J; Chakravarty, J; Das, P; Das, VN; Jha, TK; Kumar, N; Narain, MK; Pandey, K; Rai, M; Sinha, P; Sundar, S; Verma, N | 1 |
| van Blitterswijk, WJ; Verheij, M | 1 |
| Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Sorrell, TC; Wiederhold, NP | 1 |
| Boelaert, M; Dorlo, TP; Dujardin, B; Dujardin, JC; Hasker, E; Ostyn, B; Rijal, S; Uranw, S | 1 |
| Bhandari, V; Dujardin, JC; Kulshrestha, A; Maes, L; Mukhopadhyay, R; Ramesh, V; Roy, S; Salotra, P; Sundar, S | 1 |
| Arana-Guajardo, A; Becker, I; Camacho-Ortiz, A; Muñoz-Garza, FZ; Ocampo-Candiani, J; Ordaz-Farias, A; Sevilla-Gonzalez, FK; Treviño-Garza, N | 1 |
| Pandey, K; Pun, SB; Shah, R | 1 |
| Chakravarty, J; Sundar, S | 1 |
| Bastin, P; Blisnick, T; Foucher, AL; Gharbi, S; Pemberton, IK; Rachidi, N; Späth, GF | 1 |
| Csongrádi, E; Dreisbach, AW; Ferguson, LM; Fulop, T; Juncos, LA | 1 |
| Azevedo, AM; Lúcio, M; Pinto, PC; Reis, S; Ribeiro, DM; Saraiva, ML | 1 |
| Arora, A; Chauhan, PM; Gupta, S; Pandey, AK; Rastogi, N; Sharma, R; Shivahare, R | 1 |
| Aguado, JM; Fernández-Ruiz, M; Jimenez-Huerta, I; Lalueza, A; López-Medrano, F; Silva, JT | 1 |
| Singh, A; Sundar, S | 2 |
| Alam, MM; Joh, EH; Kim, B; Kim, DH; Lee, YS; Park, H | 1 |
| Beijnen, JH; Bhattarai, NR; Boelaert, M; Das, ML; Decuypere, S; Dhakal, SS; Dorlo, TP; Dujardin, JC; Karki, P; Ostyn, B; Rai, K; Rijal, S; Singh, R; Uranw, S; Vanaerschot, M | 1 |
| Abebe, T; Hailu, A; Kassahun, A; Utaile, M | 1 |
| Barratt, G; Loiseau, PM; Michel, JP; Pham, TT; Saint-Pierre-Chazalet, M | 1 |
| Alonso, A; Hansen, D; Mendanha, SA; Moreira, RA | 1 |
| Boelaert, M; Dujardin, JC; Hasker, E; Malaviya, P; Ostyn, B; Rijal, S; Singh, RP; Sundar, S; Uranw, S | 1 |
| Lüder, CG; Ni Nyoman, AD | 1 |
| Berg, M; Dujardin, JC; Mannaert, A; Van Der Auwera, G; Vanaerschot, M | 1 |
| Buckley, N; Cheshenko, N; Gonzalez, P; Herold, BC; Jacobs, W; Stefanidou, M; Trepanier, JB | 1 |
| Bogdan, C; Debus, A; Ehrchen, J; Eichner, S; Harms, G; Herrgott, I; Sebald, H; Simon, M; Sunderkötter, C; Thoma-Uszynski, S; Tsianakas, A | 1 |
| Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J | 1 |
| Das, P; Das, S; Mandal, A; Pandey, K; Rabidas, VN | 1 |
| Acuña, AU; Castro, BM; Delgado, J; Fedorov, A; Hornillos, V; Mollinedo, F; Prieto, M | 1 |
| Cruz, C; Godoy, G; López, L; Robledo, SM; Vélez, ID | 1 |
| Campino, L; Henriques, S; Maia, C; Marques, M; Nunes, M; Rolão, N | 1 |
| Antoniou, M; Christodoulou, V; Koutala, E; Mazeris, A; Messaritakis, I; Papadogiorgaki, S; Vlahou, A | 1 |
| Abed, M; Alzoubi, K; Jacobi, J; Lang, F; Munoz, C | 1 |
| Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME | 1 |
| Blum, JA; Hatz, C; Mosimann, V; Neumayr, A | 1 |
| Biswas, C; Chen, SC; Djordjevic, JT; Jolliffe, KA; Sorrell, TC; Zuo, X | 1 |
| Arnold, A; Blum, J; Holbro, A; Neumayr, A; Stoeckle, M; Weisser, M | 1 |
| Das, M; Dubey, VK; Saudagar, P; Sundar, S | 1 |
| Agarwal, AK; Chen, YL; Clark, AM; Heitman, J; Jacob, MR; Khan, SI; Li, XC; Pan, X; Ravu, RR | 1 |
| Bhaskar, KR; Mondal, D; Nabi, SG; Salam, MA; Siddiqui, MA | 1 |
| Burza, S; Lima, MA; Mahajan, R; Mitra, G; Nabi, E | 1 |
| Mishra, J; Singh, S | 1 |
| Dujardin, JC; Ostyn, B; Prajapati, VK; Rai, M; Salotra, P; Sharma, S; Sundar, S; Vanaerschot, M | 1 |
| Avishek, K; Ramesh, V; Salotra, P; Sharma, V | 1 |
| Biswas, C; Boles, E; Chen, SC; Djordjevic, JT; Jolliffe, KA; Sorrell, TC; Zuo, X | 1 |
| Ali, N; Bhattacharya, P | 1 |
| Berg, M; Bhattarai, NR; Cuypers, B; Dujardin, JC; Ostyn, B; Rai, K; Rijal, S; Uranw, S; Vanaerschot, M | 1 |
| Barrera, MC; Castro, Mdel M; Fernández, OL; Gomez, MA; Gore Saravia, N; Obonaga, R; Rubiano, LC; Valderrama, L | 1 |
| Balabanova, MB; Berger, MR; Guenova, ML; Kaloyanov, KA; Konstantinov, SM; Prisadashka, K; Yosifov, DY | 1 |
| Mesquita, JT; Reimão, JQ; Tempone, AG | 1 |
| Dieterle, R; Pillekamp, H | 1 |
| Benchimol, M; de Andrade Rosa, I; de Souza, W; Rocha, DA | 1 |
| Gradziel, CS; Redfield, AG; Roberts, MF; Stec, B; Wang, Y | 1 |
| Beijnen, JH; Bhattarai, N; Boelaert, M; de Vries, PJ; Dorlo, TP; Dujardin, JC; Huitema, AD; Ostyn, B; Rijal, S; Singh, R; Uranw, S | 1 |
| Abengózar, MA; Acuña, AU; Amat-Guerri, F; Andreu, D; de la Torre, BG; Hornillos, V; Luque-Ortega, JR; Rivas, L | 1 |
| Kulshrestha, A; Salotra, P; Sharma, V; Singh, R | 1 |
| Belaz, S; Burel, A; Cabezas, Y; Daligault, F; Dureau, R; Ferrières, V; Gangneux, JP; Legentil, L; Manuel, C; Robert-Gangneux, F; Sergent, O; Suleman, M | 1 |
| Alonso, A; Alonso, L; Dorta, ML; Fernandes, KS; Matos, GG; Mendanha, SA; Moreira, RA | 1 |
| Boulet, G; Cos, P; Delputte, P; Dujardin, JC; Hendrickx, S; Lachaud, L; Maes, L; Mondelaers, A; Rijal, S | 1 |
| Alves, V; Salvador, JA; Santos, RC; Santos-Rosa, M; Sousa, MC; Varandas, R | 1 |
| Alencar, LP; Bandeira, Tde J; Brilhante, RS; Caetano, EP; Camargo, ZP; Castelo-Branco, Dde S; Cordeiro, Rde A; Lima, RA; Malaquias, AD; Marques, FJ; Monteiro, AJ; Moreira, JL; Rocha, MF; Rodrigues, AM; Sidrim, JJ; Silva, NF | 1 |
| Das, P; Das, S; Pandey, K; Rabidas, V; Rani, M; Sahoo, GC | 1 |
| Barbas, C; Canuto, GA; Castilho-Martins, EA; López-Gonzálvez, Á; Rivas, L; Tavares, MF | 1 |
| Biswas, C; Chen, SC; Djordjevic, JT; Forwood, JK; Jolliffe, KA; Schibeci, SD; Sorrell, TC; Zuo, X | 1 |
| Gupta, S; Haq, W; Kar, S; Parmar, N; Shivahare, R; Srivastava, M; Vishwakarma, P; Yadav, PK | 1 |
| Branco, LC; Costa, A; Duarte, CM; Florindo, C; Marrucho, IM; Matias, AN; Matos, C; Nunes, SL; Rebelo, LP | 1 |
| Arevalo, J; Dujardin, JC; Dumetz, F; Ponte-Sucre, A; Roy, S; Vanaerschot, M | 1 |
| Adderley, UJ; Holt, IG | 1 |
| Hommes, DW; Peppelenbosch, MP; van den Brink, GR; Verhaar, AP; Wildenberg, ME | 1 |
| Dynarowicz-Łątka, P; Kwiatek, W; Lipiec, E; Wnętrzak, A; Łątka, K | 1 |
| Diaz-Toro, Y; Fernández, OL; Gomez, MA; Muvdi, S; Ovalle, C; Rodríguez, I; Saravia, NG; Valderrama, L | 1 |
| Carnielli, JB; Carvalho, SF; Chapeaurouge, AD; de Andrade, HM; Dietze, R; Figueiredo, SG; Lemos, EM; Monti-Rocha, R; Perales, J; Pires, SF; Ribeiro, LP | 1 |
| Jiang, J; Mathur, R; Pandharkar, T; Schmittgen, TD; Shaha, C; Werbovetz, KA; Zhu, X | 1 |
| Burza, S; Patole, S; Varghese, GM | 1 |
| A Terkawi, M; AbouLaila, M; Batadoj, D; Ichikawa-Seki, M; Igarashi, I; Munkhjargal, T; Salama, A; Yokoyama, N | 1 |
| Boelaert, M; Dorlo, TP; Dujardin, JC; Hasker, E; Ostyn, B; Rijal, S; Sundar, S | 1 |
| Abreu, S; Barratt, G; Chaminade, P; Cheron, M; Gueutin, C; Loiseau, PM; Pham, TT | 1 |
| Boelaert, M; Diro, E; Hailu, A; Lynen, L; Ritmeijer, K; van Griensven, J | 1 |
| Barrio, A; Basombrío, MA; Cardozo, RM; Cimino, RO; de Raspi, EM; García Bustos, MF; Parada, LA; Parodi, C; Prieto, GG; Soto, J; Uncos, DA; Yeo, M | 1 |
| Coelho, AC; Costa, CH; Trinconi, CT; Uliana, SR | 2 |
| Doshi, P | 1 |
| Dannaoui, E; Datry, A; Fekkar, A; Imbert, S; Mazier, D; Meyer, I; Palous, M | 1 |
| Bosschaerts, T; Caridha, DP; Fortin, A; Grogl, M; Hickman, MR; Hudson, TH; Leed, S; Ngundam, F; Parriott, S; Sena, J | 1 |
| Debastiani, RG; Greggianin, GF; Polli, DA; Ribeiro, JB; Sampaio, RN; Santarem, AA | 1 |
| Dakir, EL; Dakir, el H; López-Abán, J; Mollinedo, F; Muro, A; Varela-M, RE; Yepes, E | 1 |
| Barrio, A; Basombrio, MA; Beckar, J; Garcia Bustos, MF; Moreno, S; Parodi, C | 1 |
| Burden-Teh, E; Williams, HC; Wootton, CI | 1 |
| Acuña, AU; Barioni, MB; Ito, AS; Ramos, AP; Zaniquelli, ME | 1 |
| Gupta, S; Kant, P; Kumar, S; Shivahare, R; Suryawanshi, SN; Tiwari, A | 1 |
| Cabello, J; Mohler, WA; Mollinedo, F; Reis-Sobreiro, M; Rodríguez-Matellán, AG; Sáenz-Narciso, B; Sánchez-Blanco, A | 1 |
| Chatterjee, M; Singh, N; Sundar, S | 1 |
| Bell, AS; Heal, WP; Hutton, JA; Leatherbarrow, RJ; Paape, D; Smith, DF; Tate, EW | 1 |
| Bosschaerts, T; Boulet, G; Cos, P; Fortin, A; Maes, L; Paulussen, C | 1 |
| Botterel, F; Bougnoux, ME; Compain, F; Dannaoui, E; Paugam, A; Sitterlé, E | 1 |
| López-Vélez, R; Monge-Maillo, B | 1 |
| Coelho, AC; Cotrim, PC; Oliveira, JC; Reimão, JQ; Trinconi, CT; Uliana, SR | 1 |
| Borba-Santos, LP; de Souza, W; Gagini, T; Ishida, K; Rozental, S | 1 |
| Chakravarty, J; Rai, M; Singh, A; Sundar, S | 1 |
| Bukovský, M; Chereches, G; Devínsky, F; Fischer-Fodor, E; Garajová, M; Karlovská, J; Kubincová, J; Lukáč, M; Mrva, M; Ondriska, F; Timko, L | 1 |
| Blankschtein, D; de Sá, MM; Rangel-Yagui, CO; Sresht, V | 1 |
| Azas, N; Castera-Ducros, C; Cohen, A; Hutter, S; Kieffer, C; Laget, M; Paloque, L; Rathelot, P; Rault, S; Valentin, A; Vanelle, P; Verhaeghe, P | 1 |
| Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Lachaud, L; Maes, L; Mondelaers, A | 1 |
| Fernández, ML; García, E; Ramírez, F | 1 |
| Alvar, J; Coumbarides, GS; Croft, SL; Hawkes, GE; Kaur, H; Seifert, K | 1 |
| Fujinami, N; Shah, PJ; Vakil, NH | 1 |
| de Castro, W; Dey, R; Gangalum, PR; Majumdar, S; Rivas, L; Saha, B; Singh, S; Vieira, LQ | 1 |
| Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Maes, L; Mondelaers, A | 1 |
| Cerrone, A; Corso, R; Galiero, G; Gravino, AE; Manna, L; Muzj, P | 1 |
| Fernández, OL; Gonzalez-Fajardo, L; McMahon-Pratt, D; Saravia, NG | 1 |
| Badri Prasad, B; Poonam, L; Shakya, A; Smriti, K | 1 |
| Amer, EI; Barakat, AM; Eissa, MM; Younis, LK | 1 |
| Ali, W; Gupta, S; Natu, SM; Puri, SK; Shivahare, R; Vishwakarma, P | 1 |
| Boelaert, M; Burza, S; Das, P; Isaakidis, P; Kumar, D; Lima, MA; Mahajan, R; Mitra, G; Pandey, K; Sagili, KD; Sunyoto, T; Van Geertruyden, JP | 1 |
| Cappel, MA; Keeling, JH; Kevric, I | 1 |
| Coelho, AC; Senra, L; Trinconi, CT; Uliana, SR; Yokoyama-Yasunaka, JK | 1 |
| Beijnen, JH; Castro, MM; Dorlo, TP; Gomez, MA; Hillebrand, MJ; Kip, AE; Rosing, H; Schellens, JH | 1 |
| Barbhuiya, JN; Chatterjee, M; Das, NK; Ghosh, S; Hazra, A; Mukherjee, S; Mukhopadhyay, D | 1 |
| Brilhante, RS; Caetano, EP; Castelo Branco, DS; Cordeiro, RA; Lima, RA; Monteiro, AJ; Oliveira, JS; Rocha, MF; Serpa, R; Sidrim, JJ | 1 |
| McDowell, MA; Morales, MA; Robles-Murguia, M; Turner, KG; Vacchina, P; Wadsworth, M | 1 |
| Bhattarai, NR; Cos, P; Delputte, P; Dujardin, JC; Eberhardt, E; Hendrickx, S; Maes, L; Mondelaers, A; Rijal, S | 1 |
| Badiee, A; Farzaneh, H; Golmohammadzadeh, S; Jaafari, MR; Sadri, K; Teymouri, M | 1 |
| Amorim, AAS; de Souza Filho, J; Garcia, RD; Gomes, MRA; Graziani, D; Lima, AV; Miranda-Vilela, AL; Moreira, JR; Primo, FL; Ribeiro, JBP; Sampaio, RNR; Tedesco, AC | 1 |
| Atkins, JT; Dorlo, TP; Gennuso, R; Guglielmo, BJ; Hayes, T; Kofos, D; Kucerova, Z; Qvarnstrom, Y; Roy, SL; Sriram, RR; Visvesvara, GS | 1 |
| Aguiar, MG; de Morais-Teixeira, E; Ferreira, LA; Rabello, A; Soares de Souza Lima, B | 1 |
| Das, M; Dubey, VK; Saha, G; Saikia, AK | 1 |
| Machado Vila, TV; Rozental, S; Sousa Quintanilha, N | 1 |
| Kesselheim, AS; Maggs, LR; Sarpatwari, A | 1 |
| Chaturvedi, AK; Lopez-Ribot, JL; Rozental, S; Vila, TV | 1 |
| Basu, N; Bera, DK; Chatterjee, M; Ganguly, S; Ghosh, TK; Guha, SK; Kundu, PK; Maji, AK; Roy, S; Saha, P | 1 |
| Avishek, K; Deep, DK; Ramesh, V; Salotra, P; Singh, R; Verma, A; Verma, S | 1 |
| Chatterjee, M; Das, NK; Ghosh, S; Mukherjee, S; Mukhopadhyay, D; Roy, S; Saha, B | 1 |
| Amer, EI; Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA | 1 |
| Ansari, MY; Das, P; Das, VNR; Kumar, R; Pandey, K; Rana, S; Sahoo, GC; Topno, RK | 1 |
| Couwenberg, SM; Kortbeek, LM; Schadd, EM; Stijnis, C; van der Snoek, EM | 1 |
| Cohen, N; Conrad, DA; Cope, JR; Cotilla, M; DaSilva, A; Jackson, J; Visvesvara, GS | 1 |
| Blackburn, G; Carter, KC; Coombs, GH; Cotton, JA; Downing, T; Dujardin, JC; Freeman, TM; Illingworth, CJ; Imamura, H; Khanal, B; Lonchamp, J; Rijal, S; Sanders, M; Shaw, CD | 1 |
| Beijnen, JH; Blesson, S; Diro, E; Dorlo, TP; Hailu, A; Hillebrand, MJ; Kip, AE; Mengesha, B; Rosing, H; Schellens, JH | 1 |
| Chandrakar, P; Kar, S; Parmar, N; Vishwakarma, P; Yadav, PK | 1 |
| Coelho, AC; Reimão, JQ; Trinconi, CT; Uliana, SR | 1 |
| Bhattacharya, SK; Dash, AP | 2 |
| Dohmen, LC; Dorlo, TP; Gomez, MA; Gregory, DJ; Kip, A; Navas, A; Vargas, DA | 1 |
| Jaiswal, S; Lal, J; Sharma, A; Shukla, M | 1 |
| Alonso, A; Alonso, L | 1 |
| Dunn, AL; Levy, RA; Reed, T; Stewart, C | 1 |
| Aguilar, F; Cantizani, J; Coteron, JM; Croft, SL; Díaz, R; Martin, JJ; Peña, I; Presa, JL; Tegazzini, D; Yardley, V | 1 |
| Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA | 1 |
| Beyers, J; Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Lachaud, L; Maes, L; Mondelaers, A | 1 |
| Abengózar, MA; Morales, MA; Norris-Mullins, B; Pfrender, ME; Rivas, L; Sarro, J; Stephens, MT; Vacchina, P; Viamontes, CG | 1 |
| Caljon, G; Castanys, S; Cos, P; Cotton, J; Cuypers, B; Delputte, P; Dujardin, JC; Eberhardt, E; Gamarro, F; Garcia-Hernandez, R; Hendrickx, S; Imamura, H; Lachaud, L; Maes, L; Mondelaers, A; Sanchez-Cañete, MP; Sanders, M | 1 |
| Coelho, AC; Espada, CR; Oliveira, JC; Reimão, JQ; Trinconi, CT; Uliana, SR | 1 |
| Jett, S; Linam, WM; Sherin, K | 1 |
| Baker, J; Ghosh, D; Ghosh, P; Hamano, S; Haque, R; Hasnain, MG; Hossain, H; Hossain, MS; Matlashewski, G; Mondal, D; Nath, R | 1 |
| Croft, SL; Murdan, S; Van Bocxlaer, K; Yardley, V | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Bifeld, E; Clos, J; Höhn, K; Tejera Nevado, P | 1 |
| Mukherjee, J; Phillips, D; Roberts, RM | 1 |
| Chirouze, C; Faucher, JF; Hoen, B; Le Moing, V; Morquin, D; Reynes, J | 1 |
| Akhtari, J; Badiee, A; Golmohammadzadeh, S; Jaafari, MR; Mellat, M; Nikpoor, AR; Sadri, K; Teymouri, M | 1 |
| Ali, W; Gupta, S; Khattri, S; Natu, SM; Puri, SK; Shivahare, R; Singh, US | 1 |
| Gajate, C; Legarda-Ceballos, AL; López-Abán, J; Mollinedo, F; Muro, A; Rojas-Caraballo, J; Ruano, AL; Yepes, E | 1 |
| Caljon, G; Eberhardt, E; Hendrickx, S; Maes, L; Mondelaers, A; Van den Kerkhof, M | 1 |
| Laffitte, MC; Légaré, D; Leprohon, P; Ouellette, M | 1 |
| Gayen, JR; Husain, A; Italiya, KS; Javia, D; Mishra, PR; Riyazuddin, M; Singh, SK; Syed, AA; Tripathi, P; Valicherla, GR | 1 |
| Alves, HJ; Castelo Branco, PV; de Castro Belfort, MR; de Jesus, LC; Ferreira Pereira, SR; Moreira, VR; Silva, VL; Soares, RE | 1 |
| Barioni, MB; da Gama Bitencourt, JJ; de Paula Pinto, C; Guimarães, TH; Ito, AS; Pazin, WM; Santos, MA; Santos, MR; Valduga, CJ | 1 |
| Beltrán-López, E; Enciso, E; López-Moreno, HS; Ochoa-Terán, A; Osuna-Martínez, U; Sarmiento-Sánchez, JI | 1 |
| Bezerra-Souza, A; Laurenti, MD; Passero, LF; Ribeiro, SP; Yamamoto, ES | 1 |
| Borba-Santos, LP; Calogeropoulou, T; Ishida, K; Rozental, S; Souza, Wd | 1 |
| Dayakar, A; Gangappa, D; Kalangi, SK; Maurya, RS; Narayana Rao, D; Sathyavathi, R | 1 |
| Alexander, N; Ali, MH; Alves, F; Balasegaram, M; Dorlo, TP; Edwards, T; Elamin, MY; Ellis, S; Hailu, A; Juma, R; Khalil, EA; Kimutai, R; Kip, AE; Kirigi, G; Musa, A; Musa, B; Njenga, S; Olobo, J; Omollo, R; Schoone, GJ; Strub Wourgaft, N; Wasunna, M; Wells, S | 1 |
| Das Gupta, RK; Das, P; Dhariwal, AC; Pandey, K; Ravidas, V; Siddiqui, NA; Singh, TP; Sinha, SK; Verma, RB | 1 |
| Ishida, K; Rozental, S; Seabra, SH; Vila, T | 1 |
| Ghosh, P; Hamano, S; Hasnain, G; Hossain, S; Mondal, D; Rashid, MO; Shomik, MS | 1 |
| Boelaert, M; Hasker, E; Singh, OP; Sundar, S | 1 |
| Kritsepi-Konstantinou, M; Mylonakis, ME; Oikonomidis, IL; Papadimitriou, S; Psalla, D; Tangalidi, MK | 1 |
| Lindsley, CW | 1 |
| Aguado, JM; Alonso-Moralejo, R; Andrés, A; Carrasco-Antón, N; Fernández-Ruiz, M; González, E; López-Medrano, F; Pérez-Jacoiste Asín, MA; San Juan, R | 1 |
| Alonso, A; de Souza, PE; Dorta, ML; Fernandes, KS | 1 |
| Ali, V; Bimal, S; Das, P; Das, VNR; Lal, CS; Murti, K; Pal, B; Pandey, K; Siddiqi, NA; Topno, RK; Verma, N; Verma, RB | 1 |
| Caljon, G; Croft, SL; Guerin, PJ; Hendrickx, S; Maes, L | 1 |
| Carlson, ES; Morales, MA; Norris-Mullins, B; Vacchina, P | 1 |
| Brotherton, MC; Fernandez-Prada, C; Leprohon, P; Ouellette, M; Rivas, L; Roberts, M; Roy, G; Smith, TK; Vincent, IM | 1 |
| Arora, SK; Ratna, A | 1 |
| Goyal, N; Gupta, KC; Kumar, P; Pahuja, R; Rath, SK; Tiwari, B | 1 |
| Beijnen, JH; Dorlo, TPC; Kiers, KC; Kip, AE; Rosing, H; Schellens, JHM | 1 |
| Botero, A; Keatley, S; Peacock, C; Thompson, RC | 1 |
| Anand, D; Kar, S; Maurya, RK; Parmar, N; Patel, OP; Raju, KS; Taneja, I; Vishwakarma, P; Wahajuddin, M; Yadav, PK; Yadav, PP | 1 |
| Bairwa, G; Bakkeren, E; Caza, M; Hu, G; Kretschmer, M; Kronstad, J; Reiner, E | 1 |
| Ali, I; Babik, JM; Brondfield, MN; Cope, JR; DeMarco, T; Doernberg, SB; Hilts-Horeczko, A; Klein, L; Matanock, A; Reid, MJ; Ritter, JM; Rutishauser, RL; Tang, J | 1 |
| Carvalho, EM; Coelho, AC; Dorta, ML; Espada, CR; Machado, PR; Pereira, LIA; Ribeiro-Dias, F; Schriefer, A; Uliana, SRB; Yokoyama-Yasunaka, JKU | 1 |
| Amer, A; Asal, AM; Bekhit, AA; El-Faham, A; Guemei, AA; Haiba, NS; Khattab, SN | 1 |
| López-Arencibia, A; Lorenzo-Morales, J; Maciver, SK; Martín-Navarro, C; Piñero, JE; Reyes-Batlle, M; Sifaoui, I; Wagner, C | 1 |
| Barreira, L; Bruno de Sousa, C; Campino, L; Conserva, GA; Custódio, L; Gangadhar, KN; Lago, JH; Laurenti, MD; Levy, D; Morais, TR; Passero, LF; Pereira, H; Uemi, M; Varela, J; Vizetto-Duarte, C | 1 |
| Davies, M; Godfrey, AR; Jones, L; Townsend, R | 1 |
| Dubey, VK; Kumar, R; Tiwari, K | 1 |
| Ishida, K; Nosanchuk, JD; Rossi, DCP; Spadari, CC; Taborda, CP | 1 |
| Babu, NK; Kumar, R; Kumar, V; Singh, S; Soumya, N; Yadav, S | 1 |
| Castro, MDM; Cossio, A; Osorio, L; Velasco, C | 1 |
| Bartlett, AH; Berger, BA; Castro, MDM; Cossio, A; Pho, MT; Prada, S; Saravia, NG | 1 |
| Antinarelli, LMR; Carmo, AML; Coimbra, ES; da Silva, AD; Gameiro, J; Stroppa, PHF | 1 |
| Esposito, S; Pagliano, P | 1 |
| Caljon, G; Cos, P; Delputte, P; Hendrickx, S; Mabille, D; Maes, L; Van den Kerkhof, M | 1 |
| Cantizani, J; Coterón, JM; Martín, J; Peña, I; Tegazzini, D | 1 |
| Alvar, J; Alves, F; Balasegaram, M; Boer, MD; Ellis, S; Faiz, A; Goyal, V; Haque, R; Jamil, K; Rahman, R; Rijal, S; Samad, R; Sharma, B; Strub-Wourgaft, N | 1 |
| Bhandari, V; Deep, DK; Dujardin, JC; Ramesh, V; Salotra, P; Sharma, V; Singh, R; Sundar, S; Verma, A; Wajid, S | 1 |
| Boelaert, M; Chakravarty, J; Hasker, E; Kansal, S; Kumar, A; Malaviya, P; Ostyn, B; Sundar, S | 1 |
| Croft, SL; Murdan, S; Van Bocxlaer, K; Wijnant, GJ; Yardley, V | 1 |
| Fanani, ML; Zulueta Díaz, YLM | 1 |
| Acosta, IC; Koch, G; Kricks, L; Lopez, D; Stengel, ST; Wermser, C; Yepes, A | 1 |
| Arrese Estrada, J; Cnops, L; Darcis, G; de Leval, L; Giot, JB; Hayette, MP; Leonard, P; Moutschen, M; Tassin, F; Van der Auwera, G | 1 |
| Dube, A; Jaiswal, AK; Mishra, PR; Tripathi, P | 1 |
| Alim, D; Andes, DR; Bapat, P; Husain, F; Nobile, CJ; Panwar, SL; Rastogi, S; Ror, S; Sircaik, S; Srivastava, A; Thomas, E | 1 |
| Machado-Alba, JE; Machado-Duque, ME; Medina-Morales, DA | 1 |
| Amer, EI; Doenhoff, MJ; Eissa, MM; El-Azzouni, MZ; El-Faham, MH; Igetei, JE; Liddell, S | 1 |
| Das, AK; Khanra, S; Manna, M; Roy, S; Sarraf, NR | 1 |
| de Paula, E; Giorgio, S; Ortega, V | 1 |
| Bassères, DS; Cerize, NNP; Feitosa, VA; García, MC; Gomes-Filho, SM; Lourenço, FR; Pachioni-Vasconcelos, JA; Rangel-Yagui, CO; Valenzuela-Oses, JK | 1 |
| Alves, F; Balasegaram, M; Beijnen, JH; Dorlo, TPC; Ellis, SJ; Hailu, A; Karlsson, MO; Khalil, EAG; Kip, AE; Kirigi, G; Musa, AM; Njenga, S; Olobo, J; Wasunna, M; Younis, BM | 1 |
| Chatterjee, M; Chaudhuri, SJ; Das, NK; Ghosh, M; Moulik, S; Saha, B; Sardar, B | 1 |
| Al-Shargabi, TQ; Atta, KFM; Bekhit, AA; El Ashry, ESH; Farahat, OOM; Ibrahim, TM; Marei, MG | 1 |
| Lockwood, DN; Patel, TA; Phillips, DE; Scadding, GK | 1 |
| Basak, S; Chatterjee, A; Chowdhury, T; Mohanta, A; Pradhan, A | 1 |
| Benaim, G; Hernandez-Rodriguez, V; Pinto-Martinez, AK; Rodriguez-Durán, J; Serrano-Martin, X | 1 |
| Das, S; Giri, S; Shaha, C; Sundar, S | 1 |
| Bhalla, P; Chiranjivi, AK; Dubey, VK; Saikia, AK; Sultana, S | 1 |
| Fernando, SD; Rajapakse, S; Rodrigo, C; Weeratunga, P | 1 |
| Ansart, S; Garcia Hermoso, D; Jaffuel, S; Lanternier, F; Lortholary, O; Moalic, E; Quaesaet, L; Stindel, E; Williams, T | 1 |
| Caljon, G; Hendrickx, S; Maes, L; Mondelaers, A; Van Bockstal, L | 1 |
| Bolás-Fernández, F; Castillo, R; Dea-Ayuela, MA; Hernández-Campos, A; Maldonado-Rangel, A; Matius-Ruiz, JB; Méndez-Cuesta, C; Nieto-Meneses, R; Nogueda-Torres, B; Trejo-Soto, PJ; Yépez-Mulia, L | 1 |
| Almustafa, ZZ; Peitsch, WK; Sasama, B | 1 |
| Barrett, MP; Dujardin, JC; Gamarro, F; García-Hernández, R; López-Vélez, R; Mwenechanya, R; Papadopoulou, B; Ponte-Sucre, A; Pountain, AW | 1 |
| Kumar, D; Sundar, S; Tiwary, P | 1 |
| Agarwal, D; Sundar, S | 1 |
| Alves, SH; Loreto, ES; Oliveira, DC; Santurio, JM; Tondolo, JSM | 1 |
| Cordeiro-da-Silva, A; Dantas-Torres, F; Miró, G; Travi, BL | 1 |
| Hamzavi, SS; Kadivar, MR; Pouladfar, G; Pourabbas, B; Sanaei Dashti, A | 1 |
| Das, P; Vijayakumar, S | 1 |
| Alonso-Herranz, V; Alqaisi, AQI; Armitage, EG; Barbas, C; Barrett, MP; Denny, PW; Gabarro, R; Godzien, J; López-Gonzálvez, Á; Martín, J; Mbekeani, AJ; Peña, I | 1 |
| Calogeropoulou, T; de Souza, W; Oliveira-Menezes, A; Pinheiro, J; Railbolt, M; Sant'Anna, V | 1 |
| Croft, SL; Harris, A; Seifert, K; Sepúlveda, N; Standing, JF; Voak, AA | 1 |
| de Paula, E; Dhorm Pimentel de Moraes, AR; Giorgio, S; Soares Rocha, FJ; Tavares, GD | 1 |
| Checa, R; Fariñas, F; Fermín, ML; Flores, L; Fragío, C; Gálvez, R; Marino, V; Martínez-Nevado, E; Miró, G; Montoya, A; Rojo, C; Troyano, A | 1 |
| Bresson, E; Fernandez-Prada, C; Leprohon, P; Ouellette, M; Plourde, M; Roy, G; Sharma, M | 1 |
| Arvelo, F; Benaim, G; Dagger, F; Kouznetsov, VV; Mejías, F; Rojas-Ruiz, FA; Sojo, F; Torrealba, C; Valdivieso, E | 1 |
| Aguado, B; Camacho, E; Castanys, S; Corvo, L; Dujardin, JC; Gamarro, F; García-Hernández, R; Imamura, H; Rastrojo, A; Requena, JM; Vargas, P | 1 |
| Heli, H; Karimian, K; Motazedian, MH; Nazari-Vanani, R; Sattarahmady, N; Sharifi, F; Vais, RD | 1 |
| Beijnen, JH; Castro, MDM; Cossio, A; Dorlo, TPC; Gomez, MA; Kip, AE; Saravia, NG; Schellens, JHM | 1 |
| Das, S; Halder, A; Mukherjee, A; Roy, P; Saha, B; Shukla, D | 1 |
| Abongomera, C; Ahmed, F; Buyze, J; de Lima Pereira, A; Diro, E; Ritmeijer, K; Stille, K; van Griensven, J | 1 |
| Ishida, K; Rozental, S; Spadari, CC; Vila, T | 1 |
| Alunda, JM; Corral, MJ; Costi, MP; Escribano, MD; García-Calvo, E; Gutiérrez, C; Jiménez-Antón, MD; Kayali, N; Luque-García, JL; Olías-Molero, AI; Torrado, JJ | 1 |
| Carrillo, E; Mejías, F; Moreno, J; Sánchez, C; Valdivieso, E | 1 |
| Carrer, DC; Moody, D; Peralta, MF; Smith, H; Tristram-Nagle, S | 1 |
| Huyghues Despointes, CE; Kima, PE; Prasad, S; Young, J; Zhang, N | 1 |
| Escrivani-Oliveira, D; Falcão, CAB; Philipon, CIMDS; Rossi-Bergmann, B; Sousa-Batista, AJ | 1 |
| Cantizani, J; De Muylder, G; Dujardin, JC; Hefnawy, A; Manzano, P; Martin, J; Peña, I; Rijal, S | 1 |
| Almeida-Amaral, EE; Emiliano, YSS | 1 |
| Calixto, SL; Coimbra, ES; da Silva, AD; da Trindade Granato, J; DaMatta, RA; Glanzmann, N; Gorza Scopel, KK; Macedo, GC; Torres de Aguiar, T; Xavier Silveira, MM | 1 |
| Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V | 1 |
| Caljon, G; Cos, P; Delputte, P; Gielis, JF; Hendrickx, S; Maes, L; Van Bockstal, L; Van den Kerkhof, M | 1 |
| Alvar, J; Alves, F; Dorlo, TPC; Egondi, TW; Kimutai, R; Kip, AE; Kirigi, G; Mbui, J; Olobo, J; Omollo, R; Omollo, T; Sagaki, P; Solomos, A; Wasunna, M; Were, L | 1 |
| Aktar, F; Anuwarul, A; Basher, A; Islam, MR; Maruf, S; Mondal, D; Nath, P | 1 |
| Brown, E; Carnielli, JBT; Carvalho, SFG; Costa, CHN; Costa, DL; Crouch, K; Damasceno, JD; Dickens, NJ; Dietze, R; Forrester, S; Jeffares, DC; Mottram, JC; Silva, VC | 1 |
| Arcos, D; Prieto, MD; Uribe-Restrepo, AF; Vargas, DA | 1 |
| Bhattacharya, A; Ouellette, M | 1 |
| Aguilar, LF; Colina, JR; Jemiola-Rzeminska, M; Petit, K; Strzalka, K; Suwalsky, M | 1 |
| Alvar, J; Alves, F; Balasegaram, M; Bern, C; Burza, S; Das, P; Ellis, S; Goyal, V; Hightower, A; Lima, N; Mahajan, R; Pandey, K; Rabi Das, VN; Rijal, S; Sharma, B; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T; Topno, RK | 1 |
| Alves, SH; de Azevedo, MI; de Jesus, FPK; Kommers, GD; Loreto, ES; Santurio, JM; Tondolo, JSM; Verdi, CM; Weiblen, C; Zanette, RA | 1 |
| Actis, LA; Arivett, BA; Beckett, AC; Fiester, SE; Grier, JT; Ohneck, EJ; Schmidt, RE; Wagner, BR | 1 |
| Bulté, D; Caljon, G; Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Maes, L; Van Bockstal, L; Van den Kerkhof, M | 1 |
| Brilhante, RSN; Castelo-Branco, DSCM; Cordeiro, RA; de Camargo, ZP; de Oliveira, JS; Garcia, LGS; Guedes, GMM; Maciel, JM; Pereira, VS; Pereira-Neto, WA; Rocha, MFG; Rodrigues, AM; Sidrim, JJC; Silva, INGD; Silva, MLQD | 1 |
| New, D; Rogers, BA | 1 |
| Castro, MDM; Cossio, A; Dávalos, D; Desai, MM; Uribe-Restrepo, A | 1 |
| Berry, A; Delavigne, K; Delobel, P; Guerveno, C; Martin-Blondel, G | 1 |
| Bulté, D; Caljon, G; Cos, P; Delputte, P; Hendrickx, S; Maes, L; Van den Kerkhof, M | 1 |
| Bagga, B; Chandran, K; Garg, P; Jayabhasker, P; Joseph, J; Manjulatha, K; Sharma, S | 1 |
| Alves, HJ; Castelo-Branco, PV; Ferreira Pereira, SR; Maciel-Silva, VL; Pontes, RL | 1 |
| Gupta, U; Hira, SK; Kashif, M; Khan, FI; Manna, PP; Paladhi, A; Rub, A; Singh, R; Upadhyaya, A | 1 |
| Fernández, OL; Gómez, MA; Martínez-Salazar, B; Regli, IB; Saravia, NG; Tacchini-Cottier, F | 1 |
| Admassu, H; Alexander, N; Alvar, J; Alves, F; Bardonneau, C; Blesson, S; Diro, E; Edwards, T; Ellis, SJ; Fikre, H; Hailu, A; Kibret, A; Kimutai, R; Mutinda, B; Omollo, R; Omwalo, G; Ritmeijer, K; Soipei, P; Strub-Wourgaft, N; Tadesse, F; Wasunna, M; Zijlstra, EE | 1 |
| Alvar, J; Boelaert, M; Das, P; Mondal, D; Rijal, S; Sundar, S | 1 |
| Carvalho, GB; Carvalho, SH; Frézard, F; Moura, AS; Pereira, NP; Ramos, LMQC; Rocha, MOC | 1 |
| Alvarez-Aular, A; Arvelo, F; Bello Forero, JS; Buscema, I; García-Marchan, Y; Kouznetsov, VV; Leañez, J; Nuñez, J; Rodriguez, D; Serrano-Martín, X; Sojo, F | 1 |
| Avino, VC; Dos Santos Nogueira, F; Galvis-Ovallos, F; Menz, I; Molla, LM; Moreira, MAB; Pereira-Chioccola, VL; Romariz, APPL | 1 |
| den Boer, ML; Essink, DR; Pijpers, J; Ritmeijer, K | 1 |
| Álvarez-Velilla, R; Balaña-Fouce, R; Fresno, M; Gutiérrez-Corbo, MDC; Pérez-Pertejo, MY; Punzón, C; Reguera, RM | 1 |
| Abongomera, C; Adera, C; Battaglioli, T; Ritmeijer, K | 1 |
| Escobar, P; Mantilla, JC; Neira, LF | 1 |
| Cerón, JJ; Checa, R; Daza González, MA; Fermín Rodríguez, M; Fragío Arnold, C; Martínez Subiela, S; Miró, G; Montoya, A; Portero Fuentes, M; Rupérez Noguer, C | 1 |
| Alves, JM; Carvalho, EM; Coelho, AC; Cruz, AK; Cruz, MC; Espada, CR; Hornillos, V; Machado, PR; Magalhães, RM; Schriefer, A; Uliana, SRB | 1 |
| Calderón-Gomezcaseres, Á; Rodriguez-Morales, AJ; Villamil-Gómez, WE | 1 |
| Barroso, DH; Freire, GSM; Gomes, CM; Martins, SS; Motta, JOCD; Paula, CDR; Pereira, LIA; Porto, C; Sampaio, RNR; Silva, JSFE | 1 |
| Alipour, A; Hosseinzadeh, A; Iranpour, S | 1 |
| Alexandre-Moreira, MS; Alves, MA; Barreiro, EJ; Cavalcanti de Queiroz, A; Lima, LM | 1 |
| Azas, N; Basmaciyan, L; Casanova, M; Robinson, DR | 1 |
| Alonso, A; Alonso, L; Cardoso, ÉJS; Mendanha, SA | 1 |
| Beijnen, JH; Bhairosing, P; Dorlo, TPC; Palić, S | 1 |
| Akter, D; Azim, A; Basher, A; Chowdhury, IH; Faiz, MA; Habibullah, AM; Nath, P; Nath, R; Rashid, MM | 1 |
| Chandrasekaran, S; Dayakar, A; Devender, M; Maurya, R; Prajapati, VK; Sundar, S; Veronica, J | 1 |
| Alavizadeh, SH; Badiee, A; Golmohamadzadeh, S; Jaafari, MR; Kavian, Z; Khamesipour, A | 1 |
| Azas, N; Basmaciyan, L; Casanova, M | 1 |
| Aouthmany, S; Cooper, AM; Rega, PP; Shah, K | 1 |
| Alsford, S; Baker, N; Collett, CF; Horn, D; Hutchinson, S; Kitson, C; Santrot, MV; Steele-Stallard, HB | 1 |
| Dewan, N; Holland, SP; Iovieno, A; Ming, W; Yeung, SN | 1 |
| Georgiev, G; Maslenkova, L; Momchilova, A; Pankov, R; Skrobanska, R; Stoyanova, T; Tsonchev, Z; Tzoneva, R; Uzunova, V | 1 |
| Chen, M; Iovanna, JL; Lan, W; Liu, X; Luo, B; Peng, L; Xia, Y; Zhou, Z | 1 |
| Andro, H; Gulshan, K; Hazen, JE; Iacano, AJ; Lewis, H; Smith, JD | 1 |
| de Bastiani, FWMDS; Ishida, K; Lopes, LB; Spadari, CC | 1 |
| Jalal, R; Lari, N; Minuchehr, Z; Rajabian Noghondar, M | 1 |
| Carregal, VM; Demicheli, C; Frézard, F; Fujiwara, RT; Islam, A; Lanza, JS; Rivas, L; Souza, DM | 1 |
| Carnielli, JBT; Carvalho, SFG; Costa, CHN; Costa, DL; Dietze, R; Molina Sesana, A; Monti-Rocha, R; Mottram, JC; Pansini, LNN; Segatto, M | 1 |
| Botschuijver, S; de Jonge, WJ; Elferink, RPO; Heinsbroek, SEM; Jennings, G; Keszthelyi, D; Maria-Ferreira, D; Saia, RS; Schuren, FHJ; Strik, AS; van den Wijngaard, RM; van Diest, SA; van Thiel, IAM; Welting, O; Yu, Z | 1 |
| Ainslie, KM; Bachelder, EM; Fuchs, JR; Johnson, MM; Satoskar, AR; Tokarski, RJ; Zahid, MSH | 1 |
| Barrias, E; Calogeropoulou, T; de Souza, W; Reignault, LC | 1 |
| Braga, SS | 1 |
| Caljon, G; Hendrickx, S; Kamhawi, S; Maes, L; Meneses, C; Sádlová, J; Suau, HA; Van Bockstal, L; Volf, P | 1 |
| Alunda, JM; Baptista, C; Bifeld, E; Borsari, C; Clos, J; Cordeiro-da-Silva, A; Corral, MJ; Costantino, L; Costi, MP; Eick, J; Ellinger, B; Ferrari, S; Franco, CH; Gul, S; Jiménez-Antón, MD; Kuzikov, M; Linciano, P; Luciani, R; Moraes, CB; Olías-Molero, AI; Ponterini, G; Reinshagen, J; Santarem, N; Severi, L; Tait, A; Tejera Nevado, P; Torrado, JJ; Witt, G; Wolf, M; Zander-Dinse, D | 1 |
| Alvar, J; Alves, F; Bern, C; Burza, S; Das, P; Das, VNR; Goyal, V; Hightower, A; Lima, N; Pandey, K; Rijal, S; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T | 1 |
| Barbosa, H; Bezerra-Souza, A; Brito, JR; Ferreira, EA; Lago, JHG; Laurenti, MD; Passero, LFD; Romoff, P | 1 |
| Mahabir, M; Saurabh, S | 1 |
| Almeida, ADC; Coimbra, ES; da Silva, AD; Glanzmann, N; Meinel, RS; Stroppa, PHF | 1 |
| Kapil, S; Kashyap, A; Silakari, O; Singh, PK | 1 |
| Dar, MJ; Khalid, S; Khan, GM; McElroy, CA; Satoskar, AR | 1 |
| Crone, CG; Helleberg, M | 1 |
| Memon, W; Totten, M; Wu, Y; Ying, C; Zhang, SX | 1 |
| Bhattacharya, A; Bigot, S; Gingras, H; Leprohon, P; Mestdagh, A; Mukherjee, A; Ouellette, M; Padmanabhan, PK; Papadopoulou, B; Roy, G | 1 |
| Avdagic, E; Boggild, AK; Chew, HF; Doshi, R; Farooq, AV; Jafri, M; Reidy, JJ; Tu, EY; Veldman, P | 1 |
| Aversa, S; Di Muccio, T; Gagliardini, R; Gramiccia, M; Miracco, C; Montagnani, F; Paglicci, L; Rossetti, B; Tordini, G; Zammarchi, L; Zanelli, G | 1 |
| Dixit, KK; Ramesh, V; Salotra, P; Sharma, N; Singh, R | 1 |
| Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA | 1 |
| Berg, LJ; Jamin Keith, D; Townsend, SD; Xu, LL | 1 |
| Amado, PSM; Cabral, LIL; Cojean, S; Cristiano, MLS; Loiseau, PM; Pomel, S | 1 |
| Fernández-Rubio, C; González-Benito, J; González-Gaitano, G; Houston, JE; Nguewa, P; Puig-Rigall, J; Radulescu, A | 1 |
| Aslanidis, C; Buechler, C | 1 |
| Barakat, AM; Behour, TS; Khairalla, AS; Khairy, NM; Melek, ST; Saafan, AE | 1 |
| Aslan, H; Bulté, D; Caljon, G; Hendrickx, S; Maes, L; Mondelaers, A; Rivas, L; Van Bockstal, L | 1 |
| Coelho, AC; Pita Pedro, DP; Reimão, JQ | 1 |
| Agrawal, K; Bimal, S; Das, P; Kumar, M; Lal, CS; Madhukar, M; Pandey, K; Rabi Das, VN; Siddiqui, NA; Topno, RK; Verma, N | 1 |
| Çavuş, İ; Harman, M; Kaya, T; Özbilgin, A; Yıldırım, A | 1 |
| Barbosa, AM; Beauparlant, CJ; Carvalho, A; Cunha, C; Droit, A; Estaquier, J; Ferreira, C; Mesquita, I; Osório, NS; Saha, B; Silvestre, R; Torrado, E | 1 |
| Caplivski, D; Chai, RL; Eiras, DP; Kirkman, LA; Murray, HW | 1 |
| Davis, B; Franco-Paredes, C; Henao-Martínez, A; Mann, S; Newman, S; Phupitakphol, T; Suarez, JA | 1 |
| Camilleri, M; Checkley, A; Pomplun, S; Rabin, N; Richards, H; Wilson, A | 1 |
| Adriaensen, W; Alves, F; Blesson, S; Cnops, L; Cordero, CF; Cuypers, B; Diro, E; Kaye, PM; Mengasha, B; van Griensven, J | 1 |
| Alves, F; Caljon, G; Eberhardt, E; Hendrickx, R; Hendrickx, S; Maes, L; Monnerat, S; Van den Kerkhof, M | 1 |
| Bulté, D; Caljon, G; Hendrickx, S; Maes, L; Sadlova, J; Van Bockstal, L; Volf, P | 1 |
| Ingale, P; Kabra, R; Singh, S | 1 |
| Alves, RB; Colombo, FA; da Silva, JC; de Freitas, RP; Gontijo, VS; Laurenti, MD; Malaquias, LCC; Marques, MJ; Nunes, JB | 1 |
| Gaillard, B; Lebeau, L; Pons, F; Remy, JS | 1 |
| Calvopina, M; Jijon, S; Kato, H; Serrano, E | 1 |
| Barreto, TL; Colombo, AL; de Freitas, ALD; Ishida, K; Lopes, LB; Meis, JF; Rossato, L | 1 |
| Ambroggio, EE; Fanani, ML; Zulueta Díaz, YLM | 1 |
| Almeida, ADBPF; Ayres, EDCBS; de Carvalho, MR; de Oliveira Martins, DT; de Oliveira, RG; Dias, ÁFLR; Maruyama, FH; Mendonça, AJ; Sousa, VRF; Teixeira, ALS | 1 |
| Bazzocchi, IL; Bekhti, K; Bethencourt-Estrella, CJ; Jiménez, IA; López-Arencibia, A; Lorenzo-Morales, J; Piñero, JE; Reyes-Batlle, M; Sifaoui, I; Zeouk, I | 1 |
| Gedda, MR; Mudavath, SL; Parvez, S; Singh, A; Singh, OP; Sundar, S; Verma, A; Yadagiri, G | 1 |
| Alves, F; Beijnen, JH; Dorlo, TPC; Kip, AE; Mbui, J; Musa, A; Olobo, J; Palić, S; Solomos, A; Wasunna, M | 1 |
| Connor, BA; Pisipati, S; Riddle, MS | 1 |
| Barral-Netto, M; Carvalho, EM; Carvalho, LP; Costa, R; Guimarães, LH; Machado, PRL; Nascimento, MT; Peixoto, F; Penna, G; Renard, G; Silva, J | 1 |
| Elias, VM; Osorio-Arango, K; Pinart, M; Pinzón-Flórez, CE; Reveiz, L; Romero, GA; Rueda, JR; Silveira Maia-Elkhoury, AN; Tweed, JA | 1 |
| Barral, A; Barral-Netto, M; Boaventura, V; Carvalho, EM; Corte, TWF; Guimarães, LH; Lago, T; Machado, PRL; Penna, G; Prates, FVO; Schriefer, A | 1 |
| Akova, M; Elçin, G; Ergüven, S; Harxhi, A; İnkaya, AÇ; Jaiteh, MB; Kurtulan, O; Üner, A | 1 |
| Abdel Bary, A; Abdel Salam, SA; Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM | 2 |
| Ambasta, A; Arya, LK; Kusumesh, R; Mohan, N; Ravidas, V; Sinha, BP | 1 |
| Bhattacharyya, M; Bodhale, NP; Pai, K; Saha, B; Sundar, S | 1 |
| Çavuş, İ; Gündüz, C; Harman, M; Özbilgin, A; Tunalı, V; Turgay, N | 1 |
| Appenheimer, AB; Chodosh, J; Hou, JH; Kang, JJ; Morrill, AM; Rapuano, CJ; Saeed, HN; Thulasi, P; Tu, EY; Vyas, N; Zegans, ME; Zuckerman, R | 1 |
| Atar-Snir, V; Barzilai, A; Ben-Amitai, D; Friedland, R; Greenberger, S; Horev, A; Molho-Pessach, V; Ollech, A; Reiss-Huss, S; Solomon, M; Zvulunov, A | 1 |
| Abad-Grillo, T; Bethencourt-Estrella, CJ; Freijo, MB; López-Arencibia, A; Lorenzo-Morales, J; McNaughton-Smith, G; Nicolás-Hernández, DS; Piñero, JE; Reyes-Batlle, M; Sifaoui, I | 1 |
| Brown, T; Nash, TE; Nutman, TB; O'Connell, EM; Talaat, KR; Ware, JM; Wetzler, L | 1 |
| Berman, JD; Soto, JA | 1 |
| Call, JE; Chan, CX; Chapman, MS; Glass, JS; Simmons, BJ; Yan, S | 1 |
| Atar-Snir, V; Barzilai, A; Ben-Amitai, D; Friedland, R; Greenberger, S; Horev, A; Ollech, A; Pessach-Molcho, V; Reiss-Huss, S; Solomon, M; Zvulunov, A | 1 |
| Adhikary, S; Karki, A; Parajuli, N; Tiwari, S | 1 |
| Ali, Z; Bibi, M; Khan, AS; Khan, GM; Ud Din, F; Zahid, F; Zeb, A | 1 |
| Barral-Netto, M; Carvalho, EM; Costa, B; de Jesus, DV; Doria, SS; Guerra, JO; Guerra, MDGB; Machado, PRL; Mendes, L; Ortiz, J; Penna, G; Silva, ASD; Silva, GVD | 1 |
| Abreu-Silva, AL; Almeida-Souza, F; Behrens, MD; Bertho, AL; Calabrese, KDS; Chometon, TQ; de Sá Sousa, JC; de Souza, PVR; Dos Santos Chagas, MDS; Jesús Hardoim, D; Mondêgo-Oliveira, R; Moragas-Tellis, CJ; Taniwaki, NN | 1 |
| Das, P; Das, VNR; Lal, CS; Pal, B; Pandey, K; Topno, RK | 1 |
| Alunda, JM; Cuquerella, M; Fontán-Matilla, E; Olías-Molero, AI | 1 |
| Banerjee, S; Chattopadhy, S; Das, A; Ethirajan, A; Mukherjee, N; Pramanik, SK; Saha, KD; Tiwari, R; Tyde, D | 1 |
| Heinemann, A; Kienzl, M; Knuplez, E; Marsche, G; Schicho, R; Sturm, EM; Trakaki, A | 1 |
| Barroso, PA; Bracamonte, ME; Carrer, DC; Guzmán, ML; Marco, JD; Olivera, ME; Peralta, MF; Usseglio, NA | 1 |
| Ali, N; Ashraf, S; den Boer, M; Fernhout, J; Grobusch, MP; Kämink, S; Khan, SJ; Masih, B; Pylypenko, T; Ritmeijer, K; Ullah, A | 1 |
| Farooq, AV; Reidy, JJ; Si, Z; Veldman, PB | 1 |
| Ahronowitz, IZ; Kassardjian, AA; Kim, GH; Liang, TZ; Ochoa, MT; Rabi, S; Sattah, MV; Yim, KM | 1 |
| Batool, S; Dar, MJ; Khan, GM; Khan, MW; Naz, SS; Ud-Din, F; Zahid, F; Zeb, A | 1 |
| Angulo-Barturen, I; Coteron-Lopez, JM; Croft, SL; Ferrer-Bazaga, S; Harris, A; Seifert, K; Voak, AA | 1 |
| Berman, JD; Méndez, MI; Soto, JA | 1 |
| Albuquerque-Wendt, A; Coelho, AC; Espada, CR; Gluenz, E; Hornillos, V; Uliana, SRB | 1 |
| Ali, V; Goyal, N; Kanojia, S; Singh, Y; Yadav, S | 1 |
| Darchini-Maragheh, E; Goyonlo, VM; Kiafar, B; Layegh, P; Tayyebi, M | 1 |
| Li, SH; Liu, Y; Lu, L; Niu, YN; Yang, CY; Zhang, HW; Zhao, DY; Zhao, YL; Zhou, RM; Zhu, X | 1 |
| Alves, F; Brack, M; Dahal, P; Guerin, PJ; Halleux, CM; Hawryszkiewycz, A; Maguire, BJ; Ngu, R; Olliaro, PL; Rashan, S; Singh-Phulgenda, S; Stepniewska, K | 1 |
| Antinarelli, LMR; Bandeira, RS; Brito, RCF; Chávez-Fumagalli, MA; Coelho, EAF; Coimbra, ES; Costa, RR; Duarte, MC; Freitas, CS; Humbert, MV; Lage, DP; Ludolf, F; Machado, AS; Martins, VT; Mendonça, DVC; Menezes-Souza, D; Oliveira-da-Silva, JA; Reis, TAR; Roatt, BM; Santos, TTO; Tavares, GSV | 1 |
| Alonso, A; Alonso, L; Dorta, ML; Gomes, RS; Mendanha, SA | 1 |
| El-Khordagui, LK; El-Moslemany, RM; El-Sheridy, NA; Helmy, MW; Ramadan, AA | 1 |
| Nepal, S | 1 |
| Buckner, FS; Cogen, AL; Joseph, S; Whitman, TJ | 1 |
| Ali, Z; Choi, HG; Imran, M; Jamshaid, H; Sajjad Khan, A; Sarwar, S; Ud Din, F; Ullah, K; Yu, G; Zeb, A | 1 |
| Abdela, SG; Buyze, J; Cnops, L; Diro, E; Fikre, H; Kassa, M; Mohammed, R; Pareyn, M; Tesfaye, AB; Tilahun, F; van Griensven, J; van Henten, S; Vogt, F | 1 |
| Cardoso, L; Leal, RO; Monteiro, M; Pereira da Fonseca, I; Prata, S | 1 |
| Kaur, A; Sahu, SK | 1 |
| Bakhos, D; Desoubeaux, G; Lemaignen, A; Renard, L | 1 |
| Charan Raja, MR; Debnath, J; Jayaraman, A; Kar Mahapatra, S; Kar, A; Srinivasan, S | 1 |
| Ayral, X; Buffet, P; Canouï, E; Charlier, C; Chouchana, L; Contejean, A; Dorlo, TPC; Gana, I; Roseboom, IC; Yera, H | 1 |
| Thulasi, P; Tu, EY | 1 |
| Murta, SMF; Santi, AMM; Santos, IFM; Silva, PA | 1 |
| Barroso, DH; da Motta, JOC; Freire, GSM; Gomes, CM; Kurisky, PS; Martins, SS; Pereira, LIA; Rodrigues, BC; Sampaio, RNR | 1 |
| Hossann, M; Lindner, LH; Lokerse, WJM; Paal, M; Rysin, A; Vogeser, M; Wedmann, B; Winter, G | 1 |
| Bulté, D; Caljon, G; De Trez, C; Dirkx, L; Hendrickx, S; Maes, L; Timmermans, JP; Van Bockstal, L; Van den Kerkhof, M | 1 |
| Bastos, RW; Colabardini, AC; Del Poeta, M; Dos Reis, TF; Fernandes, CM; Fonseca, MVL; Goldman, GH; Horta, MAC; Martins, C; Rodrigues, ML; Silva Pereira, C; Silva, LP; Wang, F; Wong, KH | 1 |
| Li, C; Li, L; Liu, Y; Yang, M | 1 |
| Kim, S; Matoba, A; Weikert, MP | 1 |
| Alcover, MM; Fernández, A; Fisa, R; Giner, J; Riera, C; Verde, M; Villanueva-Saz, S; Yzuel, A | 1 |
| Berdahl, J; de la Presa, M; Holland, EJ; Ibach, M | 1 |
| Barreto, TL; Ishida, K; Lopes, LB; Melo, AS | 1 |
| Alves, F; Beijnen, JH; Dorlo, TPC; Mondal, D; Roseboom, IC; Rosing, H; Teunissen, MBM; Thijssen, B | 1 |
| Chamorro-Tojeiro, S; Chicharro, C; Gioia, F; López-Vélez, R; Monge-Maillo, B; Moreno, J; Norman, FF; Pérez-Molina, JA | 1 |
| Atapalkar, RS; Chavan, SP; Kulkarni, AA; Patil, NB | 1 |
| Adamson, PJ; Badenoch, PR; Brennan, C; Gordon, DL; Marshman, G; Tam, PCK; Teh, JSK | 1 |
| Chatterjee, M; Sengupta, S | 1 |
| Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY | 1 |
| Campos, MP; Figueiredo, FB; Gonçalves, AS; Gonçalves, G; Medeiros, LCS | 1 |
| Chan, A; Kuruvath, S; Smith, S; Tan, E | 1 |
| Alonso, A; Alonso, L; Kipnis, A; Pimenta, LKL | 1 |
| Alexander, N; Alves, F; Burza, S; Das, P; Das, VNR; de Lima Pereira, A; Gill, N; Goyal, V; Harshana, A; Kazmi, S; Kumar, D; Kumar, V; Lal, CS; Lasry, E; Mahajan, R; Pandey, K; Rewari, B; Rijal, S; Verma, N | 1 |
| Alvarez, F; Arana, B; Boni, M; Echevarria, J; Jiménez, A; Llanos-Cuentas, A; López, L; Méndez, C; Quintero, J; Ramos, AP; Rode, J; Tabares, Y; Valencia, B; Vélez, I | 1 |
| Aguiar-Soares, RDO; Cardoso, JMO; Carneiro, CM; Carvalho, LM; Costa, AFP; de Brito, RCF; Gusmão, MR; Reis, AB; Roatt, BM | 1 |
| Kabra, R; Singh, S | 1 |
| Bravo-Cossio, F; Cabello-Vilchez, AM; Carreazo, NY; Martínez, DY; Valdivia-Tapia, MDC | 1 |
| Altcheh, J; Bisio, MMC; García-Bournissen, F; Gulin, JEN; Rocco, D; Solana, ME | 1 |
| Almeida, ADBPF; Ayres, EDCBS; Barbosa, MEC; Dias, ÁFLR; Dutra, V; Macedo, LFDC; Monteiro, BRG; Nakazato, L; Pazzini, SS; Silva, EBD; Sousa, VRF | 1 |
| Araújo, MS; Bartholomeu, DC; Borges, VM; Cardoso, CDA; Laurenti, MD; Monte-Neto, RLD; Moreira, POL; Nogueira, PM; Rêgo, FD; Reis, AB; Soares, RP | 1 |
| Banerjee, R; Chaudhari, P; Dutt, S; Goda, JS; Mohanty, B; Sandbhor, P | 1 |
| Barba, PJ; Morgado-Carrasco, D; Quera, A | 1 |
| Alcoba, G; Alvar, J; Alves, F; Dorlo, TPC; Egondi, T; Fikre, H; Ismail Omer Haroun, A; Khalil, EAG; Mbui, J; Mekonnen, T; Mersha, D; Mohammed, R; Musa Younis, B; Musa, AM; Muthoni Ouattara, G; Nakanwagi, P; Njenga, S; Nour, A; Olobo, J; Omollo, T; Ritmeijer, K; Sagaki, P; Sisay, K; Solomos, A; Taha Ahmed Elmukashfi, E; Verrest, L; Wasunna, M | 1 |
| Dotsika, E; Gogou, G; Halabalaki, M; Koutsoni, OS; Skaltsounis, LA; Stathopoulos, P | 1 |
| Bano, S; Bibi, M; Choudhary, MI; Farooq, S; Khoso, BK; Shaikh, M; Yousuf, S; Zafar, H | 1 |
| Abourehab, MAS; Amagase, K; Bekhit, AA; Bekhit, SA; El-Saghier, AMM; Ibrahim, TM; Kadry, AM; Mohamed, MAA | 1 |
| Carnielli, JBT; Costa, CHN; Dave, A; de Faria, PR; Dietze, R; Forrester, S; Graham, IA; Monti-Rocha, R; Mottram, JC; Romano, A | 1 |
| Coelho, AC; Coser, EM; Ferreira, BA; Lindoso, JAL; Saborito, C; Yamashiro-Kanashiro, EH | 1 |
| Balaña-Fouce, R; Galli, G; García-Estrada, C; Melcon-Fernandez, E; Pérez-Pertejo, Y; Reguera, RM | 1 |
| Campos, MP; Castilhos, MMS; Figueiredo, FB; Gonçalves, G; Hartin, TP; Negrão, DD; Poleto, APCM; Silva, GMPD; Silva, JBA; Tirado, TC | 1 |
| Alavijeh, M; Croft, SL; Dixon, J; Harris, A; Mcarthur, KN; Platteeuw, JJ; Van Bocxlaer, K; Van Den Heuvel, D; Yardley, V | 1 |
| Alves, F; Chu, WY; Dorlo, TPC; Huitema, ADR; Mbui, J; Mohammed, R; Musa, AM; Njenga, S; Olobo, J; Ritmeijer, K; Roseboom, IC; Solomos, A; Verrest, L; Wasunna, M | 1 |
| Borba-Santos, LP; Ishida, K; Rozental, S; Spadari, CC | 1 |
| Jariyapan, N; Junkum, A; Kongkaew, A; Mano, C; Siriyasatien, P; Tippawangkosol, P | 1 |
100 review(s) available for miltefosine and phosphorylcholine
| Article | Year |
|---|---|
Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug.
Topics: Adult; Aged; Antineoplastic Agents; Cell Division; Cell Line; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Neoplasms; Phosphorylcholine | 1991 |
Hexadecylphosphocholine: a new and selective antitumor drug.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Mammary Neoplasms, Experimental; Phosphorylcholine; Rats; Remission Induction; Skin Neoplasms; Structure-Activity Relationship | 1990 |
Alkylphosphocholines: a new class of membrane-active anticancer agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Drug Screening Assays, Antitumor; Humans; Immune System; Neoplasms; Phosphorylcholine; Protein Kinase C; Rats; Tumor Cells, Cultured; Type C Phospholipases | 1993 |
Heterocyclic alkylphospholipids with an improved therapeutic range.
Topics: Animals; Antineoplastic Agents; Heterocyclic Compounds; Humans; Phospholipids; Phosphorylcholine; Tumor Cells, Cultured | 1996 |
The inhibition of cell signaling pathways by antitumor ether lipids.
Topics: Animals; Antineoplastic Agents; Calcium; Furans; Humans; Phospholipid Ethers; Phosphorylcholine; Protein Kinases; Receptors, Cell Surface; Signal Transduction | 1998 |
Cytotoxic etherphospholipid analogues.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; In Vitro Techniques; Phospholipid Ethers; Phosphorylcholine | 1998 |
Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis.
Topics: Antineoplastic Agents; Phosphodiesterase Inhibitors; Phospholipid Ethers; Phospholipids; Phosphorylcholine; Signal Transduction | 2001 |
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
Topics: Adult; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Child; Humans; Leishmania donovani; Leishmaniasis, Visceral; Mice; Paromomycin; Phosphorylcholine; Treatment Outcome | 2000 |
[Drug development from phospholipids].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Drug Design; Humans; Liposomes; Neoplasms; Phospholipids; Phosphorylcholine; Structure-Activity Relationship | 2001 |
Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Administration Schedule; Drug Industry; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine; World Health Organization | 2001 |
Chemotherapy of cutaneous leishmaniasis: a review.
Topics: Antifungal Agents; Antimony; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Ointments; Organometallic Compounds; Phosphorylcholine | 2001 |
Treatment of visceral leishmaniasis: a review of current treatment practices.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Developing Countries; HIV Infections; Humans; Leishmaniasis, Visceral; Mice; Phosphorylcholine; World Health Organization | 2002 |
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Asia, Western; Brazil; Developing Countries; Dogs; Female; Humans; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Sudan | 2002 |
Antiprotozoal activities of phospholipid analogues.
Topics: Animals; Antiprotozoal Agents; Leishmania; Parasitic Sensitivity Tests; Phospholipid Ethers; Phospholipids; Phosphorylcholine; Structure-Activity Relationship; Trypanosoma | 2003 |
[New drugs for treatment of parasitic infections].
Topics: Antiparasitic Agents; Humans; Intestinal Diseases, Parasitic; Leishmaniasis; Nitro Compounds; Phosphorylcholine; Thiazoles | 2003 |
Current treatment approaches to leishmaniasis.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Clinical Trials as Topic; Fluconazole; Humans; Leishmaniasis; Paromomycin; Pentamidine; Phosphorylcholine | 2003 |
Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Topics: Administration, Oral; Aminoquinolines; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; India; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine | 2003 |
[Visceral leishmaniasis: new drugs].
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2003 |
Miltefosine: an oral drug for visceral leishmaniasis.
Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2004 |
Inhibition of phosphatidylcholine synthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis.
Topics: Animals; Apoptosis; CHO Cells; Cricetinae; Phosphatidylcholines; Phosphorylcholine | 2004 |
Treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Amebicides; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antiprotozoal Agents; Benzamidines; Biguanides; Chlorhexidine; Contact Lenses; Humans; Neomycin; Phosphorylcholine; Treatment Failure | 2003 |
Cutaneous leishmaniasis: current and future management.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Humans; Immunotherapy; Leishmania; Leishmaniasis, Cutaneous; Paromomycin; Phosphorylcholine | 2003 |
Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; Drug Costs; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphatidylcholines; Phosphatidylglycerols; Phosphorylcholine; Practice Guidelines as Topic | 2004 |
Challenges and new discoveries in the treatment of leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania; Leishmaniasis; Pentamidine; Phosphorylcholine; Psychodidae | 2004 |
[Visceral leishmaniases].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Brazil; Child, Preschool; Dogs; Ethiopia; Europe; Humans; Incidence; India; Infant; Infant, Newborn; Leishmaniasis, Visceral; Phosphorylcholine; Prevalence; Time Factors; Zoonoses | 2004 |
Miltefosine to treat leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine | 2005 |
Clinical status of agents being developed for leishmaniasis.
Topics: Aminoquinolines; Antiprotozoal Agents; Fluconazole; Humans; Imiquimod; Ketoconazole; Leishmaniasis; Paromomycin; Phosphorylcholine | 2005 |
Development of miltefosine for the leishmaniases.
Topics: Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Design; HIV Infections; Humans; Leishmaniasis; Phosphorylcholine | 2006 |
Miltefosine: oral treatment of leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine | 2006 |
Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Humans; India; Leishmaniasis, Visceral; Multicenter Studies as Topic; Phosphorylcholine; Pilot Projects; Treatment Outcome | 2006 |
TDR collaboration with the pharmaceutical industry.
Topics: Antiprotozoal Agents; Drug Evaluation; Drug Industry; Female; Humans; Interprofessional Relations; Leishmaniasis; Male; Phosphorylcholine; Public Sector; Tropical Medicine | 2006 |
Development of miltefosine as an oral treatment for leishmaniasis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Antiprotozoal Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Dogs; Drug Evaluation; Eye Diseases; Female; Hematologic Diseases; Humans; Kidney Diseases; Leishmaniasis; Phosphorylcholine; Pregnancy; Rats; Teratogens | 2006 |
Miltefosine: issues to be addressed in the future.
Topics: Abnormalities, Drug-Induced; Antiprotozoal Agents; Drug Resistance; Female; Forecasting; HIV Infections; Humans; Leishmaniasis; Phosphorylcholine; Pregnancy; Pregnancy Complications, Parasitic | 2006 |
Childhood visceral leishmaniasis.
Topics: Administration, Oral; Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; Psychodidae | 2006 |
Drug unresponsiveness & combination therapy for kala-azar.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance; Humans; India; Leishmania; Leishmaniasis, Visceral; Phosphorylcholine | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Models, Chemical; Paromomycin; Phosphorylcholine | 2006 |
Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Drug Design; Glycerylphosphorylcholine; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine; Technology, Pharmaceutical | 2006 |
Treatment of New World cutaneous leishmaniasis with miltefosine.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans; Leishmaniasis, Cutaneous; Multicenter Studies as Topic; Phosphorylcholine; Pilot Projects; Treatment Outcome | 2006 |
[Miltefosine: a new remedy for leishmaniasis].
Topics: Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine; Treatment Outcome | 2006 |
[Oral miltefosine to treat leishmaniasis].
Topics: Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine | 2006 |
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Female; Humans; Male; Metronidazole; Odorants; Ointments; Phosphorylcholine; Skin Neoplasms; Skin Ulcer; Wounds and Injuries | 2007 |
Cutaneous leishmaniasis treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Humans; Imiquimod; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis, Cutaneous; Paromomycin; Pentamidine; Phosphorylcholine | 2007 |
Chemotherapy of leishmaniasis: past, present and future.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Phosphorylcholine | 2007 |
[Treatment of visceral leishmaniasis in children].
Topics: Amphotericin B; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2007 |
[The leishmaniasis - a parasitel infection as differential diagnosis of malignant tumours of oral mucosa. A case report and review of literature].
Topics: Animals; Combined Modality Therapy; Diagnosis, Differential; Hepatitis C, Chronic; Histiocytes; Humans; Leishmania infantum; Leishmaniasis, Visceral; Liver Cirrhosis; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Opportunistic Infections; Oral Ulcer; Phosphorylcholine; Recurrence; Stomatitis | 2007 |
Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Americas; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Asia; Humans; Italy; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Pentamidine; Phosphorylcholine; Travel | 2007 |
Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
Topics: Animals; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2008 |
Treatment of leishmaniasis with miltefosine: 2008 status.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Female; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2008 |
Cellular transport and lipid interactions of miltefosine.
Topics: Animals; Antineoplastic Agents; Biological Transport; Enterocytes; Humans; Leishmania; Liposomes; Membrane Lipids; Phosphorylcholine | 2009 |
Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Therapy, Combination; HIV Seropositivity; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine; Treatment Outcome | 2009 |
Combination therapy for visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Asia; Brazil; Cost-Benefit Analysis; Drug Therapy, Combination; Europe; Humans; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Safety; South Africa | 2010 |
Current diagnosis and treatment of visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antigens, Protozoan; Antiprotozoal Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Humans; Leishmaniasis, Visceral; Phosphorylcholine; Protozoan Proteins; Recombinant Proteins | 2010 |
Drug combinations for visceral leishmaniasis.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cost-Benefit Analysis; Drug Resistance; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine | 2010 |
Visceral leishmaniasis in children: a review.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Child; Drug Resistance; Drug Therapy, Combination; Global Health; Humans; Italy; Leishmania; Leishmaniasis, Visceral; Phosphorylcholine; Treatment Outcome | 2010 |
Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis.
Topics: Adverse Drug Reaction Reporting Systems; Antiprotozoal Agents; Clinical Trials as Topic; Female; Humans; India; Leishmaniasis, Visceral; Male; Pharmacoepidemiology; Phosphorylcholine; Public Health; Risk Factors; Vulnerable Populations | 2011 |
Visceral leishmaniasis: elimination with existing interventions.
Topics: Amphotericin B; Antiprotozoal Agents; Communicable Disease Control; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine | 2011 |
Miltefosine and cutaneous leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmaniasis; Phosphorylcholine | 2012 |
Miltefosine: a novel treatment option for mast cell-mediated diseases.
Topics: Antineoplastic Agents; Dermatitis, Atopic; Humans; Mast Cells; Mastocytosis; Phosphorylcholine; Urticaria Pigmentosa | 2013 |
Leishmaniasis in the United States: treatment in 2012.
Topics: Administration, Oral; Amphotericin B; Antiprotozoal Agents; Humans; Immunocompromised Host; Injections, Intravenous; Leishmaniasis; Phosphorylcholine; United States | 2012 |
Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Topics: Amiodarone; Antiprotozoal Agents; Calcium; Chagas Disease; Homeostasis; Humans; Leishmania; Leishmaniasis; Phosphorylcholine; Triazoles; Trypanosoma brucei brucei; Trypanosoma cruzi | 2011 |
Leishmaniasis: current status of available drugs and new potential drug targets.
Topics: Aminoquinolines; Amphotericin B; Antigens, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agents; Caspase Inhibitors; Cyclin-Dependent Kinases; Drug Discovery; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Leishmaniasis; Macrophages; Microbodies; Mitogen-Activated Protein Kinase Kinases; Paromomycin; Pentamidine; Phosphorylcholine; Polyamines; Protease Inhibitors; Sterols; Sulfhydryl Compounds; Topoisomerase Inhibitors | 2012 |
Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Topics: Administration, Cutaneous; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Delivery Systems; Humans; Imiquimod; Leishmaniasis, Cutaneous; Naphthoquinones; Paromomycin; Phosphorylcholine; Skin Absorption | 2012 |
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmania; Leishmaniasis; Phosphorylcholine; Treatment Outcome | 2012 |
Anticancer mechanisms and clinical application of alkylphospholipids.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Endocytosis; Humans; Neoplasms; Organophosphates; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phospholipid Ethers; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Quaternary Ammonium Compounds; Signal Transduction | 2013 |
Leishmaniasis: an update of current pharmacotherapy.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania donovani; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Practice Guidelines as Topic; Species Specificity; Treatment Outcome | 2013 |
(Post-) Genomic approaches to tackle drug resistance in Leishmania.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Genome, Protozoan; Genomics; Humans; Leishmania; Leishmaniasis; Metabolomics; Phenotype; Phosphorylcholine | 2013 |
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Insect Vectors; Leishmania; Leishmaniasis; Phosphorylcholine; Psychodidae; Recurrence; Treatment Failure | 2014 |
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Female; Humans; Male; Metronidazole; Odorants; Ointments; Phosphorylcholine; Randomized Controlled Trials as Topic; Silver Compounds; Skin Neoplasms; Skin Ulcer; Wounds and Injuries | 2014 |
Visceral Leishmaniasis and HIV coinfection in East Africa.
Topics: Africa, Eastern; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; Coinfection; HIV Infections; Humans; Leishmaniasis, Visceral; Phosphorylcholine; Prevalence | 2014 |
Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.
Topics: Administration, Cutaneous; Ambulatory Care; Aminoglycosides; Antiprotozoal Agents; Child, Preschool; Humans; Leishmaniasis, Cutaneous; Male; Paromomycin; Phosphorylcholine; Randomized Controlled Trials as Topic | 2015 |
Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Topics: Administration, Oral; Africa, Eastern; Antiprotozoal Agents; Bangladesh; Coinfection; Drug Therapy, Combination; Evidence-Based Medicine; Half-Life; HIV Infections; Humans; India; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Leishmaniasis, Visceral; Nepal; Phosphorylcholine | 2015 |
Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine; United States | 2015 |
New World and Old World Leishmania Infections: A Practical Review.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Deoxycholic Acid; Drug Combinations; Humans; Incidence; Leishmania braziliensis; Leishmania donovani; Leishmania mexicana; Leishmania tropica; Leishmaniasis, Diffuse Cutaneous; Leishmaniasis, Mucocutaneous; Leishmaniasis, Visceral; Phosphorylcholine; Polymerase Chain Reaction; Travel | 2015 |
Elimination of visceral leishmaniasis on the Indian subcontinent.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Health Services Accessibility; Humans; India; Insect Control; Insect Vectors; Leishmaniasis, Visceral; Neglected Diseases; Phosphorylcholine; Psychodidae; Public Health | 2016 |
Evaluating drug resistance in visceral leishmaniasis: the challenges.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance, Multiple; Humans; Leishmania donovani; Leishmaniasis, Visceral; Meglumine Antimoniate; Parasitic Sensitivity Tests; Phosphorylcholine; Psychodidae; Recurrence | 2018 |
Disseminated Acanthamoeba infection in a heart transplant recipient treated successfully with a miltefosine-containing regimen: Case report and review of the literature.
Topics: Acanthamoeba; Amebiasis; Amebicides; Amphotericin B; Anti-Bacterial Agents; Antilymphocyte Serum; Biopsy; Cardiomyopathies; Drugs, Investigational; Endoscopy; Female; Fluconazole; Flucytosine; Heart Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Magnetic Resonance Imaging; Metacarpal Bones; Metronidazole; Middle Aged; Phosphorylcholine; Polymerase Chain Reaction; Radiography; Sinusitis; Skin | 2017 |
Visceral leishmaniosis in immunocompromised host: an update and literature review.
Topics: Amphotericin B; HIV Infections; Humans; Immunocompromised Host; Leishmaniasis, Visceral; Phosphorylcholine; Recurrence | 2017 |
Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Compounding; Drug Delivery Systems; Drug Liberation; Humans; Leishmaniasis; Liposomes; Nanoparticles; Paromomycin; Particle Size; Pentamidine; Phosphorylcholine; Surface Properties | 2017 |
Keratitis After Post-Kala-Azar Dermal Leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Corneal Stroma; Eye Infections, Parasitic; Glucocorticoids; Humans; Keratitis; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Prednisolone | 2018 |
Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.
Topics: Amphotericin B; Antiprotozoal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; Drug Compounding; Evidence-Based Medicine; Female; Humans; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Survival Analysis; Treatment Outcome | 2018 |
Chemotherapeutics of visceral leishmaniasis: present and future developments.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Meglumine Antimoniate; Paromomycin; Phosphorylcholine; Psychodidae; Sheep; South America; Treatment Outcome | 2018 |
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Drug Therapy, Combination; Humans; Leishmania; Leishmania donovani; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Molecular Epidemiology; Phosphorylcholine; Treatment Failure | 2017 |
Visceral Leishmaniasis-Optimum Treatment Options in Children.
Topics: Amphotericin B; Antiprotozoal Agents; Child; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2018 |
Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Reservoirs; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Molecular Diagnostic Techniques; Organometallic Compounds; Phosphorylcholine; Point-of-Care Systems; Serologic Tests | 2018 |
Recent progress in drug targets and inhibitors towards combating leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Phosphorylcholine | 2018 |
Interventions to treat cutaneous leishmaniasis in children: A systematic review.
Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Phosphorylcholine; Rifampin | 2018 |
American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Topics: Antiprotozoal Agents; Brazil; Humans; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Patents as Topic; Phosphorylcholine | 2019 |
The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
Topics: Antiprotozoal Agents; Asia; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine | 2019 |
Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis.
Topics: Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Non-Randomized Controlled Trials as Topic; Phosphorylcholine; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.
Topics: Animals; Antiprotozoal Agents; Cytokines; Humans; Immunomodulation; Leishmania; Leishmaniasis; Phosphorylcholine | 2019 |
Killer amoebas: Primary amoebic meningoencephalitis in a changing climate.
Topics: Amebicides; Aminoglycosides; Amphotericin B; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiparasitic Agents; Azithromycin; Central Nervous System Protozoal Infections; Climate Change; Dexamethasone; Early Diagnosis; Early Medical Intervention; Fluconazole; Geography; Glucocorticoids; Humans; Hypothermia, Induced; Macrolides; Naegleria fowleri; Phosphorylcholine; Rifampin; United States; Ventriculostomy | 2019 |
Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing.
Topics: Amphotericin B; Antifungal Agents; Drug Repositioning; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Leishmaniasis; Molecular Targeted Therapy; Phosphorylcholine; Sterol 14-Demethylase; Triazoles; Voriconazole | 2019 |
Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Diagnosis, Differential; Disease Models, Animal; Disease Progression; Humans; Lipid Metabolism; Lipids; Liver; Liver Cirrhosis; Liver Neoplasms; Oxidative Stress; Phospholipid Ethers; Phosphorylcholine; Plasmalogens; Severity of Illness Index | 2020 |
The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Topics: Animals; Antiprotozoal Agents; Drug Development; Drug Discovery; Humans; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine | 2020 |
Updates on the epidemiology, pathogenesis, diagnosis, and management of postinfectious irritable bowel syndrome.
Topics: Adult; Animals; Anti-Bacterial Agents; Child; Colon; Gastroenteritis; Humans; Infections; Inflammation; Intestinal Mucosa; Irritable Bowel Syndrome; Mast Cells; Mice; Moxibustion; Peroxiredoxins; Phosphorylcholine; Polymerase Chain Reaction; Quality of Life; Randomized Controlled Trials as Topic; Receptor, PAR-2; Rifamycins | 2020 |
Interventions for American cutaneous and mucocutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Azithromycin; BCG Vaccine; Female; Humans; Hyperthermia, Induced; Immunocompetence; Injections, Intramuscular; Injections, Intravenous; Interferon-gamma; Leishmaniasis Vaccines; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate; Pentoxifylline; Phosphorylcholine; Randomized Controlled Trials as Topic | 2020 |
Diffuse cutaneous leishmaniasis and HIV co-infection: A case report and review of the literature.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Darier Disease; Drug Therapy, Combination; HIV Infections; Humans; Infusions, Intravenous; Leishmaniasis, Diffuse Cutaneous; Male; Phosphorylcholine; Skin Diseases, Parasitic; Treatment Outcome; Trypanosoma cruzi | 2021 |
Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Deoxycholic Acid; Drug Combinations; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2021 |
Case Report: First Successful Treatment of Acanthamoeba Brain Abscess with Combination Surgical Excision and Miltefosine-Led Antimicrobial Therapy.
Topics: Acanthamoeba; Anti-Bacterial Agents; Brain Abscess; Humans; Male; Melioidosis; Middle Aged; Phosphorylcholine | 2022 |
Miltefosine repositioning: A review of potential alternative antifungal therapy.
Topics: Animals; Antifungal Agents; Drug Repositioning; Mycoses; Phosphorylcholine | 2023 |
81 trial(s) available for miltefosine and phosphorylcholine
| Article | Year |
|---|---|
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Phosphorylcholine | 1992 |
Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma; Male; Middle Aged; Phosphorylcholine; Skin Neoplasms | 1992 |
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Leukocyte Count; Leukocytosis; Lung Neoplasms; Male; Middle Aged; Phosphorylcholine; Platelet Count; Prospective Studies; Sarcoma; Thrombocytosis | 1994 |
Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Female; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Phosphorylcholine; Remission Induction; Skin; Skin Neoplasms | 1993 |
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Nausea; Phosphorylcholine; Sarcoma; Soft Tissue Neoplasms; Vomiting | 1993 |
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leukocytosis; Liver Neoplasms; Male; Middle Aged; Nausea; Phosphorylcholine; Thrombocytosis; Vomiting | 1993 |
Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Phosphorylcholine | 1993 |
Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Electrooculography; Electroretinography; Humans; Intraocular Pressure; Lung Neoplasms; Phosphorylcholine; Pigment Epithelium of Eye; Retinal Diseases; Visual Acuity | 1993 |
Trial of oral miltefosine for visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Drug Administration Schedule; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Treatment Outcome; Vomiting | 1998 |
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Pharmaceutical Vehicles; Phosphorylcholine; Skin Neoplasms | 1999 |
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Aspartate Aminotransferases; Female; Gastrointestinal Diseases; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Recurrence; Treatment Outcome | 1999 |
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Female; Humans; Male; Middle Aged; Phosphorylcholine; Skin Neoplasms; Treatment Outcome | 1999 |
Oral treatment of visceral leishmaniasis with miltefosine.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Female; Humans; Kidney; Leishmaniasis, Visceral; Liver; Male; Phosphorylcholine; Pilot Projects; Treatment Outcome | 1999 |
Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Diarrhea; Drug Administration Schedule; Female; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine; Vomiting | 2000 |
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Phosphorylcholine; Skin Neoplasms; Solutions | 2000 |
[Treatment with Miltex for metastatic skin lesions in breast cancer] .
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Phosphorylcholine; Skin Neoplasms; Treatment Outcome | 2000 |
Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Colombia; Humans; Leishmaniasis, Cutaneous; Male; Military Personnel; Phosphorylcholine; Treatment Outcome | 2001 |
Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Palliative Care; Phosphorylcholine; Proportional Hazards Models; Quality of Life; Skin Neoplasms | 2001 |
Oral miltefosine for Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Amphotericin B; Animals; Antiprotozoal Agents; Female; Humans; India; Infusions, Intravenous; Leishmania donovani; Leishmaniasis, Visceral; Male; Phosphorylcholine; Recurrence; Spleen | 2002 |
Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Biological Availability; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; India; Leishmaniasis, Visceral; Male; Maximum Tolerated Dose; Phosphorylcholine; Probability; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2003 |
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
Topics: Animals; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine; Treatment Outcome | 2004 |
Miltefosine for new world cutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Animals; Antiprotozoal Agents; Colombia; Double-Blind Method; Drug Tolerance; Female; Guatemala; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Patient Compliance; Phosphorylcholine; Treatment Outcome | 2004 |
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Topics: Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Comorbidity; Ethiopia; HIV Infections; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine; Prevalence; Treatment Outcome | 2006 |
A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Phosphorylcholine; Skin Neoplasms | 2006 |
Oral miltefosine to treat new world cutaneous leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Phosphorylcholine | 2007 |
Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cross-Sectional Studies; Drug Resistance; Humans; Leishmaniasis, Visceral; Phosphorylcholine; Prospective Studies; Treatment Outcome | 2006 |
Treatment of Bolivian mucosal leishmaniasis with miltefosine.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Female; Humans; Leishmania braziliensis; Leishmaniasis, Mucocutaneous; Male; Phosphorylcholine; Severity of Illness Index; Treatment Outcome | 2007 |
Miltefosine in cutaneous leishmaniasis.
Topics: Adult; Antimony; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2007 |
Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Female; Humans; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Zoonoses | 2007 |
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiprotozoal Agents; Aspartate Aminotransferases; Capsules; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Creatinine; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; India; Leishmaniasis, Visceral; Liver Diseases; Male; Middle Aged; Patient Compliance; Phosphorylcholine; Treatment Outcome | 2007 |
Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Child; Female; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Time Factors; Treatment Outcome | 2008 |
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
Topics: Adult; Afghanistan; Animals; Antiprotozoal Agents; Chromatography, Liquid; Female; Humans; Leishmania major; Leishmaniasis, Cutaneous; Male; Mass Spectrometry; Metabolic Clearance Rate; Military Personnel; Models, Biological; Netherlands; Phosphorylcholine; Young Adult | 2008 |
Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo.
Topics: Antineoplastic Agents; Humans; Hypersensitivity; In Vitro Techniques; Inflammation Mediators; Mast Cells; Phosphorylcholine | 2009 |
New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Topics: Adult; Amphotericin B; Drug Therapy, Combination; Female; Humans; India; Leishmaniasis, Visceral; Male; Phosphorylcholine; Treatment Outcome | 2008 |
Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Leishmaniasis, Visceral; Male; Phosphorylcholine; Treatment Outcome | 2009 |
Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.
Topics: Adult; Antiprotozoal Agents; Bolivia; Drug Administration Schedule; Female; Humans; Leishmaniasis, Mucocutaneous; Male; Phosphorylcholine | 2009 |
Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Cell Count; Clobetasol; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mast Cells; Mastocytosis, Cutaneous; Middle Aged; Phosphorylcholine; Young Adult | 2010 |
Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis.
Topics: Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Dermatitis, Atopic; Female; Forkhead Transcription Factors; Humans; Inflammation; Male; Membrane Microdomains; Middle Aged; Phosphorylcholine; Severity of Illness Index; Signal Transduction; Skin; T-Lymphocytes; Time Factors; Treatment Outcome; Young Adult | 2010 |
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Capsules; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Military Personnel; Organometallic Compounds; Phosphorylcholine; Young Adult | 2010 |
Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment.
Topics: Adult; Afghanistan; Antiprotozoal Agents; Cryotherapy; Humans; Leishmania major; Leishmaniasis, Cutaneous; Male; Military Personnel; Netherlands; Phosphorylcholine; Time Factors | 2010 |
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Female; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Middle Aged; Nausea; Phosphorylcholine; Prevalence; Treatment Outcome; Vomiting; Young Adult | 2010 |
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemoglobins; Humans; India; Leishmaniasis, Visceral; Liver; Liver Function Tests; Male; Middle Aged; Paromomycin; Phosphorylcholine; Recurrence; Young Adult | 2011 |
Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Female; Humans; Leishmania guyanensis; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Treatment Outcome; Young Adult | 2011 |
In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality.
Topics: Adult; AIDS-Related Opportunistic Infections; Cryptosporidiosis; Diarrhea; Early Termination of Clinical Trials; Female; Fluid Therapy; Humans; Liver; Male; Phosphorylcholine; Renal Insufficiency; Treatment Outcome; Young Adult | 2011 |
Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Amphotericin B; Antimony Sodium Gluconate; Child; Drug Therapy, Combination; Humans; Kenya; Leishmaniasis, Visceral; Middle Aged; Phosphorylcholine; Research Design; Sudan; Time Factors; Treatment Outcome; Trypanocidal Agents; Young Adult | 2011 |
Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh.
Topics: Adolescent; Adult; Antiprotozoal Agents; Bangladesh; Child; Child, Preschool; Female; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Treatment Outcome | 2011 |
Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Topics: Administration, Oral; Antiprotozoal Agents; Child; Child, Preschool; Colombia; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Treatment Failure | 2012 |
Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Cohort Studies; Female; Humans; India; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Statistics, Nonparametric; Treatment Outcome | 2012 |
Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Young Adult | 2012 |
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria.
Topics: Chronic Disease; Double-Blind Method; Histamine Antagonists; Humans; Phosphorylcholine; Placebos; Urticaria | 2013 |
Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.
Topics: Administration, Oral; Adolescent; Adult; Female; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Treatment Outcome; Trypanocidal Agents; Young Adult | 2013 |
Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia.
Topics: Adult; Antiprotozoal Agents; Colombia; Follow-Up Studies; Humans; Hyperthermia, Induced; Leishmaniasis, Cutaneous; Male; Military Personnel; Phosphorylcholine; Recurrence; Treatment Outcome; Young Adult | 2013 |
[Cutaneous leishmaniasis. Diagnosis and therapy in northern Afghanistan].
Topics: Administration, Topical; Adult; Afghanistan; Antimony Sodium Gluconate; Antiprotozoal Agents; Combined Modality Therapy; Cryotherapy; Dermatologic Agents; Humans; Internationality; Leishmaniasis, Cutaneous; Male; Military Personnel; Phosphorylcholine; Treatment Outcome; Young Adult | 2014 |
TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Cells, Cultured; Dendritic Cells; Drug Combinations; Female; HEK293 Cells; Humans; Interleukin-10; Interleukin-12; Leishmaniasis, Visceral; Male; Myeloid Differentiation Factor 88; Paromomycin; Phosphorylcholine; Toll-Like Receptor 9 | 2014 |
Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes.
Topics: Antiprotozoal Agents; Brazil; Drug Resistance; Female; Humans; Leishmania infantum; Leishmaniasis, Visceral; Male; Phosphorylcholine; Protozoan Proteins | 2014 |
[Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Comparative Effectiveness Research; Female; Humans; Injury Severity Score; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Nasopharynx; Organometallic Compounds; Phosphorylcholine; Young Adult | 2014 |
Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Skin; Time Factors; Treatment Outcome | 2015 |
Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Retrospective Studies | 2015 |
Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Drug Administration Schedule; Female; Humans; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2015 |
Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
Topics: Antiprotozoal Agents; Calibration; Chromatography, Liquid; Coinfection; Dried Blood Spot Testing; Drug Stability; Ethiopia; Hematocrit; HIV; HIV Infections; Humans; Leishmania donovani; Leishmaniasis, Visceral; Limit of Detection; Liquid Phase Microextraction; Phosphorylcholine; Tandem Mass Spectrometry | 2016 |
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
Topics: Adolescent; Adult; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Drug Therapy, Combination; Female; Humans; Kenya; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Parasite Load; Phosphorylcholine; Sudan; Treatment Outcome; Young Adult | 2016 |
Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Pilot Projects; Treatment Outcome | 2017 |
Miltefosine: a novel internal standard approach to lysophospholipid quantitation using LC-MS/MS.
Topics: Algorithms; Blood Chemical Analysis; Chromatography, Liquid; Humans; Internationality; Lysophospholipids; Mass Spectrometry; Phosphorylcholine; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2017 |
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Bangladesh; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Phosphorylcholine; Recurrence; Treatment Outcome; Young Adult | 2017 |
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
Topics: Adolescent; Adult; Africa, Eastern; Antiprotozoal Agents; Biological Availability; Child; Female; Humans; Leishmaniasis, Visceral; Male; Models, Statistical; Nonlinear Dynamics; Phosphorylcholine; Population Health; Recurrence; Young Adult | 2017 |
Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.
Topics: Adult; Child; Child, Preschool; Colombia; Dose-Response Relationship, Drug; Female; Humans; Leishmaniasis, Cutaneous; Leukocytes, Mononuclear; Male; Middle Aged; Models, Statistical; Phosphorylcholine; Plasma; Young Adult | 2018 |
Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
Topics: Africa, Eastern; Antiprotozoal Agents; Area Under Curve; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Leishmania donovani; Leishmaniasis, Visceral; Male; Patient Safety; Phosphorylcholine; Treatment Outcome | 2019 |
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; India; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Phosphorylcholine; Prospective Studies; Treatment Outcome; Young Adult | 2018 |
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
Topics: Adult; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Parasite Load; Phosphorylcholine; Treatment Outcome; Young Adult | 2019 |
A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis.
Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate; Middle Aged; Phosphorylcholine; Pilot Projects; Time Factors; Treatment Outcome | 2019 |
Natural Resistance of
Topics: Adolescent; Adult; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Female; Humans; Immunity, Innate; Leishmania infantum; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Treatment Failure; Young Adult | 2019 |
Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Endoribonucleases; Female; Gene Expression Regulation; HIV; HIV Infections; Host-Pathogen Interactions; Humans; Interleukin-10; Leishmania donovani; Leishmaniasis, Visceral; Male; Phagosomes; Phosphorylcholine; Receptors, Histamine H4; Recurrence; Serine Proteases; Transcriptome; Treatment Failure | 2020 |
A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.
Topics: Antimony; Antiprotozoal Agents; Brazil; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Macrophage Colony-Stimulating Factor; Phosphorylcholine; Treatment Outcome | 2021 |
Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Antiprotozoal Agents; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leishmaniasis, Cutaneous; Macrophage Colony-Stimulating Factor; Male; Meglumine Antimoniate; Middle Aged; Phosphorylcholine; Young Adult | 2021 |
A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Pentoxifylline; Phosphorylcholine; Pilot Projects; Treatment Outcome; United States | 2021 |
IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Amphotericin B; Antibodies, Protozoan; Biomarkers; Drug Monitoring; Female; Humans; Immunoglobulin G; Interleukin-10; Leishmania donovani; Leishmaniasis, Visceral; Male; Phosphorylcholine; Young Adult | 2021 |
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; HIV; HIV Infections; Humans; India; Leishmaniasis, Visceral; Pharmaceutical Preparations; Phosphorylcholine; Recurrence; Treatment Outcome | 2022 |
A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World.
Topics: Adult; Antiprotozoal Agents; Humans; Hyperthermia, Induced; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Treatment Outcome | 2022 |
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Topics: Adult; Africa, Eastern; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome | 2023 |
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Child; Humans; Kenya; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome; Uganda | 2023 |
797 other study(ies) available for miltefosine and phosphorylcholine
| Article | Year |
|---|---|
Hexadecylphosphocholine amplifies the effect of granulocyte colony-stimulating factor on differentiating hematopoietic progenitor cells.
Topics: Antineoplastic Agents; Cell Differentiation; Drug Synergism; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Phosphorylcholine | 1992 |
Effect of miltefosine on transplanted methylnitrosourea-induced mammary carcinoma growing in Fischer 344 rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Weight; Female; Keratins; Mammary Neoplasms, Experimental; Neoplasm Transplantation; Phosphorylcholine; Rats; Rats, Inbred F344; Vimentin | 1992 |
Hexadecylphosphocholine inhibits translocation of CTP:choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells.
Topics: Animals; Biological Transport; Cells, Cultured; Choline; Choline-Phosphate Cytidylyltransferase; Diglycerides; Dogs; Kidney; Nucleotidyltransferases; Phosphatidylcholines; Phosphorylcholine; Tetradecanoylphorbol Acetate | 1992 |
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice.
Topics: Administration, Oral; Animals; Antimony Sodium Gluconate; Bone Marrow; Female; Leishmania; Leishmania donovani; Leishmaniasis, Visceral; Liver; Mice; Mice, Inbred BALB C; Phosphorylcholine; Spleen | 1992 |
Kinetics of Bacillus cereus phosphatidylinositol-specific phospholipase C with thiophosphate and fluorescent analogs of phosphatidylinositol.
Topics: Bacillus cereus; Chromatography, High Pressure Liquid; Hydrolysis; Kinetics; Micelles; Phosphatidylinositol Diacylglycerol-Lyase; Phosphatidylinositols; Phosphoinositide Phospholipase C; Phosphoric Diester Hydrolases; Phosphorylcholine; Spectrometry, Fluorescence; Substrate Specificity | 1992 |
Hexadecylphosphocholine stimulates the colony-stimulating factor-dependent growth of hemopoietic progenitor cells.
Topics: Aged; Aged, 80 and over; Cell Division; Cells, Cultured; Colony-Stimulating Factors; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylcholine | 1992 |
Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Deoxyglucose; Drug Screening Assays, Antitumor; Fluorodeoxyglucose F18; Humans; Phosphorylcholine; Tomography, Emission-Computed; Tumor Cells, Cultured | 1992 |
Synthesis of hexadecylphosphocholine (miltefosine).
Topics: Antineoplastic Agents; Phosphorylcholine | 1992 |
Experimental therapeutic studies with miltefosine in rats and mice.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Mice; Mice, Nude; Phosphorylcholine; Rats; Rats, Sprague-Dawley | 1992 |
Hexadecylphosphocholine in liposomal dispersions.
Topics: Antineoplastic Agents; Hemolysis; Lipid Bilayers; Liposomes; Phosphorylcholine | 1992 |
Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution.
Topics: Animals; Antineoplastic Agents; Female; Hemolysis; Phospholipid Ethers; Phosphorylcholine; Rats; Rats, Wistar; Tissue Distribution | 1992 |
Comparison of the tissue distribution of hexadecylphosphocholine and erucylphosphocholine.
Topics: Animals; Antineoplastic Agents; Female; Phosphorylcholine; Rats; Rats, Wistar; Tissue Distribution | 1992 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Phosphorylcholine; Skin Neoplasms | 1992 |
Cellular uptake and metabolic fate of hexadecylphosphocholine.
Topics: Antineoplastic Agents; Cell Line; Cells; Humans; Phosphorylcholine; Tumor Cells, Cultured | 1992 |
Morphological changes of adherent and nonadherent cells by treatment with hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine observed by scanning electron microscopy.
Topics: Antineoplastic Agents; Cell Adhesion; Humans; Microscopy, Electron, Scanning; Phospholipid Ethers; Phosphorylcholine; Tumor Cells, Cultured | 1992 |
Effects of hexadecylphosphocholine on cellular function.
Topics: Animals; Antineoplastic Agents; Humans; Phosphorylcholine; Tumor Cells, Cultured | 1992 |
Determination of alkylphosphocholines and of alkyl-glycero-phosphocholines in biological fluids and tissues.
Topics: Animals; Antineoplastic Agents; Body Fluids; Female; Phospholipid Ethers; Phosphorylcholine; Rats; Rats, Wistar; Viscera | 1992 |
Early effects of hexadecylphosphocholine on gene expression in leukemia cell lines.
Topics: Antineoplastic Agents; Humans; Leukemia; Phosphorylcholine; Transcription, Genetic; Tumor Cells, Cultured | 1992 |
In vitro and in vivo antitumoral activity of alkylphosphonates.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Screening Assays, Antitumor; Female; Mammary Neoplasms, Experimental; Mitosis; Phospholipase D; Phosphorylcholine; Prodrugs; Rats; Tumor Cells, Cultured; Type C Phospholipases | 1992 |
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Neoplasm Transplantation; Phosphorylcholine; Ploidies; Tumor Cells, Cultured | 1992 |
Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Membrane; Cell Survival; Dose-Response Relationship, Drug; Furans; Liver Neoplasms, Experimental; Lung Neoplasms; Magnetic Resonance Spectroscopy; Phospholipase D; Phospholipid Ethers; Phosphorus; Phosphorylcholine; Rats; Tumor Cells, Cultured; Type C Phospholipases | 1992 |
Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Chromatography, Thin Layer; Densitometry; Drug Administration Schedule; Female; Phospholipid Ethers; Phosphorylcholine; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 1992 |
Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties.
Topics: Animals; Antineoplastic Agents; Cell Count; Cell Division; Coloring Agents; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Nitrosourea Compounds; Phosphorylcholine; Rats; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Vinblastine | 1992 |
Synthesis of alkylphosphonates, a new class of antineoplastic agents.
Topics: Antineoplastic Agents; Organophosphonates; Phosphorylcholine | 1992 |
Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells.
Topics: Cells, Cultured; Colony-Stimulating Factors; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Interferon-gamma; Interleukin-2; Monocytes; Phosphorylcholine; RNA, Messenger; Transcription, Genetic | 1992 |
Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.
Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Male; Mammary Neoplasms, Experimental; Methylnitrosourea; Phosphatidylcholines; Phosphorylcholine; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Tissue Distribution | 1992 |
Effects of antineoplastic phospholipids on parameters of cell differentiation in U937 cells.
Topics: Antigens, Surface; Antineoplastic Agents; Blotting, Northern; Cell Transformation, Neoplastic; DNA Probes; Fatty Alcohols; Gene Expression Regulation, Neoplastic; Histones; Leukemia, Promyelocytic, Acute; Lysophosphatidylcholines; Phorbol Esters; Phospholipid Ethers; Phospholipids; Phosphorylcholine; RNA; RNA, Messenger; Tetradecanoylphorbol Acetate | 1990 |
The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; Mitosis; Phosphorylcholine; Protein Kinase C; Tetradecanoylphorbol Acetate | 1991 |
Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations.
Topics: Animals; Antineoplastic Agents; Hemolysis; Humans; Leukemia P388; Liposomes; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Neoplasms, Experimental; Phosphorylcholine | 1991 |
Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity.
Topics: Bombesin; Carrier Proteins; Cell Division; Inositol Phosphates; Lithium; Phosphorylcholine; Protein Kinase C; Sodium-Hydrogen Exchangers; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1991 |
The phospholipid analogue hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells.
Topics: Animals; Cell Line; Choline; Dogs; Kinetics; N-Acylneuraminate Cytidylyltransferase; Phosphatidylcholines; Phosphatidylethanolamines; Phosphorylcholine | 1991 |
Investigation into the immunological effects of miltefosine, a new anticancer agent under development.
Topics: Animals; Antibody Formation; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Immunity, Cellular; Macrophages; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Phagocytosis; Phosphorylcholine; Rats; Rats, Inbred Strains; Spleen; Tumor Cells, Cultured | 1991 |
Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2.
Topics: Drug Synergism; HLA-DR Antigens; Humans; In Vitro Techniques; Interferon-gamma; Interleukin-2; Leukocytes, Mononuclear; Lymphocyte Activation; Phosphorylcholine; Phytohemagglutinins; Receptors, Interleukin-2; T-Lymphocytes; Time Factors | 1991 |
In vitro investigations on the antineoplastic effect of hexadecylphosphocholine.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Colony-Forming Units Assay; Humans; KB Cells; Mammary Neoplasms, Experimental; Methylnitrosourea; Neoplasm Transplantation; Nitrosourea Compounds; Phospholipid Ethers; Phosphorylcholine; Rats; Rats, Inbred Strains; Tumor Cells, Cultured | 1991 |
Structural requirements of lysophospholipid-regulated mitochondrial Ca2+ transport.
Topics: Animals; Biological Transport; Calcium; Lysophospholipids; Membrane Potentials; Mitochondria, Liver; Phosphorylcholine; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1991 |
Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by cis-platin.
Topics: Acquired Immunodeficiency Syndrome; Cell Line; Chloramphenicol O-Acetyltransferase; Cisplatin; Ethylenediamines; Genetic Markers; HIV Long Terminal Repeat; HIV-1; Humans; Kanamycin Kinase; Phosphatidylcholines; Phosphorylcholine; Phosphotransferases; Plasmids; Transcriptional Activation; Transfection; Virus Replication | 1990 |
Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells.
Topics: Cell Differentiation; Cell Line; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Phospholipid Ethers; Phosphoproteins; Phosphorylation; Phosphorylcholine; Protein Kinase C; Tetradecanoylphorbol Acetate | 1991 |
New pharmaceuticals: miltefosine.
Topics: Animals; Antineoplastic Agents; Mammary Neoplasms, Experimental; Neoplasms; Phosphorylcholine | 1990 |
New cytostatics--more activity and less toxicity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colorectal Neoplasms; Female; Male; Mammary Neoplasms, Experimental; Ovariectomy; Phenylenediamines; Phosphorylcholine; Rats; Rats, Inbred Strains; Remission Induction; Structure-Activity Relationship | 1990 |
Interstitial chemotherapy of experimental gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Screening Assays, Antitumor; Glioma; Humans; Injections, Intralesional; Male; Methotrexate; Mice; Mice, Nude; Neoplasm Transplantation; Phospholipid Ethers; Phosphorylcholine; Polyesters; Rats; Rats, Inbred Strains | 1990 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Phosphorylcholine; Remission Induction; Skin Neoplasms | 1990 |
Tumor heterogeneity and chemosensitivity to cyclophosphamide, vinblastine and hexadecylphosphocholine.
Topics: Animals; Antineoplastic Agents; Clone Cells; Cyclophosphamide; Drug Screening Assays, Antitumor; Female; Humans; Mammary Neoplasms, Experimental; Phosphorylcholine; Rats; Rats, Inbred Strains; Tumor Cells, Cultured; Vinblastine | 1990 |
Quantitation of hexadecylphosphocholine by high-performance thin-layer chromatography with densitometry.
Topics: Choline; Chromatography, Thin Layer; Densitometry; Humans; Lipids; Phosphorylcholine | 1990 |
Effect of ether lipids on mouse granulocyte-macrophage progenitor cells.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Female; Hematopoietic Stem Cells; Leukocyte Count; Lysophosphatidylcholines; Mice; Phospholipid Ethers; Phosphorylcholine | 1989 |
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Choline; Drug Screening Assays, Antitumor; Female; Humans; Liver; Mammary Neoplasms, Experimental; Mice; Neoplasm Recurrence, Local; Phosphorylcholine; Rats; Rats, Inbred Strains; Skin Neoplasms; Tumor Cells, Cultured | 1989 |
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Topics: Administration, Topical; Breast Neoplasms; Choline; Drug Evaluation; Female; Humans; Neoplasm Recurrence, Local; Phosphorylcholine; Skin Neoplasms | 1988 |
Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Benzopyrenes; Choline; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Leukocytosis; Mammary Neoplasms, Experimental; Phosphorylcholine; Rats; Rats, Inbred Strains; Sarcoma, Experimental | 1988 |
Ether lipids and analogues.
Topics: Antineoplastic Agents; Humans; Phospholipid Ethers; Phosphorylcholine; Structure-Activity Relationship | 1988 |
New cytostatics with experimentally different toxic profiles.
Topics: Animals; Antineoplastic Agents; Choline; Dogs; Female; Male; Neoplasms, Experimental; Phospholipid Ethers; Phosphorylcholine; Rats | 1987 |
Distribution and metabolism of hexadecylphosphocholine in mice.
Topics: Administration, Oral; Animals; Choline; Female; Mice; Phosphorylcholine; Tissue Distribution | 1987 |
Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Choline; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Male; Mammary Neoplasms, Experimental; Phospholipid Ethers; Phosphorylcholine; Rats | 1987 |
Alkyl phosphocholines: toxicity and anticancer properties.
Topics: Animals; Antineoplastic Agents; Carcinoma; Choline; Dose-Response Relationship, Drug; Female; Male; Mammary Neoplasms, Experimental; Phospholipid Ethers; Phosphorylcholine; Rats; Rats, Inbred Strains; Sex Factors | 1987 |
Comparative optically detected magnetic resonance studies of mammalian phospholipase A2-lipid interactions.
Topics: Animals; Cattle; Choline; Horses; Kinetics; Magnetics; Micelles; Pancreas; Phospholipases; Phospholipases A; Phospholipases A2; Phosphorylcholine; Protein Binding; Species Specificity; Spectrum Analysis; Swine | 1987 |
Investigation of phospholipase-lipid interactions by optical detection of triplet state magnetic resonance spectroscopy.
Topics: Animals; Choline; Enzyme Precursors; Magnetic Resonance Spectroscopy; Micelles; Phospholipases; Phospholipases A; Phospholipases A2; Phosphorylcholine; Swine | 1985 |
pH dependence of the binding constant of a phospholipase A2 from Agkistrodon halys blomhoffii venom to micelles of n-hexadecylphosphorylcholine.
Topics: Binding Sites; Chemical Phenomena; Chemistry; Choline; Crotalid Venoms; Hydrogen-Ion Concentration; Mathematics; Micelles; Models, Chemical; Phospholipases; Phospholipases A; Phospholipases A2; Phosphorylcholine; Protein Binding; Spectrometry, Fluorescence | 1984 |
Bindings of Ca2+ and substrate analogs to a cobra venom phospholipase A2 in which the alpha-amino group is modified to an alpha-keto group.
Topics: Animals; Calcium; Chemical Phenomena; Chemistry; Circular Dichroism; Elapid Venoms; Hydrogen-Ion Concentration; Kinetics; Micelles; Phospholipases; Phospholipases A; Phospholipases A2; Phosphorylcholine; Spectrometry, Fluorescence; Structure-Activity Relationship | 1984 |
Bindings of cobra venom phospholipases A2 to micelles of n-hexadecylphosphorylcholine.
Topics: Animals; Choline; Elapid Venoms; Hydrogen-Ion Concentration; Kinetics; Micelles; Phospholipases; Phospholipases A; Phosphorylcholine; Protein Binding; Spectrometry, Fluorescence | 1983 |
The amido black assay: a simple and quantitative multipurpose test of adhesion, proliferation, and cytotoxicity in microplate cultures of keratinocytes (HaCaT) and other cell types growing adherently or in suspension.
Topics: 3T3 Cells; Adult; Amido Black; Animals; Cell Adhesion; Cell Count; Cell Division; Cell Line; Culture Techniques; Fibroblasts; Humans; Keratinocytes; Killer Cells, Lymphokine-Activated; Mice; Phosphorylcholine; Photometry; Staining and Labeling | 1994 |
The effect of two synthetic phospholipids on cell proliferation and phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells.
Topics: Animals; Antineoplastic Agents; Biological Transport, Active; Cell Division; Cell Line; Choline-Phosphate Cytidylyltransferase; Dogs; Kidney; Nucleotidyltransferases; Phosphatidylcholines; Phospholipid Ethers; Phosphorylcholine | 1995 |
Capillary gas chromatography of hexadecylphosphocholine in Caco-2T cells and cell culture media.
Topics: Antineoplastic Agents; Cell Death; Chromatography, Gas; Chromatography, Ion Exchange; Culture Media; Dose-Response Relationship, Drug; Humans; Phospholipid Ethers; Phosphorylcholine; Trimethylsilyl Compounds; Tumor Cells, Cultured | 1995 |
Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzo(a)pyrene; Cyclophosphamide; Female; Leukocyte Count; Leukopenia; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Sarcoma, Experimental | 1995 |
Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells.
Topics: Cell Line; Dose-Response Relationship, Drug; Drug Carriers; Histiocytes; Humans; Liposomes; Macrophages; Nitric Oxide; Phosphorylcholine; Time Factors; Tumor Necrosis Factor-alpha | 1995 |
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Humans; Male; Phosphorylcholine; Prostatic Neoplasms; Suramin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1994 |
Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Division; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Phosphorylcholine; Receptors, Colony-Stimulating Factor; Receptors, IgG; Transcription, Genetic; Tumor Cells, Cultured | 1994 |
Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.
Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Carriers; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraperitoneal; Liposomes; Male; Mice; Mice, Inbred Strains; Mice, Nude; Middle Aged; Phosphorylcholine; Tumor Cells, Cultured | 1994 |
Effects of hexadecylphosphocholine on fatty acid metabolism: relation to cytotoxicity.
Topics: Acyl Coenzyme A; Antineoplastic Agents; Cell Survival; Cells, Cultured; Coenzyme A Ligases; Fatty Acids; Glomerular Mesangium; Humans; Monocytes; Phospholipids; Phosphorylcholine; Repressor Proteins; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured | 1995 |
Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro.
Topics: Animals; Lipopolysaccharides; Liposomes; Macrophage Activation; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Nitric Oxide; Phosphorylcholine; Sarcoma, Experimental; Tumor Necrosis Factor-alpha | 1995 |
Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines.
Topics: Antineoplastic Agents; Cell Division; Cell Membrane; Cytosol; Diglycerides; Dose-Response Relationship, Drug; Humans; Leukemia; Phospholipid Ethers; Phosphorylcholine; Protein Kinase C; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1994 |
A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems.
Topics: Colloids; Drug Carriers; Erythrocytes; Hemoglobins; Hemolysis; Humans; In Vitro Techniques; Phosphorylcholine | 1994 |
Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Chromatography, High Pressure Liquid; Drug Carriers; Female; Half-Life; Injections, Intravenous; Liposomes; Mammary Neoplasms, Experimental; Methylnitrosourea; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Rats, Wistar | 1994 |
Uptake, subcellular distribution and metabolism of the phospholipid analogue hexadecylphosphocholine in MDCK cells.
Topics: Animals; Carbon Radioisotopes; Cell Division; Cell Line; Cell Membrane; Phosphatidylcholines; Phosphorylcholine; Subcellular Fractions; Temperature; Time Factors | 1994 |
Phospholipid analogue hexadecylphosphocholine inhibits proliferation and phosphatidylcholine biosynthesis of human epidermal keratinocytes in vitro.
Topics: Cell Division; Choline-Phosphate Cytidylyltransferase; Humans; Keratinocytes; Nucleotidyltransferases; Phosphatidylcholines; Phosphorylcholine; Protein Biosynthesis; Proteins | 1994 |
Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Cell Differentiation; Female; Ferrets; Mammary Neoplasms, Experimental; Phosphorylcholine; Piperidines; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Vomiting | 1993 |
Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Phosphorylcholine; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Tumor Cells, Cultured | 1993 |
Investigations on the cellular uptake of hexadecylphosphocholine.
Topics: Animals; Antineoplastic Agents; Biological Transport, Active; Cytochalasin B; Endocytosis; Humans; Kinetics; Lipid Metabolism; Membranes; Mice; Monensin; Phosphorylcholine; Temperature; Tumor Cells, Cultured | 1993 |
The effects of hexadecylphosphocholine (HPC) a mixture of alkylphosphocholines (APC) and different dietary oils on the growth of a human mammary tumor.
Topics: Animals; Breast Neoplasms; Corn Oil; Dietary Fats, Unsaturated; Dinoprostone; Fish Oils; Humans; Mice; Neoplasm Transplantation; Phosphatidylcholines; Phosphorylcholine; Structure-Activity Relationship | 1993 |
Antagonism of phorbol-ester-stimulated phosphatidylcholine biosynthesis by the phospholipid analogue hexadecylphosphocholine.
Topics: Animals; Biological Transport; Cell Division; Cell Line; Cell Survival; Choline; Choline-Phosphate Cytidylyltransferase; Digitonin; Diglycerides; Dogs; HeLa Cells; Humans; Kidney; Nucleotidyltransferases; Phosphatidylcholines; Phosphorylcholine; Tetradecanoylphorbol Acetate | 1993 |
Hexadecylphosphocholine differs from conventional cytostatic agents.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Chromatography, High Pressure Liquid; DNA, Viral; Dose-Response Relationship, Drug; Herpes Simplex; Mammary Neoplasms, Experimental; Methylnitrosourea; Nucleotides; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Simplexvirus; Vesicular stomatitis Indiana virus; Virus Diseases; Virus Replication | 1993 |
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Resistance; Drug Screening Assays, Antitumor; Female; Mammary Neoplasms, Animal; Methotrexate; Mice; Mice, Inbred Strains; Organ Size; Ovarian Neoplasms; Phosphorylcholine; Tumor Cells, Cultured; Uterus | 1993 |
Inhibition of phospholipase C delta by hexadecylphosphorylcholine and lysophospholipids with antitumor activity.
Topics: Animals; Antineoplastic Agents; Enzyme Activation; Isoenzymes; Liver; Lysophosphatidylcholines; Lysophospholipids; Phosphorylcholine; Rats; Spermine; Time Factors; Type C Phospholipases | 1993 |
Alkylphosphocholines inhibit choline uptake and phosphatidylcholine biosynthesis in rat sympathetic neurons and impair axonal extension.
Topics: Animals; Animals, Newborn; Axons; Biological Transport; Cells, Cultured; Choline; Choline-Phosphate Cytidylyltransferase; Enzyme Inhibitors; Kinetics; Neurons; Nucleotidyltransferases; Phosphatidylcholines; Phosphorylcholine; Protein Kinase C; Rats; Rats, Sprague-Dawley; Superior Cervical Ganglion; Tetradecanoylphorbol Acetate | 1995 |
Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells.
Topics: Antineoplastic Agents; Cell Division; Cell Membrane; Choline; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Inositol; Phospholipids; Phosphorylcholine; Tumor Cells, Cultured | 1995 |
The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D.
Topics: Antineoplastic Agents; Breast; Enzyme Activation; Fibroblasts; Humans; Hydrolysis; Kinetics; Lysophosphatidylcholines; Phospholipase D; Phospholipid Ethers; Phosphorylcholine; Protein Kinase C; Signal Transduction; Structure-Activity Relationship; Tritium | 1996 |
Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation.
Topics: Animals; Chemical Phenomena; Chemistry, Physical; Drug Stability; Half-Life; Hydrogen-Ion Concentration; Lipopolysaccharides; Liposomes; Macrophage Activation; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Nitric Oxide; Phosphorylcholine; Polyethylene Glycols; Tumor Necrosis Factor-alpha | 1996 |
Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB.
Topics: Antineoplastic Agents; Choline; Drug Resistance, Neoplasm; Humans; Inositol; KB Cells; Phospholipid Ethers; Phosphorylcholine | 1996 |
Cellular signalling as a target in cancer chemotherapy. Phospholipid analogues as inhibitors of mitogenic signal transduction.
Topics: Antineoplastic Agents; Calcium; Enzyme Inhibitors; Inositol 1,4,5-Trisphosphate; Molecular Structure; Neoplasms; Phospholipase D; Phospholipids; Phosphorylcholine; Phosphoserine; Protein Kinase C; Signal Transduction; Sodium-Hydrogen Exchangers; Thrombin; Type C Phospholipases | 1996 |
Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines.
Topics: Animals; Chemical Phenomena; Chemistry; Electrophoresis; Endocytosis; Fluorescent Dyes; Liposomes; Macrophages; Mice; Particle Size; Phospholipids; Phosphorylcholine; Polyethylene Glycols | 1996 |
Cell-matrix interactions of normal and transformed human keratinocytes in vitro are modulated by the synthetic phospholipid analogue hexadecylphosphocholine.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Differentiation; Cell Division; Cell Line, Transformed; Down-Regulation; Extracellular Matrix Proteins; Flow Cytometry; Humans; Integrins; Keratinocytes; Phosphorylcholine | 1996 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Leishmaniasis, Visceral; Lysophospholipids; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Phospholipid Ethers; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma cruzi; Trypanosomiasis, African | 1996 |
Ether lipids are effective cytotoxic drugs against multidrug-resistant acute leukemia cells and can act by the induction of apoptosis.
Topics: Adult; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Phospholipid Ethers; Phosphorylcholine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Stem Cell Assay | 1997 |
Miltefosine in recurrent cutaneous breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Phosphorylcholine; Skin Neoplasms; Treatment Outcome | 1997 |
Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Synergism; Drug Therapy, Combination; Female; Mice; Microbial Sensitivity Tests; Molecular Structure; Phenylbutazone; Phosphorylcholine; Piperidines; Platelet Activating Factor; Specific Pathogen-Free Organisms; Trypanosoma brucei brucei; Trypanosomiasis, African | 1997 |
The phospholipid analogue hexadecylphosphocholine (HePC) inhibits proliferation of keloid fibroblasts in vitro and modulates their fibronectin and integrin synthesis.
Topics: Cell Division; Cells, Cultured; Collagen; Extracellular Matrix; Fibroblasts; Fibronectins; Humans; Integrins; Keloid; Male; Phosphatidylcholines; Phosphorylcholine; Reference Values | 1997 |
Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Half-Life; Injections, Intravenous; Liposomes; Mammary Neoplasms, Experimental; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tumor Cells, Cultured | 1996 |
Influence of hexadecylphosphocholine (miltefosine) on cytokine synthesis and biological responses.
Topics: Animals; Antineoplastic Agents; Blotting, Northern; Colony-Forming Units Assay; Concanavalin A; Cytokines; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Interleukin-3; Leukemia, Myeloid; Lipopolysaccharides; Mice; Phosphorylcholine; Rats; Receptors, Granulocyte Colony-Stimulating Factor; Recombinant Proteins; RNA, Messenger; Tumor Necrosis Factor-alpha | 1996 |
[Spectrographic studies on the radioresistance of Miltex and miltefosine].
Topics: Antineoplastic Agents; Drug Stability; Phosphorylcholine; Radiation Dosage; Radiation Tolerance; Solutions; Spectrophotometry, Ultraviolet; Time Factors | 1997 |
Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Cholesterol; Ethanolamines; Humans; Liposomes; Metabolic Clearance Rate; Mice; Phosphatidylcholines; Phosphorylcholine; Polyethylene Glycols; Receptors, Estrogen; Tumor Cells, Cultured | 1997 |
D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Body Weight; Dose-Response Relationship, Drug; Female; Mammary Neoplasms, Experimental; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured | 1997 |
IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-1; Lymphocytes, Tumor-Infiltrating; Macrophages; Mice; Mice, Nude; Phosphorylcholine; Transplantation, Heterologous | 1997 |
Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine.
Topics: Acylation; Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Survival; Drug Resistance; Enzyme Activation; Humans; Phospholipases A; Phospholipases A2; Phospholipids; Phosphorylcholine; Protein Kinase C; Signal Transduction; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Comparison of hexadecylphosphocholine with fish oil as an antitumor agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dinoprostone; Docosahexaenoic Acids; Drug Combinations; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Fatty Acids; Female; Fish Oils; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phospholipids; Phosphorylcholine; Tumor Cells, Cultured | 1997 |
Antiproliferation effects of hexadecylphosphocholine on solid tumour and leukaemia selectively in vitro.
Topics: Animals; Antineoplastic Agents; Cell Division; Dose-Response Relationship, Drug; Leukemia, Experimental; Mice; Phosphorylcholine; Tumor Cells, Cultured | 1997 |
Hexadecylphosphocholine inhibits phosphatidylinositol and phosphatidylcholine phospholipase C in human leukemia cells.
Topics: Antineoplastic Agents; Cell Membrane; Cells, Cultured; Chromatography, Thin Layer; Enzyme Activation; Humans; Leukemia; N-Formylmethionine Leucyl-Phenylalanine; Phosphatidylinositol Diacylglycerol-Lyase; Phosphorylcholine; Tumor Necrosis Factor-alpha; Type C Phospholipases | 1996 |
Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues.
Topics: Antigens, Surface; Antineoplastic Agents; Cholesterol; Chromosomes; Drug Resistance, Neoplasm; Flow Cytometry; HL-60 Cells; Humans; Leukemia; Neoplasm Proteins; Phospholipids; Phosphorylcholine | 1996 |
The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cell Survival; Choline; Choline-Phosphate Cytidylyltransferase; Cytidine Diphosphate Choline; DNA Fragmentation; Enzyme Inhibitors; Flow Cytometry; HL-60 Cells; Humans; Lysophosphatidylcholines; Phosphatidylcholines; Phospholipid Ethers; Phospholipids; Phosphorylcholine; Recombinant Proteins | 1998 |
Structure-activity relationships in the fusion of small unilamellar phosphatidylcholine vesicles induced by a model peptide.
Topics: Animals; Circular Dichroism; Hydrogen-Ion Concentration; Membrane Fusion; Phosphatidylcholines; Phosphorylcholine; Protein Structure, Secondary; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Structure-Activity Relationship | 1997 |
Expression of two 50 kDa proteins is associated with sensitivity towards etherlipid analogues in the human leukaemia cell line HL 60.
Topics: Antineoplastic Agents; Cell Differentiation; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Neoplasm Proteins; Phospholipid Ethers; Phosphorylcholine | 1997 |
Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.
Topics: Animals; Antiprotozoal Agents; Female; Leishmania infantum; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Phosphorylcholine; Treatment Outcome | 1998 |
Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line.
Topics: Apoptosis; Carcinoma, Embryonal; Cell Differentiation; Cell Survival; Cisplatin; DNA Damage; DNA Fragmentation; Docosahexaenoic Acids; Drug Resistance, Neoplasm; Humans; Male; Phosphorylcholine; Tretinoin; Tumor Cells, Cultured | 1998 |
Hexadecylphosphocholine and 2-modified 1,3-diacylglycerols as effectors of phospholipase D.
Topics: Brassica; Diglycerides; Kinetics; Models, Biological; Phosphatidylcholines; Phospholipase D; Phosphorylcholine; Sodium Dodecyl Sulfate; Substrate Specificity; Surface-Active Agents | 1998 |
Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine.
Topics: Antineoplastic Agents; Apoptosis; Carboxylic Acids; Cell Division; Cell Line; Ceramides; Fumonisins; Phosphatidylcholines; Phosphorylcholine; Sphingomyelins | 1998 |
The effect of hexadecylphosphocholine on the degradation of mitochondrial phospholipids.
Topics: Animals; Calcium; Chromatography, Thin Layer; Dose-Response Relationship, Drug; Mitochondria, Liver; Phospholipids; Phosphorylcholine; Rats; Time Factors | 1998 |
Opposite effects on cytosolic Ca2+ of antitumor phospholipids by induction of calcium influx and activation of endoplasmic reticulum Ca(2+)-ATPase.
Topics: Antineoplastic Agents; Breast; Calcium; Calcium-Transporting ATPases; Cell Division; Cell Line, Transformed; Cytarabine; Cytosol; Endoplasmic Reticulum; Enzyme Activation; Epithelial Cells; Female; Humans; Ion Transport; Lysophospholipids; Manganese; Phosphorylcholine; Phosphoserine; Signal Transduction; Structure-Activity Relationship | 1998 |
Quaternary ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Survival; Culture Media, Serum-Free; Drug Resistance; Enzyme Activation; Furans; HL-60 Cells; Humans; Phospholipid Ethers; Phosphorylcholine; Protein Kinase C; Quaternary Ammonium Compounds; Structure-Activity Relationship; Tetradecanoylphorbol Acetate | 1998 |
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.
Topics: Animals; Breast Neoplasms; Cell Division; Female; Humans; Liposomes; Metallothionein 3; Mice; Mice, Nude; Phosphorylcholine; Tumor Cells, Cultured | 1998 |
Influence of probes for calcium-calmodulin and protein kinase C signalling on the plasma membrane Ca2+-ATPase activity of rat synaptosomes and leukocyte membranes.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium-Transporting ATPases; Calmodulin; Cell Membrane; Enzyme Inhibitors; Gallic Acid; Imidazoles; Leukocytes; Male; Phosphodiesterase Inhibitors; Phospholipid Ethers; Phosphorylcholine; Protein Kinase C; Quercetin; Rats; Rats, Wistar; Signal Transduction; Sphingosine; Staurosporine; Synaptosomes | 1998 |
The interference effects of hexadecylphosphocholine on proliferation and membrane phospholipid metabolism in human myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Division; Cytosol; HL-60 Cells; Humans; Phospholipids; Phosphorylcholine; Tumor Cells, Cultured | 1998 |
Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis.
Topics: Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Endothelium, Vascular; Gamma Rays; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phospholipid Ethers; Phosphorylcholine; Protein Kinases; Signal Transduction; U937 Cells | 1999 |
Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography.
Topics: Antineoplastic Agents; Breast Neoplasms; Chromatography, Gas; Humans; Leukemia; Phosphorylcholine; Reference Standards; Tumor Cells, Cultured | 1999 |
[Visceral leishmaniasis: a new oral treatment?].
Topics: Antiprotozoal Agents; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 1999 |
Synthetic analogues of irlbacholine: a novel antifungal plant metabolite isolated from Irlbachia alata.
Topics: Antifungal Agents; Aspergillus fumigatus; Candida albicans; Central America; Cryptococcus neoformans; Microbial Sensitivity Tests; Phosphorylcholine; Plants, Medicinal; South America | 1999 |
Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Design; Drug Resistance; Gene Expression; Genes, bcl-2; Genes, MDR; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Phosphorylcholine; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 1999 |
BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines.
Topics: Apoptosis; Cell Adhesion; Cell Survival; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Molecular Structure; Phosphorylcholine; Structure-Activity Relationship; Tumor Cells, Cultured | 1999 |
Miltefosine--the long-awaited therapy for visceral leishmaniasis?
Topics: Administration, Oral; Antiprotozoal Agents; Female; Gastrointestinal Diseases; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 1999 |
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Carriers; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Liposomes; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Phosphorylcholine; Specific Pathogen-Free Organisms; Tissue Distribution | 1999 |
Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
Topics: Animals; Antiprotozoal Agents; Leishmania donovani; Leishmaniasis, Visceral; Macrophage Activation; Mice; Phosphorylcholine; T-Lymphocytes | 2000 |
Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Dose-Response Relationship, Drug; Heart; Life Cycle Stages; Lysophospholipids; Macrophages; Mice; Microscopy, Electron; Phospholipid Ethers; Phosphorylcholine; Temperature; Time Factors; Trypanosoma cruzi | 2000 |
Miltefosine for visceral leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2000 |
Miltefosine for visceral leishmaniasis.
Topics: Administration, Oral; Aminoquinolines; Antiprotozoal Agents; Drug Synergism; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2000 |
Mumps virus can suppress the effective augmentation of HPC-induced apoptosis by IFN-gamma through disruption of IFN signaling in U937 cells.
Topics: Apoptosis; DNA-Binding Proteins; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Interferon Regulatory Factor-1; Interferon-gamma; Interferon-Stimulated Gene Factor 3; Interferon-Stimulated Gene Factor 3, gamma Subunit; Mumps virus; Phosphoproteins; Phosphorylcholine; Signal Transduction; STAT1 Transcription Factor; STAT2 Transcription Factor; Trans-Activators; Transcription Factors; U937 Cells | 2000 |
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylcholine; Secondary Prevention; T-Lymphocytes | 2000 |
Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.
Topics: Acylation; Acyltransferases; Alcohol Oxidoreductases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Leishmania mexicana; Microbodies; Phospholipid Ethers; Phosphorylcholine | 2000 |
Surface remodeling associated with vasopressin-induced membrane traffic in L6 myogenic cells.
Topics: Acridine Orange; Acrylamide; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line; Cell Membrane; Cell Movement; Cytochalasin B; Enzyme Inhibitors; Exocytosis; Fluorescent Dyes; Fluorometry; Kinetics; Ligands; Microscopy, Electron; Microscopy, Electron, Scanning; Muscles; Paclitaxel; Phosphatidylcholines; Phosphatidylinositol 3-Kinases; Phospholipids; Phosphorylcholine; Rats; Signal Transduction; Time Factors; Vasopressins; Wortmannin | 2000 |
Effects of hexadecylphosphocholine on thrombocytopoiesis.
Topics: Antineoplastic Agents; Blood Platelets; Cell Division; Enzyme-Linked Immunosorbent Assay; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Humans; Megakaryocytes; Phosphorylcholine; RNA, Messenger; Thrombocytosis; Tumor Cells, Cultured | 2001 |
Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: Participation of activated macrophages in the antitumor mechanism.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Humans; Interleukin-6; Liposomes; Lymphocytes, Tumor-Infiltrating; Macrophage Activation; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasms, Experimental; Phosphorylcholine; RNA, Messenger; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2001 |
Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.
Topics: Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Drug Carriers; Drug Evaluation, Preclinical; Entamoeba histolytica; Entamoebiasis; Humans; Intestinal Diseases; Liposomes; Phosphorylcholine | 2001 |
Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Cells, Cultured; Choline Kinase; Enzyme Activation; Epithelial Cells; Humans; Hydrolysis; Kinetics; Mice; Phospholipase D; Phosphorylcholine; Protein Kinase C; Rats; Signal Transduction; Structure-Activity Relationship | 2001 |
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Leishmania donovani; Leishmaniasis, Visceral; Liver; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Mice, SCID; Phosphorylcholine; Species Specificity | 2001 |
MDR1 causes resistance to the antitumour drug miltefosine.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Female; HeLa Cells; Humans; Phosphorylcholine; Recombinant Proteins; RNA, Messenger; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2001 |
Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator.
Topics: Animals; Antibiotics, Antineoplastic; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Daunorubicin; Drug Resistance, Multiple; Fluorescence; Humans; Leishmania tropica; Parasitic Sensitivity Tests; Phospholipid Ethers; Phosphorylcholine | 2001 |
Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Cell Cycle; Cholesterol; Drug Screening Assays, Antitumor; Endocytosis; Humans; Phospholipids; Phosphorylcholine; Tumor Cells, Cultured | 2001 |
Drug resistance in Indian visceral leishmaniasis.
Topics: Aminoquinolines; Amphotericin B; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Resistance; Geography; History, 20th Century; History, 21st Century; Humans; India; Leishmaniasis, Visceral; Paromomycin; Pentamidine; Phosphorylcholine; Treatment Outcome | 2001 |
Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Dose-Response Relationship, Drug; Leishmania; Macrophages, Peritoneal; Mice; Phospholipid Ethers; Phosphorylcholine; Species Specificity | 2002 |
Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Alkanes; Amebicides; Animals; Cell Survival; Hexokinase; Humans; Mice; Phosphorylcholine | 2002 |
Miltefosine Zentaris.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Administration Schedule; Humans; Leishmaniasis, Visceral; Phosphorylcholine; Structure-Activity Relationship; Trypanocidal Agents | 2002 |
Phospholipase C-gamma modulates epithelial tight junction permeability through hyperphosphorylation of tight junction proteins.
Topics: Actins; Animals; Cell Line; Cell Membrane Permeability; Coumarins; Dogs; Enzyme Inhibitors; Estrenes; Isoenzymes; Membrane Proteins; Nitro Compounds; Phospholipase C gamma; Phosphorylation; Phosphorylcholine; Pyrrolidinones; Tight Junctions; Type C Phospholipases | 2002 |
Determination of total acidity and of divalent cations by ion chromatography with n-hexadecylphosphocholine as the stationary phase.
Topics: Acids; Cations, Divalent; Chromatography, Liquid; Phosphorylcholine; Sensitivity and Specificity | 2002 |
New therapy for visceral leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine | 2002 |
Miltefosine presents new hope for leishmaniasis patients.
Topics: Antiprotozoal Agents; Government Programs; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine | 2002 |
Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis.
Topics: Adult; Animals; Antibodies, Protozoan; Antibody Formation; Antigens, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Immunoblotting; Leishmania donovani; Leishmaniasis, Visceral; Peptides; Phosphorylcholine; Predictive Value of Tests; Prognosis | 2002 |
New treatment for leishmaniasis is 95% effective.
Topics: Antiprotozoal Agents; Developing Countries; Humans; India; Leishmaniasis; Phosphorylcholine; Treatment Outcome; World Health Organization | 2002 |
Hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis and the proliferation of HepG2 cells.
Topics: Antineoplastic Agents; Cell Division; Choline; Humans; Phosphatidylcholines; Phosphorylcholine; Tumor Cells, Cultured | 2002 |
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.
Topics: Animals; Antiprotozoal Agents; Chagas Disease; Drug Resistance; Exudates and Transudates; Inflammation; Male; Mice; Mice, Inbred BALB C; Nitric Oxide; Nitric Oxide Synthase; Nitroimidazoles; omega-N-Methylarginine; Phosphorylcholine; Survival Analysis; Trypanosoma cruzi; Tumor Necrosis Factor-alpha | 2002 |
An oral drug for leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Clinical Trials as Topic; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine | 2002 |
Kala-azar--progress against a neglected disease.
Topics: Administration, Oral; Antiprotozoal Agents; Endemic Diseases; Leishmaniasis, Visceral; Phosphorylcholine; Protozoan Vaccines | 2002 |
Role of phospholipase C-beta in the modulation of epithelial tight junction permeability.
Topics: Animals; Cell Line; Dogs; Enzyme Inhibitors; Epithelial Cells; Estrenes; Isoenzymes; Permeability; Phospholipase C beta; Phosphorylcholine; Pyrrolidinones; Tight Junctions; Type C Phospholipases | 2003 |
Miltefosine in visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Fertility; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2003 |
Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.
Topics: Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Growth Inhibitors; HeLa Cells; Humans; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinases; Neoplasms, Glandular and Epithelial; Phosphatidylinositol 3-Kinases; Phospholipid Ethers; Phosphorylation; Phosphorylcholine; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction | 2003 |
Miltefosine for Indian visceral leishmaniasis.
Topics: Antiprotozoal Agents; Hemorrhage; HIV Infections; Humans; Leishmaniasis, Visceral; Phosphorylcholine; Spleen; Suction; Thrombocytopenia | 2003 |
Miltefosine for Indian visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Phosphorylcholine; Research Design; Spleen; Suction | 2003 |
The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Buthionine Sulfoximine; Drug Resistance; Female; Glutathione; Leishmania donovani; Leishmaniasis, Visceral; Male; Mice; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine | 2003 |
New therapy for "black fever" is 95% effective: India licenses the first oral drug for visceral leishmaniasis, a lethal disease of poverty.
Topics: Administration, Oral; Antiprotozoal Agents; Drug Approval; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine; Poverty | 2002 |
Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.
Topics: Alleles; Antiprotozoal Agents; Biological Transport; Cell Division; Cell Membrane; Cycloheximide; Dose-Response Relationship, Drug; Drug Resistance; Drug Resistance, Multiple; Endocytosis; Gene Deletion; Ketoconazole; Leishmaniasis; Lipid Metabolism; Lysophosphatidylcholines; Membrane Transport Proteins; Microscopy, Fluorescence; Mutation; Nuclear Envelope; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylserines; Phosphodiesterase Inhibitors; Phospholipid Ethers; Phosphorylcholine; Point Mutation; Protein Structure, Tertiary; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Time Factors | 2003 |
Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Endocytosis; Energy Metabolism; Fluorescent Dyes; Leishmania donovani; Phospholipids; Phosphorylcholine; Proteins; Temperature; Translocation, Genetic | 2003 |
Miltefosine (Impavido): the first oral treatment against leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine | 2004 |
Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.
Topics: Adenosine Triphosphatases; Alleles; Amino Acid Sequence; Animals; Antiprotozoal Agents; Biological Transport; Blotting, Southern; Carrier Proteins; Cell Membrane; Chromosome Mapping; Cloning, Molecular; Cosmids; Dose-Response Relationship, Drug; Drug Resistance; Genotype; Immunoblotting; Leishmania donovani; Membrane Proteins; Membrane Transport Proteins; Microscopy, Fluorescence; Models, Genetic; Molecular Sequence Data; Phenotype; Phosphodiesterase Inhibitors; Phospholipid Ethers; Phospholipid Transfer Proteins; Phosphorylcholine; Plasmids; Point Mutation; Protozoan Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transfection | 2003 |
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
Topics: Animals; Antiprotozoal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; DNA, Protozoan; Drug Resistance; Gene Amplification; Leishmania donovani; Phosphorylcholine | 2003 |
Hexadecylphosphocholine inhibits phosphatidylcholine synthesis via both the methylation of phosphatidylethanolamine and CDP-choline pathways in HepG2 cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Ethanolamines; Humans; Methylation; Phosphatidylcholines; Phosphorylcholine | 2004 |
Breakthrough in the management of visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine | 2003 |
Synthesis and antiproliferative activity of alkylphosphocholines.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; HeLa Cells; Hemolysis; Humans; Inhibitory Concentration 50; Jurkat Cells; K562 Cells; Macrophages; Mice; Molecular Structure; Phospholipase D; Phosphorylcholine; Structure-Activity Relationship; Tetrazolium Salts; Thymidine | 2003 |
Controlled plasmid gene transfer to murine renal carcinoma by hexadecylphosphocholine.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Mice; Mice, Inbred C57BL; Phosphorylcholine; Plasmids; Transfection | 2004 |
Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Cell Cycle; Chromatography, Agarose; Colorimetry; DNA Fragmentation; Flow Cytometry; Leishmania donovani; Phosphatidylserines; Phosphorylcholine; Protease Inhibitors; Tetrazolium Salts; Thiazoles | 2004 |
Hexadecylphosphocholine interaction with lipid monolayers.
Topics: Adsorption; Lipids; Phosphorylcholine | 2004 |
[Multiple cutaneous plasmocytoma treated with topical applications of miltefosine].
Topics: Administration, Topical; Aged; Antineoplastic Agents; Female; Humans; Multiple Myeloma; Phosphorylcholine; Skin Neoplasms | 2004 |
Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Cell Division; Coloring Agents; Cricetinae; Cricetulus; DNA Fragmentation; DNA, Protozoan; In Situ Nick-End Labeling; Indicators and Reagents; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Nucleosomes; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Propidium; Tetrazolium Salts; Thiazoles | 2004 |
Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Dose-Response Relationship, Drug; Flow Cytometry; Inhibitory Concentration 50; Leishmania; Lysophospholipids; Macrophages, Peritoneal; Mice; Microscopy, Electron; Phospholipid Ethers; Phosphorylcholine | 2004 |
Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Humans; Insect Control; Leishmania; Leishmaniasis; Paromomycin; Phosphorylcholine; Protozoan Vaccines | 2004 |
Hexadecylphosphocholine causes rapid cell death in canine mammary tumour cells.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; CHO Cells; Cricetinae; Dogs; Dose-Response Relationship, Drug; Growth Inhibitors; Mammary Neoplasms, Animal; Osteosarcoma; Phosphorylcholine; Time Factors | 2004 |
Short report: fluorescent Leishmania: application to anti-leishmanial drug testing.
Topics: Animals; Antiprotozoal Agents; Flow Cytometry; Green Fluorescent Proteins; Humans; Leishmania donovani; Leishmaniasis, Visceral; Microscopy, Confocal; Parasitic Sensitivity Tests; Phosphorylcholine; Transfection | 2004 |
Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Female; HIV Infections; Humans; Immunocompromised Host; Leishmaniasis; Male; Middle Aged; Phosphorylcholine | 2004 |
Surface behavior of oleoyl palmitoyl phosphatidyl ethanolamine (OPPE) and the characteristics of mixed OPPE-miltefosine monolayers.
Topics: Ethanolamines; Hydrogen-Ion Concentration; Phase Transition; Phosphorylcholine; Pressure; Surface Properties | 2004 |
Leishmanicidal activity of edelfosine, miltefosine and ilmofosine.
Topics: Animals; Antiprotozoal Agents; Cell Line; DNA, Protozoan; Flow Cytometry; Leishmania donovani; Mice; Phospholipid Ethers; Phosphorylcholine; Protozoan Proteins; RNA, Protozoan | 2005 |
[Leishmaniasis--oral treatment with hexadecylphosphocholine].
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Resistance; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meta-Analysis as Topic; Phosphorylcholine; Recurrence; Treatment Outcome | 2004 |
Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba.
Topics: Acanthamoeba; Acanthamoeba castellanii; Amebicides; Animals; Chlorhexidine; Colony Count, Microbial; Colorimetry; Culture Media; Indicators and Reagents; Oxazines; Parasitic Sensitivity Tests; Phospholipid Ethers; Phosphorylcholine; Xanthenes | 2005 |
Interactions between the ganglioside GM1 and hexadecylphosphocholine (miltefosine) in monolayers at the air/water interface.
Topics: Air; G(M1) Ganglioside; Phosphorylcholine; Pressure; Surface Tension; Water | 2005 |
Efficacy of Desmodium gangeticum extract and its fractions against experimental visceral leishmaniasis.
Topics: 1-Butanol; Administration, Oral; Animals; Chloroform; Cricetinae; Drug Administration Schedule; Drug Evaluation, Preclinical; Ethanol; Fabaceae; India; Leishmania donovani; Leishmaniasis, Visceral; Macrophages, Peritoneal; Medicine, Ayurvedic; Phosphorylcholine; Plant Extracts; Plants, Medicinal | 2005 |
Miltefosine-cholesterol interactions: a monolayer study.
Topics: Cholesterol; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Models, Chemical; Phosphorylcholine; Surface Tension; Thermodynamics | 2004 |
Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2-deoxy-D-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane Permeability; Daunorubicin; Drug Resistance, Multiple; Fluorodeoxyglucose F18; Humans; Membrane Fluidity; Mice; NIH 3T3 Cells; Phosphorylcholine; Rhodamine 123; Technetium Tc 99m Sestamibi; Verapamil | 2005 |
Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis.
Topics: Animals; Chlorocebus aethiops; Drug Synergism; Drug Therapy, Combination; Ergosterol; Ketoconazole; Lysophospholipids; Microscopy, Electron; Microscopy, Electron, Scanning; Parasitic Sensitivity Tests; Phospholipid Ethers; Phosphorylcholine; Trypanocidal Agents; Trypanosoma cruzi; Vero Cells | 2005 |
Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania donovani; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Phosphorylcholine; Tetrazolium Salts; Thiazoles | 2005 |
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Line; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Humans; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Male; Mesocricetus; Mice; Parasitic Diseases, Animal; Phosphorylcholine | 2005 |
[Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Leg; Neoplasm Recurrence, Local; Phosphorylcholine; Skin Neoplasms | 2005 |
Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis.
Topics: Adjuvants, Immunologic; Animals; Antiprotozoal Agents; Biopsy; Cinnamates; Cricetinae; Drug Interactions; Drug Therapy, Combination; Female; Glycosides; Leishmania donovani; Leishmaniasis, Visceral; Male; Mesocricetus; Parasitemia; Phosphorylcholine; Picrorhiza; Vanillic Acid | 2005 |
Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
Topics: Adult; Antiprotozoal Agents; HIV Infections; Humans; Immunocompromised Host; Leishmaniasis, Diffuse Cutaneous; Male; Phosphorylcholine; Skin | 2005 |
Availability of miltefosine for the treatment of kala-azar in India.
Topics: Antiprotozoal Agents; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine; Poverty | 2005 |
Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
Topics: Animals; Antiprotozoal Agents; Cell Membrane; Drug Resistance; Fatty Acids; Humans; Leishmania donovani; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Phosphorylcholine; Sterols | 2005 |
Challenges in the management of visceral leishmaniasis.
Topics: Amebicides; Amphotericin B; Antimony Sodium Gluconate; Antiparasitic Agents; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique, Indirect; Humans; Immunoglobulin G; Leishmaniasis, Visceral; Paromomycin; Pentamidine; Phosphorylcholine | 2005 |
Miltefosine decreases the cytotoxic effect of epirubicine and cyclophosphamide on mouse spermatogenic, thymic and bone marrow cells.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Chromosome Aberrations; Chromosomes; Cyclophosphamide; Drug Interactions; Epirubicin; Female; Male; Mice; Mice, Inbred C57BL; Mutagens; Phosphorylcholine; Spermatogenesis; Spermatozoa; Testis; Thymus Gland | 2006 |
The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Humans; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages, Peritoneal; Mice; Nepal; Parasitic Sensitivity Tests; Peru; Phosphorylcholine; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length | 2005 |
Synthesis and biological evaluation of spin-labeled alkylphospholipid analogs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclic N-Oxides; Drug Screening Assays, Antitumor; Hemolysis; Humans; Liposomes; Micelles; Organophosphates; Phospholipids; Phosphorylcholine; Solutions; Spin Labels; Structure-Activity Relationship; Surface-Active Agents | 2005 |
Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Melanoma; Neoplasm Recurrence, Local; Phosphorylcholine; Skin Neoplasms | 2005 |
A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
Topics: Amines; Antibiotics, Antineoplastic; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Stability; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Liposomes; Particle Size; Phosphorylcholine; Solubility | 2006 |
Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Topics: Adult; Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Europe; Germany; HIV Infections; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Liposomes; Male; Phosphorylcholine; Recurrence; Treatment Outcome | 2006 |
Development of a semi-automated colorimetric assay for screening anti-leishmanial agents.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Colorimetry; Drug Evaluation, Preclinical; Humans; Indicators and Reagents; Inhibitory Concentration 50; Kinetics; Leishmania; Leishmania donovani; Leishmaniasis, Visceral; Pentamidine; Phosphorylcholine; Tetrazolium Salts; Thiazoles | 2006 |
Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Topics: Amines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Stability; Inhibitory Concentration 50; Leishmania donovani; Liposomes; Mice; Particle Size; Phosphatidylcholines; Phosphorylcholine; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2005 |
Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Topics: Administration, Oral; Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Injections, Intravenous; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Treatment Outcome | 2006 |
Modulation of intestinal barrier properties by miltefosine.
Topics: Actin Cytoskeleton; Antiprotozoal Agents; Biological Transport; Caco-2 Cells; Carbon Radioisotopes; Cell Membrane Permeability; Cell Survival; Dose-Response Relationship, Drug; Humans; Intestinal Mucosa; L-Lactate Dehydrogenase; Mannitol; Membrane Proteins; Peptide Transporter 1; Phosphorylcholine; Symporters; Temperature; Testosterone; Tight Junctions; Time Factors | 2006 |
In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis.
Topics: Animals; Antifungal Agents; DNA, Fungal; Drug Resistance, Fungal; Metronidazole; Microbial Sensitivity Tests; Microscopy, Phase-Contrast; Phosphorylcholine; Species Specificity; Trichomonas vaginalis | 2006 |
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cricetinae; Drug Synergism; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Parasitic Sensitivity Tests; Phosphorylcholine | 2006 |
Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.
Topics: Acyltransferases; Animals; Antifungal Agents; Cryptococcosis; Disease Models, Animal; Enzyme Inhibitors; Female; Fungi; Hemolysis; Humans; Lysophospholipase; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Multienzyme Complexes; Phosphorylcholine | 2006 |
Hexadecylphosphocholine disrupts cholesterol homeostasis and induces the accumulation of free cholesterol in HepG2 tumour cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Ceramides; Chlorocebus aethiops; Cholesterol; Cholesterol Esters; DNA Fragmentation; Homeostasis; Humans; Phosphorylcholine; Sphingomyelins; Vero Cells | 2006 |
Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
Topics: Administration, Oral; Adult; Anti-Retroviral Agents; Antiprotozoal Agents; Drug Therapy, Combination; HIV Seropositivity; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Treatment Outcome | 2006 |
Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
Topics: Administration, Oral; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Psoriasis; Self-Sustained Sequence Replication; Treatment Outcome | 2006 |
HPLC detection of miltefosine using an evaporative light scattering detector.
Topics: Antiprotozoal Agents; Calibration; Chromatography, High Pressure Liquid; Light; Phosphorylcholine; Reference Standards; Scattering, Radiation | 2006 |
The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Drug Evaluation, Preclinical; Glucose; Insulin; Insulin Resistance; Muscle Fibers, Skeletal; Oncogene Protein v-akt; Phosphorylcholine; Rats | 2006 |
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzamidines; Betamethasone; Biguanides; Chronic Disease; Corneal Stroma; Disease Models, Animal; Drug Evaluation; Drug Therapy, Combination; Glucocorticoids; Male; Parasitic Sensitivity Tests; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Specific Pathogen-Free Organisms | 2006 |
Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.
Topics: Adenosine Triphosphatases; Animals; Biological Transport; Gene Targeting; Genetic Complementation Test; Green Fluorescent Proteins; Leishmania donovani; Membrane Transport Proteins; Molecular Sequence Data; Phospholipids; Phosphorylcholine; Point Mutation; Protein Subunits; Protozoan Proteins | 2006 |
Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report.
Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Treatment Outcome; Warts | 2006 |
The influence of subphase temperature on miltefosine-cholesterol mixed monolayers.
Topics: Adsorption; Air; Antineoplastic Agents; Cholesterol; Hydrogen-Ion Concentration; Membranes, Artificial; Microscopy; Models, Chemical; Phosphorylcholine; Surface Properties; Surface Tension; Temperature; Water | 2006 |
Synthesis of 16-mercaptohexadecylphosphocholine, a miltefosine analog with leishmanicidal activity.
Topics: Animals; Antiprotozoal Agents; Chromatography, Affinity; Humans; Leishmania; Phosphorylcholine; Protozoan Proteins; Structure-Activity Relationship; Sulfhydryl Compounds | 2006 |
Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Membrane; Chlorocebus aethiops; Cytosol; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Humans; Leishmania; Mice; NIH 3T3 Cells; Phosphorylcholine; Protein Structure, Tertiary; Quinolines; Tetrahydroisoquinolines; Vero Cells | 2006 |
Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Biological Transport, Active; Caco-2 Cells; Chromatography, High Pressure Liquid; Circular Dichroism; Drug Interactions; Epithelial Cells; Humans; Intestinal Absorption; Intestinal Mucosa; Leishmania donovani; Phosphorylcholine; Spectrophotometry, Ultraviolet | 2006 |
Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism.
Topics: Animals; Antiprotozoal Agents; Cetrimonium; Cetrimonium Compounds; Choline Kinase; Dose-Response Relationship, Drug; Malaria, Falciparum; Phosphorylcholine; Plasmodium falciparum; Protozoan Proteins; Recombinant Proteins | 2007 |
Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Cell Cycle; Cell Line; Cricetinae; Female; Humans; Hydrogen-Ion Concentration; Leishmania donovani; Macrophages; Mice; Mice, Inbred BALB C; Phospholipid Ethers; Phosphorylcholine | 2006 |
Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Arsenites; Cytochromes c; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance; In Situ Nick-End Labeling; Leishmania donovani; Membrane Potentials; Microscopy, Fluorescence; Microscopy, Interference; Mitochondria; Phosphorylcholine | 2007 |
Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Topics: Adult; Animals; Antiprotozoal Agents; Humans; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Recurrence; Treatment Outcome | 2006 |
Miltefosine in children with visceral leishmaniasis.
Topics: Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine; Prospective Studies | 2006 |
Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.
Topics: Animals; Antiprotozoal Agents; Leishmania donovani; Lipid Metabolism; Parasitic Sensitivity Tests; Phosphorylcholine | 2007 |
Intestinal absorption of miltefosine: contribution of passive paracellular transport.
Topics: Antiprotozoal Agents; Biological Transport; Caco-2 Cells; Carbon Radioisotopes; Cell Membrane Permeability; Chelating Agents; Diffusion; Dose-Response Relationship, Drug; Edetic Acid; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Mannitol; Models, Biological; Phosphorylcholine; Temperature; Testosterone; Tight Junctions; Time Factors | 2007 |
Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.
Topics: Animals; Cell Line; Electron Transport Complex IV; Leishmania donovani; Phosphorylcholine | 2007 |
Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Cost-Benefit Analysis; Decision Trees; Deoxycholic Acid; Drug Combinations; Endemic Diseases; Health Care Costs; Humans; Leishmaniasis, Visceral; Phosphorylcholine; Treatment Outcome | 2007 |
Hexadecyl-phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial.
Topics: Administration, Cutaneous; Analysis of Variance; Animals; Anti-Infective Agents, Local; Antiprotozoal Agents; Benzethonium; Cricetinae; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Evaluation, Preclinical; Leishmaniasis, Cutaneous; Mesocricetus; Ointments; Phosphorylcholine; Recurrence; Treatment Outcome | 2006 |
Lysosomal and mitochondrial pathways in miltefosine-induced apoptosis in U937 cells.
Topics: Apoptosis; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Caspases; Cathepsins; Humans; Lysosomes; Mitochondria; Phosphorylcholine; Protease Inhibitors; Subcellular Fractions; U937 Cells | 2007 |
In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci.
Topics: Antiprotozoal Agents; Microbial Sensitivity Tests; N-Acetylmuramoyl-L-alanine Amidase; Phosphorylcholine; Streptococcus; Streptococcus pneumoniae | 2007 |
[Miltefosine for disseminated cutaneous leishmaniasis].
Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Diffuse Cutaneous; Male; Phosphorylcholine | 2006 |
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
Topics: Antifungal Agents; Arthrodermataceae; Cations; Chlorides; Humans; Microbial Sensitivity Tests; Phosphorylcholine; Pyridinium Compounds; Quaternary Ammonium Compounds | 2007 |
Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process.
Topics: Biological Transport; Caco-2 Cells; Cell Membrane; Endocytosis; Humans; Phosphorylcholine; Subcellular Fractions | 2007 |
Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; Leishmaniasis, Diffuse Cutaneous; Male; Middle Aged; Phosphorylcholine; Quality of Life; Recurrence; Treatment Failure | 2007 |
First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
Topics: Administration, Oral; Adult; Animals; Antiprotozoal Agents; Diagnosis, Differential; DNA, Protozoan; Humans; Leishmania major; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Polymerase Chain Reaction | 2007 |
[Cutaneous leishmaniasis].
Topics: Animals; Biopsy; Cross-Sectional Studies; Diagnosis, Differential; Humans; Leishmania; Leishmaniasis, Cutaneous; Opportunistic Infections; Phosphorylcholine; Recurrence; Skin; Th1 Cells; Th2 Cells; Travel | 2007 |
Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
Topics: Administration, Oral; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphorylcholine | 2007 |
Mucosal leishmaniasis and miltefosine.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmania; Leishmaniasis, Mucocutaneous; Phosphorylcholine | 2007 |
A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids.
Topics: Animals; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Biological Transport; Cell Membrane; Dimerization; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Green Fluorescent Proteins; Leishmania infantum; Phosphatidylcholines; Phospholipid Ethers; Phosphorylcholine; Saccharomyces cerevisiae; Transformation, Genetic | 2007 |
Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine | 2007 |
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Topics: Adenosine Triphosphatases; Animals; Antiprotozoal Agents; Drug Resistance; Female; Genotype; Leishmania donovani; Leishmaniasis, Visceral; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Mutation; Phenotype; Phosphorylcholine; Protozoan Proteins | 2007 |
Biorelevant refinement of the Caco-2 cell culture model to assess efficacy of paracellular permeability enhancers.
Topics: Caco-2 Cells; Electric Impedance; Humans; Intestinal Absorption; Palmitoylcarnitine; Permeability; Phosphorylcholine | 2008 |
Wilson disease with visceral leishmaniasis: an extremely uncommon presentation.
Topics: Adolescent; Chelating Agents; Hepatolenticular Degeneration; Humans; Leishmaniasis, Visceral; Male; Penicillamine; Phosphorylcholine; Pyridoxine; Zinc Sulfate | 2007 |
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Bone Marrow; Female; HIV Infections; HIV-1; Humans; Immunity, Cellular; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Treatment Failure | 2008 |
Miltefosine in the treatment of a case of visceral leishmaniasis with renal dysfunction.
Topics: Administration, Oral; Antiprotozoal Agents; Humans; India; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Renal Insufficiency; Spleen | 2007 |
Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine.
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine; Thrombocytopenia | 2007 |
Synthesis and biological evaluation of fluorescent leishmanicidal analogues of hexadecylphosphocholine (miltefosine) as probes of antiparasite mechanisms.
Topics: Animals; Drug Resistance; Fluorescent Dyes; Leishmania donovani; Microscopy, Confocal; Phosphorylcholine; Stereoisomerism; Structure-Activity Relationship; Trypanocidal Agents | 2007 |
Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2008 |
Granulomatous amoebic encephalitis caused by Acanthamoeba amoebae of genotype T2 in a human immunodeficiency virus-negative patient.
Topics: Acanthamoeba; Adult; Amebiasis; Amikacin; Animals; Antiprotozoal Agents; Antitubercular Agents; DNA, Protozoan; Encephalitis; Genotype; HIV Infections; Humans; Male; Molecular Sequence Data; Phosphorylcholine; Sequence Analysis, DNA; Skin Diseases, Parasitic; Tuberculosis | 2008 |
Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Antiprotozoal Agents; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Chromatography, Thin Layer; Hot Temperature; Liposomes; Phospholipids; Phosphorylcholine; Rats | 2008 |
Effect of alkyl-lysophospholipids on some aspects of the metabolism of Leishmania donovani.
Topics: Animals; Carbohydrate Metabolism; Humans; Leishmania donovani; Magnetic Resonance Spectroscopy; Parasitic Sensitivity Tests; Phospholipid Ethers; Phosphorylcholine; Protozoan Proteins; Superoxide Dismutase; Type C Phospholipases | 2007 |
Successful treatment of a married couple for American leishmaniasis with miltefosine.
Topics: Animals; Antiprotozoal Agents; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphorylcholine; Skin; Spouses; Treatment Outcome | 2008 |
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy.
Topics: Cells, Cultured; Down-Regulation; HIV Infections; HIV-1; Humans; Macrophages; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Virus Replication | 2008 |
Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells.
Topics: Acetates; Biological Transport; Cell Line, Tumor; Cell Membrane; Cholesterol; Endoplasmic Reticulum; Enzyme Activation; Esters; Gene Expression Regulation; Humans; Linoleic Acid; Mevalonic Acid; Oxo-Acid-Lyases; Phosphorylcholine; Triglycerides | 2008 |
HIV infection, visceral leishmaniasis and Guillain-Barré syndrome in the same patient: a case report.
Topics: Adult; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; Guillain-Barre Syndrome; HIV Infections; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2008 |
Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Antiprotozoal Agents; Chromatography, Liquid; Humans; Phosphorylcholine; Sensitivity and Specificity; Tandem Mass Spectrometry | 2008 |
Proteomic analysis of miltefosine-resistant Leishmania reveals the possible involvement of eukaryotic initiation factor 4A (eIF4A).
Topics: Animals; Antifungal Agents; Antiprotozoal Agents; Drug Resistance; Electrophoresis, Polyacrylamide Gel; Eukaryotic Initiation Factor-4A; Isoelectric Focusing; Leishmania; Phosphorylcholine; Proteomics; Transcription Factors | 2008 |
Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII.
Topics: Animals; Antimony Potassium Tartrate; Cosmids; Drug Resistance; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine; Protozoan Proteins; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
[New antiparasitic drugs].
Topics: Albendazole; Antimalarials; Antiparasitic Agents; Benzimidazoles; Cyclohexanes; Fatty Acids, Unsaturated; Humans; Ivermectin; Nitro Compounds; Phosphorylcholine; Praziquantel; Sesquiterpenes; Thiazoles; Triclabendazole | 2008 |
Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine.
Topics: Administration, Topical; Animals; Antifungal Agents; Child, Preschool; Female; Humans; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine; Treatment Outcome | 2008 |
In vitro antileishmanial activity of fluoro-artemisinin derivatives against Leishmania donovani.
Topics: Aminoquinolines; Animals; Antiparasitic Agents; Artemisinins; Drug Resistance; Erythrocytes; Indicators and Reagents; Leishmania donovani; Macrophages; Phosphorylcholine | 2008 |
Efficacy of pentavalent antimony, amphotericin B, and miltefosine in Leishmania amazonensis-infected macrophages under normoxic and hypoxic conditions.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Hypoxia; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Leishmania mexicana; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Oxygen; Phosphorylcholine | 2008 |
Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Topics: Adult; Antiprotozoal Agents; Chemoprevention; HIV Infections; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Secondary Prevention | 2008 |
Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis.
Topics: Adolescent; Animals; Antiprotozoal Agents; Clofazimine; Diagnosis, Differential; Humans; Hypopigmentation; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Leprostatic Agents; Male; Medication Errors; Phosphorylcholine; Polymerase Chain Reaction | 2008 |
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Base Sequence; Biological Transport, Active; Chloroquine; DNA, Protozoan; Drug Resistance; Fluorescent Dyes; Genes, Protozoan; Humans; Leishmania infantum; Leishmaniasis, Visceral; Lipid Bilayers; Phosphorylcholine; Protozoan Proteins; Recombinant Proteins; Transformation, Genetic | 2008 |
Edelfosine induces an apoptotic process in Leishmania infantum that is regulated by the ectopic expression of Bcl-XL and Hrk.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Leishmania infantum; Membrane Potential, Mitochondrial; Phospholipid Ethers; Phosphorylcholine; Recombinant Proteins; Transfection | 2008 |
Development of new antileishmanial drugs--current knowledge and future prospects.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania; Leishmaniasis; Phosphorylcholine | 2008 |
In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains.
Topics: Animals; Anti-Bacterial Agents; Bacteriological Techniques; Dose-Response Relationship, Drug; Mice; Microbial Sensitivity Tests; Penicillin Resistance; Peritonitis; Phosphorylcholine; Sepsis; Streptococcus pneumoniae | 2008 |
Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; fas Receptor; Fas-Associated Death Domain Protein; Flow Cytometry; Glioma; Humans; Immunoprecipitation; Membrane Microdomains; p38 Mitogen-Activated Protein Kinases; Phosphorylcholine; ras Proteins | 2008 |
Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole.
Topics: Acanthamoeba; Amebiasis; Animals; Antifungal Agents; Antiprotozoal Agents; Drug Therapy, Combination; Encephalitis; Fatal Outcome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lung; Male; Middle Aged; Phosphorylcholine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Skin; Triazoles; Voriconazole | 2008 |
Effect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleri.
Topics: Amebiasis; Amebicides; Amphotericin B; Animals; Central Nervous System Protozoal Infections; Chlorpromazine; Female; In Vitro Techniques; Mice; Mice, Inbred BALB C; Naegleria fowleri; Parasitic Sensitivity Tests; Phosphorylcholine | 2008 |
Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
Topics: Adolescent; Amphotericin B; Animals; Antiprotozoal Agents; Female; Humans; Interferon-gamma; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2008 |
In vivo activity of perifosine against Leishmania amazonensis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Female; Leishmania mexicana; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Phospholipid Ethers; Phosphorylcholine; Survival Analysis | 2008 |
Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Models, Animal; Disease Reservoirs; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Humans; Leishmania infantum; Leishmaniasis, Visceral; Male; Phosphorylcholine; Recurrence; Treatment Outcome; Zoonoses | 2009 |
Interferon-gamma (INF-gamma), IL4 expression levels and Leishmania DNA load as prognostic markers for monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Biomarkers; DNA, Protozoan; Dog Diseases; Dogs; Interferon-gamma; Interleukin-4; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine | 2008 |
Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients.
Topics: Adult; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; CD4 Lymphocyte Count; HIV Infections; Humans; Leishmaniasis; Male; Phosphorylcholine | 2008 |
Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine.
Topics: Acanthamoeba; Administration, Oral; Administration, Topical; Adult; Amebiasis; Animals; Antiprotozoal Agents; Encephalitis; Granuloma; Humans; Immunocompromised Host; Male; Phosphorylcholine; Skin Ulcer; Treatment Outcome; Tuberculosis, Miliary | 2008 |
Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antiparasitic Agents; Female; HIV-1; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine; Treatment Outcome | 2008 |
Na(+)-ATPase and protein kinase C are targets to 1-O-hexadecylphosphocoline (miltefosine) in Trypanosoma cruzi.
Topics: Animals; Calcium; Cell Membrane; Furosemide; Hydrogen-Ion Concentration; Kinetics; Phosphorylcholine; Protein Kinase C; Sodium-Potassium-Exchanging ATPase; Swine; Trypanocidal Agents; Trypanosoma cruzi | 2009 |
Synthesis of BODIPY-labeled alkylphosphocholines with leishmanicidal activity, as fluorescent analogues of miltefosine.
Topics: Animals; Antiprotozoal Agents; Boron Compounds; Chemistry, Pharmaceutical; Drug Design; Fluorescent Dyes; Humans; Leishmania donovani; Lipids; Models, Chemical; Phosphorylcholine; Solvents; Spectrophotometry | 2008 |
In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; DNA Primers; Drug Resistance; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine).
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Fas Ligand Protein; fas Receptor; Humans; p38 Mitogen-Activated Protein Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction | 2008 |
Cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani.
Topics: Animals; Antiprotozoal Agents; Facial Dermatoses; Female; Humans; Leishmania donovani; Leishmaniasis, Cutaneous; Lymphatic Diseases; Middle Aged; Phosphorylcholine | 2009 |
Hexadecylphosphocholine alters nonvesicular cholesterol traffic from the plasma membrane to the endoplasmic reticulum and inhibits the synthesis of sphingomyelin in HepG2 cells.
Topics: Biological Transport; Cell Line, Tumor; Cell Membrane; Ceramides; Cholesterol; Cholesterol Esters; Cholesterol, LDL; Endoplasmic Reticulum; Humans; Lysosomes; Phosphorylcholine; Sphingomyelin Phosphodiesterase; Sphingomyelins | 2009 |
Neurotoxicity of inverted-cone shaped lipids.
Topics: Animals; Cells, Cultured; HeLa Cells; Humans; Lipids; Mice; Neurites; Neuromuscular Junction; Neurotoxicity Syndromes; Phosphorylcholine; Phrenic Nerve; Rats; Rats, Sprague-Dawley | 2009 |
Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine.
Topics: Animals; Base Sequence; DNA Primers; DNA, Protozoan; Dogs; Leishmania; Leishmaniasis, Visceral; Phosphorylcholine; Polymerase Chain Reaction | 2008 |
Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
Topics: Adolescent; Adult; Age Distribution; Aged; Amphotericin B; Anthropometry; Antiprotozoal Agents; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Costs; Female; Humans; India; Infant; Leishmaniasis, Visceral; Liposomes; Male; Middle Aged; Paromomycin; Phosphorylcholine; Sex Distribution | 2009 |
Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Biopsy; Bolivia; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Cutaneous; Middle Aged; Phosphorylcholine; Travel; Treatment Outcome | 2009 |
Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug.
Topics: Adenosine Triphosphatases; Animals; Antiprotozoal Agents; Biological Transport; Cell Membrane; Drug Resistance; Leishmania braziliensis; Membrane Transport Proteins; Phosphorylcholine; Protozoan Proteins | 2009 |
Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica.
Topics: Animals; Antiprotozoal Agents; Child; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Treatment Outcome; Young Adult | 2009 |
Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Bone Marrow; Dog Diseases; Dogs; Female; Injections, Subcutaneous; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Dermatitis; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine | 2009 |
Newer strategies for the kala-azar elimination programme in India.
Topics: Amphotericin B; Data Collection; Humans; India; Information Dissemination; Leishmaniasis, Visceral; Phosphorylcholine; Primary Prevention | 2009 |
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report.
Topics: Antifungal Agents; Child; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Mycoses; Naphthalenes; Osteomyelitis; Phosphorylcholine; Pyrimidines; Scedosporium; Terbinafine; Treatment Outcome; Triazoles; Voriconazole; Wounds and Injuries | 2009 |
Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Male; Nepal; Phosphorylcholine; Recurrence; Treatment Failure; Young Adult | 2009 |
Flow cytometric determination of intracellular non-protein thiols in Leishmania promastigotes using 5-chloromethyl fluorescein diacetate.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Culture Media, Serum-Free; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Humans; Leishmania donovani; Pentamidine; Phosphorylcholine; Sensitivity and Specificity; Sulfhydryl Compounds | 2009 |
Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Topics: Animals; Antiprotozoal Agents; Immunity; Interferon gamma Receptor; Interferon-gamma; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice; Mice, Knockout; Phosphorylation; Phosphorylcholine; Receptors, Interferon; Signal Transduction; STAT1 Transcription Factor; T-Lymphocytes, Helper-Inducer | 2009 |
Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
Topics: Administration, Oral; Amphotericin B; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Leishmaniasis, Visceral; Liver; Mice; Mice, Inbred BALB C; Parasitemia; Phosphorylcholine | 2009 |
In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis; Mice; Microscopy, Electron, Transmission; Parasitic Sensitivity Tests; Phosphorylcholine; Saponins; Triterpenes | 2009 |
Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent.
Topics: Acanthamoeba; Animals; Antiprotozoal Agents; Candida albicans; Drug Stability; Drug Storage; Humans; In Vitro Techniques; Phosphorylcholine; Skin Diseases; Staphylococcus | 2009 |
Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Cost-Benefit Analysis; Direct Service Costs; Drug Administration Schedule; Drug Costs; Female; Hospital Costs; Humans; India; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Practice Guidelines as Topic; Young Adult | 2009 |
Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys.
Topics: Animals; Antiprotozoal Agents; Body Weight; Dogs; Female; Fluorescent Antibody Technique; Histocytochemistry; Kidney; Kidney Diseases; Kidney Tubules; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Microscopy, Electron; Organometallic Compounds; Phosphorylcholine; Random Allocation; Toxicity Tests | 2009 |
Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes.
Topics: Animals; Antiprotozoal Agents; Cell Membrane; Drug Resistance; Leishmania donovani; Lipid Metabolism; Microbial Viability; Mitochondria; Models, Molecular; Molecular Structure; Parasitic Sensitivity Tests; Phosphorylcholine; Sterols; Tetrazolium Salts; Thiazoles | 2009 |
In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Flow Cytometry; Leishmania; Leishmaniasis; Macrophages, Peritoneal; Mice; Microscopy; Parasitic Sensitivity Tests; Phosphorylcholine; Saponins; Temperature; Triterpenes | 2009 |
[Mucosal complication of cutaneous leishmaniasis].
Topics: Aged; Anemia; Antiprotozoal Agents; Contraindications; Eyelid Diseases; Humans; Hypertension; Kidney Failure, Chronic; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Lip Diseases; Male; Meglumine; Meglumine Antimoniate; Nose Diseases; Organometallic Compounds; Phosphorylcholine | 2009 |
Dialkylamino and nitrogen heterocyclic analogues of hexadecylphosphocholine and cetyltrimetylammonium bromide: effect of phosphate group and environment of the ammonium cation on their biological activity.
Topics: Antifungal Agents; Antineoplastic Agents; Candida albicans; Cations; Cell Line, Tumor; Cetrimonium; Cetrimonium Compounds; Heterocyclic Compounds; Humans; Molecular Structure; Nitrogen; Phosphates; Phosphorylcholine; Quaternary Ammonium Compounds | 2009 |
Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.
Topics: Amiodarone; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Synergism; Female; Leishmaniasis, Cutaneous; Mice; Phosphorylcholine; Polymerase Chain Reaction | 2009 |
Synthesis and biological activity of dialkylphosphocholines.
Topics: Acanthamoeba; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antiprotozoal Agents; Candida albicans; Drug Screening Assays, Antitumor; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Phosphorylcholine; Plant Extracts; Structure-Activity Relationship | 2009 |
Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Topics: Administration, Oral; Administration, Topical; Animals; Disease Models, Animal; Drug Therapy, Combination; Female; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome | 2009 |
The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Arachidonic Acid; Disease Models, Animal; Ear; Female; Hypersensitivity; Immunologic Factors; Inflammation; Interleukins; Membrane Microdomains; Mice; Phosphorylcholine; Pruritus; Skin; T-Lymphocytes; Toluene 2,4-Diisocyanate | 2010 |
Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan.
Topics: Adult; Afghanistan; Female; Humans; Leishmania major; Leishmaniasis, Cutaneous; Male; Middle Aged; Military Personnel; Netherlands; Phosphorylcholine; Retrospective Studies; Travel; Treatment Outcome | 2010 |
Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.
Topics: Animals; Antiprotozoal Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Dendritic Cells; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, Inbred C57BL; Phosphorylcholine | 2010 |
Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Topics: Adult; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Biopsy; Female; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Pregnancy; Treatment Outcome | 2009 |
Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment.
Topics: Administration, Oral; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Treatment Outcome | 2010 |
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Cytokines; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lymphoma, Primary Effusion; Mice; Mice, Inbred NOD; Mice, SCID; Paracrine Communication; Phosphoinositide-3 Kinase Inhibitors; Phosphorylcholine; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Rosiglitazone; Thiazolidinediones; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.
Topics: Antineoplastic Agents; Antiprotozoal Agents; Biological Transport; Cell Line, Tumor; Cell Proliferation; Cholesterol; Esterification; Homeostasis; Humans; Phospholipids; Phosphorylcholine | 2010 |
Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species.
Topics: Amphotericin B; Animals; Antimony Potassium Tartrate; Antiprotozoal Agents; Culture Media; Drug Resistance; Inhibitory Concentration 50; Leishmania; Leishmaniasis; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Paromomycin; Phenotype; Phosphorylcholine; Selection, Genetic; Serial Passage; Spleen; Virulence | 2010 |
Surface-active properties of nitrogen heterocyclic and dialkylamino derivates of hexadecylphosphocholine and cetyltrimethylammonium bromide.
Topics: Amines; Cetrimonium Compounds; Heterocyclic Compounds; Micelles; Nitrogen; Phosphorylcholine; Surface Tension; Surface-Active Agents | 2010 |
Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Drug Resistance; Histones; Humans; India; Leishmania donovani; Mitogen-Activated Protein Kinase 1; Oligonucleotide Array Sequence Analysis; Phosphorylcholine; Protozoan Proteins | 2010 |
In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole.
Topics: Antiprotozoal Agents; Colombia; Nifurtimox; Nitroimidazoles; Parasitic Sensitivity Tests; Phosphorylcholine; Trypanosoma cruzi | 2009 |
CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cytokines; Drug Synergism; Female; Hydrogen Peroxide; Immunologic Factors; Leishmania donovani; Leishmaniasis, Visceral; Male; Mice; Mice, Inbred BALB C; Nitric Oxide; Oligodeoxyribonucleotides; Phosphorylcholine; Reactive Oxygen Species; Th1 Cells | 2010 |
Use of miltefosine in the treatment of visceral leishmaniasis in children at a tertiary care hospital of Karachi.
Topics: Administration, Oral; Antiprotozoal Agents; Child; Hospitals, University; Humans; Infant; Leishmania donovani; Leishmaniasis, Visceral; Male; Pakistan; Phosphorylcholine; Treatment Outcome | 2010 |
Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Diffuse Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Treatment Outcome | 2010 |
Flow cytometric screening for anti-leishmanials in a human macrophage cell line.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Line; Cell Survival; Coloring Agents; Drug Evaluation, Preclinical; Flow Cytometry; Formazans; Humans; Leishmania mexicana; Macrophages; Phosphorylcholine; Tetrazolium Salts; Trypan Blue | 2010 |
Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement.
Topics: Adult; Aged; Albendazole; Amebiasis; Amoebozoa; Antiprotozoal Agents; Brain; Child; Child, Preschool; Encephalitis; Female; Fluconazole; Histocytochemistry; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Phosphorylcholine; Radiography; Skin Diseases, Parasitic; Treatment Outcome; Young Adult | 2010 |
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Opportunistic Infections; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Recurrence; Treatment Failure | 2010 |
Screen for inducers of autolysis in Bacillus subtilis.
Topics: Anti-Bacterial Agents; Bacillus subtilis; Bacteriolysis; beta-Galactosidase; Daptomycin; Miconazole; Phosphorylcholine | 2010 |
Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Female; Leishmania; Leishmaniasis; Mice; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Skin | 2010 |
Design and synthesis of new adamantyl-substituted antileishmanial ether phospholipids.
Topics: Antiprotozoal Agents; Cell Line; Cell Survival; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Phospholipid Ethers; Phosphorylcholine | 2010 |
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
Topics: Amphotericin B; Antiprotozoal Agents; Bangladesh; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; India; Leishmaniasis, Visceral; Models, Statistical; Nepal; Paromomycin; Phosphorylcholine | 2010 |
Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cinnamates; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycosides; Leishmania donovani; Leishmaniasis, Visceral; Lymphocytes; Male; Mesocricetus; Paromomycin; Phagocytosis; Phosphorylcholine; Random Allocation; Reactive Nitrogen Species; Reactive Oxygen Species; Vanillic Acid | 2011 |
Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome | 2010 |
Miltefosine, a promising novel agent for schistosomiasis mansoni.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Liver; Male; Mice; Microscopy, Electron, Scanning; Phosphorylcholine; Schistosoma mansoni; Schistosomiasis mansoni; Time Factors | 2011 |
Ambisome plus miltefosine for Indian patients with kala-azar.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Treatment Outcome; Young Adult | 2011 |
Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis.
Topics: Adolescent; Adult; Aged; Animals; Antimony Potassium Tartrate; Antiprotozoal Agents; Benzoates; Female; Flow Cytometry; Fluorescein; Humans; Imidazoles; In Vitro Techniques; Leishmania; Leishmaniasis, Visceral; Macrophages, Peritoneal; Male; Mice; Mice, Inbred BALB C; Middle Aged; Monocytes; Nitric Oxide; Phosphorylcholine; Species Specificity; Young Adult | 2011 |
A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.
Topics: Adult; Aged; Amphotericin B; Antiprotozoal Agents; Child; Female; Humans; Ketoconazole; Leishmania; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphorylcholine; Species Specificity | 2011 |
Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.
Topics: Animals; Antiprotozoal Agents; Cinnamates; Cricetinae; Drug Therapy, Combination; Fluconazole; Glycosides; Hydrogen Peroxide; Immunity, Cellular; Leishmania donovani; Leishmaniasis, Visceral; Phagocytosis; Phosphorylcholine; Reactive Oxygen Species; Treatment Outcome; Vanillic Acid | 2011 |
Combination therapy for visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; India; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Randomized Controlled Trials as Topic | 2011 |
Cutaneous leishmaniasis after travel to Cyprus and successful treatment with miltefosine.
Topics: Antiprotozoal Agents; Austria; Cyprus; Female; Humans; Leishmaniasis, Cutaneous; Middle Aged; Phosphorylcholine; Travel | 2011 |
Miltefosine-induced apoptotic cell death on Leishmania major and L. tropica strains.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line; DNA Fragmentation; Humans; Leishmania major; Leishmania tropica; Leishmaniasis, Cutaneous; Mice; Phosphorylcholine | 2011 |
Mucosal Leishmania infantum infection.
Topics: Adult; Aged; Amphotericin B; Antiprotozoal Agents; Esophagus; Europe; Female; Humans; Leishmania infantum; Leishmaniasis, Mucocutaneous; Male; Middle Aged; Mouth Mucosa; Nasal Mucosa; Phosphorylcholine; Treatment Outcome | 2011 |
Weak cytotoxic activity of miltefosine against clinical isolates of Acanthamoeba spp.
Topics: Acanthamoeba; Acanthamoeba castellanii; Acanthamoeba Keratitis; Antiprotozoal Agents; Cornea; Dose-Response Relationship, Drug; Humans; Phosphorylcholine; Trophozoites | 2011 |
CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.
Topics: Animals; Cricetinae; Drug Combinations; Female; Leishmaniasis, Visceral; Male; Mice; Mice, Inbred BALB C; Oligodeoxyribonucleotides; Phosphorylcholine; Trypanocidal Agents | 2011 |
Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Secondary Prevention; Treatment Outcome; Young Adult | 2011 |
Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.
Topics: Animals; Antifungal Agents; Bronchoalveolar Lavage Fluid; Cystic Fibrosis; Disease Models, Animal; Humans; Injections, Intraperitoneal; Lung; Mice; Mice, Inbred C57BL; Opportunistic Infections; Phosphorylcholine; Pseudomonas aeruginosa; Pseudomonas Infections; Respiration, Artificial; Respiratory Tract Infections | 2011 |
Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy.
Topics: Animals; Anthelmintics; Biomphalaria; Disinfectants; Microscopy, Electron, Scanning; Phosphorylcholine; Schistosoma haematobium; Schistosoma mansoni; Survival Analysis | 2011 |
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
Topics: Aminophenols; Animals; Antiprotozoal Agents; Cell Line, Tumor; Cyanates; Humans; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Life Cycle Stages; Monocytes; Neoplasms; Phospholipid Ethers; Phosphorylcholine; Selenium Compounds; Structure-Activity Relationship | 2011 |
Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase.
Topics: Antifungal Agents; Apoptosis; Base Sequence; DNA Primers; Electron Transport Complex IV; Phosphorylcholine; Saccharomyces cerevisiae | 2011 |
Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil.
Topics: Animals; Antiprotozoal Agents; Brazil; Dog Diseases; Dogs; Immunoglobulin G; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine; Time Factors | 2011 |
Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania.
Topics: Aminoquinolines; Antimony; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Drug Resistance, Bacterial; Ketoconazole; Leishmania tropica; Leishmaniasis; Phosphorylcholine; Protein Binding | 2011 |
Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Topics: Animals; Antiprotozoal Agents; Cinnamates; Cricetinae; Disease Models, Animal; Drug Therapy, Combination; Female; Glycosides; Hydrogen Peroxide; Immunologic Factors; Ketoconazole; Leishmania donovani; Leishmaniasis, Visceral; Male; Phagocytosis; Phosphorylcholine; Reactive Nitrogen Species; Reactive Oxygen Species; Rodent Diseases; Treatment Outcome; Vanillic Acid | 2011 |
The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil.
Topics: Animals; Antiprotozoal Agents; Inhibitory Concentration 50; Leishmania; Macrophages; Mice; Mice, Inbred BALB C; Parasitic Sensitivity Tests; Phosphorylcholine | 2011 |
Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes.
Topics: Antiprotozoal Agents; Apoptosis; DNA Fragmentation; DNA, Protozoan; Flow Cytometry; Leishmania mexicana; Phosphorylcholine | 2011 |
Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzamidines; Biguanides; Cricetinae; Disease Models, Animal; Humans; Male; Mesocricetus; Phosphorylcholine; Treatment Outcome | 2012 |
Tender ulceronecrotic nodules in a patient with leukemia. Cutaneous acanthamebiasis.
Topics: Acanthamoeba; Amebiasis; Antiprotozoal Agents; Drug Therapy, Combination; Female; Fluconazole; Flucytosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Necrosis; Pentamidine; Phosphorylcholine; Pyrimidines; Skin Diseases, Parasitic; Skin Ulcer; Sulfadoxine; Triazoles; Voriconazole | 2011 |
Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.
Topics: Animals; Antimony; Antiprotozoal Agents; Drug Resistance; India; Leishmania donovani; Liver; Mice; Mice, Inbred BALB C; Phosphorylcholine; Spleen | 2011 |
A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine; Recurrence | 2011 |
Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Apoptosis; Cell Death; Drug Resistance, Multiple; Drug Tolerance; Leishmania infantum; Methotrexate; Paromomycin; Phosphorylcholine; Reactive Oxygen Species | 2011 |
Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro.
Topics: Animals; Antiprotozoal Agents; Drug Evaluation, Preclinical; Female; Leishmania infantum; Leishmaniasis, Visceral; Life Cycle Stages; Liver; Luciferases; Luminescent Measurements; Mice; Mice, Inbred BALB C; Organisms, Genetically Modified; Parasite Load; Phosphorylcholine; Protozoan Proteins; Reproducibility of Results; Sensitivity and Specificity; Spectrum Analysis; Spleen; Statistics, Nonparametric; Whole Body Imaging | 2011 |
Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; B7-1 Antigen; B7-2 Antigen; Child; Cytokines; Female; GPI-Linked Proteins; Humans; Immunologic Factors; India; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Leukocytes, Mononuclear; Lipopolysaccharide Receptors; Male; Middle Aged; Phosphorylcholine; Receptors, IgG; Serum; Young Adult | 2011 |
Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cysteine; Female; Leishmaniasis, Visceral; Lipoproteins; Male; Mice; Mice, Inbred BALB C; Phosphorylcholine | 2011 |
Treatment of imported New World cutaneous leishmaniasis in Germany.
Topics: Adolescent; Adult; Aged; Amphotericin B; Animals; Antiprotozoal Agents; Female; Germany; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Travel; Young Adult | 2011 |
Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.
Topics: Antiprotozoal Agents; Chromatography, High Pressure Liquid; Humans; Leishmania donovani; Leishmaniasis, Visceral; Phospholipids; Phosphorylcholine; Spectrometry, Mass, Electrospray Ionization | 2012 |
Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Disease Models, Animal; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Phosphorylcholine; Quinolines | 2011 |
Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Cytokines; Disease Models, Animal; Leishmania donovani; Leishmaniasis, Visceral; Lymphocytes; Nitric Oxide; Phosphorylcholine; Real-Time Polymerase Chain Reaction; RNA, Messenger; Th1 Cells; Th2 Cells | 2012 |
Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.
Topics: Antiprotozoal Agents; Female; Humans; Leishmania infantum; Leishmania major; Leishmaniasis, Cutaneous; Male; Middle Aged; Parasite Load; Phosphorylcholine; Skin | 2011 |
Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms.
Topics: Animals; Anthelmintics; Dose-Response Relationship, Drug; Microscopy, Electron, Scanning; Phosphorylcholine; Schistosoma mansoni; Survival Analysis; Time Factors | 2012 |
Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Synergism; Fluoroquinolones; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine | 2012 |
Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Topics: Animals; Antiprotozoal Agents; Azure Stains; DNA, Protozoan; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasite Load; Phosphorylcholine; Time Factors; Ulcer | 2012 |
Characterization and identification of suspected counterfeit miltefosine capsules.
Topics: Capsules; Chromatography, Liquid; Colorimetry; Counterfeit Drugs; Phosphorylcholine; Spectroscopy, Fourier Transform Infrared; Tandem Mass Spectrometry; Time Factors | 2012 |
Cutaneous leishmaniasis acquired in Jura, France.
Topics: Antiprotozoal Agents; France; Humans; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphorylcholine | 2012 |
Effects of miltefosine treatment in fibroblast cell cultures and in mice experimentally infected with Neospora caninum tachyzoites.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Chlorocebus aethiops; Coccidiosis; Disease Models, Animal; Female; Fibroblasts; Humans; Mice; Mice, Inbred BALB C; Neospora; Parasitic Sensitivity Tests; Phosphorylcholine; Treatment Outcome; Vero Cells | 2012 |
Leishmania donovani mitochondrial iron superoxide dismutase A is released into the cytosol during miltefosine induced programmed cell death.
Topics: Antiprotozoal Agents; Apoptosis; Cytochromes c; Cytosol; DNA Fragmentation; Leishmania donovani; Mitochondrial Proteins; Phosphorylcholine; Protozoan Proteins; Reactive Oxygen Species; Sulfhydryl Compounds; Superoxide Dismutase | 2012 |
Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Genome, Protozoan; Humans; Leishmania major; Mutant Proteins; Mutation, Missense; Phosphorylcholine; Protozoan Proteins; Selection, Genetic; Sequence Analysis, DNA | 2012 |
Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.
Topics: Adult; Antiprotozoal Agents; Cell Line; Cytokines; Female; Humans; Leishmania donovani; Leishmaniasis, Visceral; Leukocytes, Mononuclear; Male; Phosphorylcholine; RNA, Messenger; Toll-Like Receptor 4; Toll-Like Receptor 9; Young Adult | 2012 |
Leishmania strains causing self-healing cutaneous leishmaniasis have greater susceptibility towards oxidative stress.
Topics: Antimony; Free Radicals; Humans; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Nitric Oxide; Oxidative Stress; Phosphorylcholine; Superoxide Dismutase | 2012 |
Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hydrogen Peroxide; Immunity, Cellular; Leishmania donovani; Leishmaniasis, Visceral; Liposomes; Macrophages, Peritoneal; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Phagocytosis; Phosphorylcholine; Reactive Nitrogen Species; Reactive Oxygen Species; Tuftsin | 2012 |
Miltefosine enhances phagocytosis but decreases nitric oxide production by peritoneal macrophages of C57BL/6 mice.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Female; Immunologic Factors; Leishmania; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Nitric Oxide; Phagocytosis; Phosphorylcholine; Saccharomyces cerevisiae | 2012 |
Leishmania resistance to miltefosine associated with genetic marker.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Female; Humans; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis, Visceral; Maintenance Chemotherapy; Middle Aged; Phosphorylcholine; Recurrence | 2012 |
[Exotic imported disease and scourge of the poor].
Topics: Antiprotozoal Agents; Child, Preschool; Developing Countries; Diagnosis, Differential; Humans; Insect Bites and Stings; Leishmania donovani; Leishmaniasis, Visceral; Male; Nepal; Phosphorylcholine | 2012 |
Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.
Topics: Antiprotozoal Agents; Cell Line; Humans; Leishmania; Leishmaniasis; Macrophages; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasite Load; Parasitic Sensitivity Tests; Phosphorylcholine; Temperature | 2012 |
Comparison of electrospray ionization, atmospheric pressure chemical ionization and atmospheric pressure photoionization for a lipidomic analysis of Leishmania donovani.
Topics: Atmospheric Pressure; Drug Resistance; Leishmania donovani; Limit of Detection; Lipids; Metabolome; Phosphorylcholine; Photochemistry; Reproducibility of Results; Signal-To-Noise Ratio; Spectrometry, Mass, Electrospray Ionization | 2012 |
Development of splenic marginal zone lymphoma in a HIV-negative patient with visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Bone Marrow; HIV; HIV Infections; Humans; Immunophenotyping; Kidney; Leishmania infantum; Leishmaniasis, Visceral; Liver; Lymphoma, B-Cell, Marginal Zone; Macrophages; Male; Middle Aged; Multimodal Imaging; Phosphorylcholine; Positron-Emission Tomography; Splenic Neoplasms; Tomography, X-Ray Computed | 2012 |
Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Contraceptive Agents; Female; Humans; India; Leishmaniasis, Visceral; Models, Statistical; Phosphorylcholine; Teratogens; Time Factors; Young Adult | 2012 |
Synthesis and anti-leishmanial activity of 1-aryl-β-carboline derivatives against Leishmania donovani.
Topics: Carbolines; Cell Survival; Humans; Inhibitory Concentration 50; Leishmania donovani; Phosphorylcholine; Structure-Activity Relationship; Trypanocidal Agents | 2012 |
Defeating Leishmania resistance to miltefosine (hexadecylphosphocholine) by peptide-mediated drug smuggling: a proof of mechanism for trypanosomatid chemotherapy.
Topics: Animals; Antiprotozoal Agents; Cell Membrane; Cell-Penetrating Peptides; Drug Resistance, Microbial; Leishmania donovani; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Peptide Fragments; Phosphorylcholine; tat Gene Products, Human Immunodeficiency Virus; Trypanosoma brucei brucei | 2012 |
Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cytokines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Immunologic Factors; Leishmania donovani; Leishmaniasis, Visceral; Lipoproteins; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Phagocytosis; Phosphorylcholine; Reactive Nitrogen Species; Reactive Oxygen Species | 2012 |
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Female; Humans; India; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Male; Middle Aged; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Young Adult | 2012 |
Effects of miltefosine on the proliferation, ultrastructure, and phospholipid composition of Angomonas deanei, a trypanosomatid protozoan that harbors a symbiotic bacterium.
Topics: Bacteria; Cell Membrane; Cell Wall; Choline-Phosphate Cytidylyltransferase; Crithidia; Microscopy, Electron, Transmission; Mitochondria; Phosphatidylcholines; Phosphorus Isotopes; Phosphorylcholine; Symbiosis | 2012 |
A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal.
Topics: Antiprotozoal Agents; Bangladesh; Drugs, Generic; Humans; Leishmaniasis, Visceral; Neglected Diseases; Phosphorylcholine | 2012 |
Nuclease activity and ultrastructural effects of new sulfonamides with anti-leishmanial and trypanocidal activities.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Deoxyribonucleases; Leishmania infantum; Macrophages; Mice; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Molecular Structure; Nitroimidazoles; Phosphorylcholine; Sulfonamides | 2012 |
Interaction of miltefosine with intercellular membranes of stratum corneum and biomimetic lipid vesicles.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Animals, Newborn; Antineoplastic Agents; Biomimetic Materials; Cattle; Ceramides; Cholesterol; Electron Spin Resonance Spectroscopy; Fatty Acids; Fluorescence Polarization; Membrane Fluidity; Membrane Lipids; Phosphorylcholine; Rats; Rats, Wistar; Skin; Spin Labels; Temperature | 2012 |
Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon.
Topics: CD4-Positive T-Lymphocytes; Cell Line; Coculture Techniques; Dendritic Cells; HIV-1; Humans; Interferon Type I; Phosphorylcholine; Virus Replication | 2012 |
Leishmania donovani pteridine reductase 1: comparative protein modeling and protein-ligand interaction studies of the leishmanicidal constituents isolated from the fruits of Piper longum.
Topics: Amino Acid Sequence; Catalytic Domain; Cell Survival; Hydrogen Bonding; Inhibitory Concentration 50; Leishmania donovani; Molecular Docking Simulation; Molecular Sequence Data; NADP; Oxidoreductases; Phosphorylcholine; Piper; Plant Extracts; Protein Structure, Secondary; Protein Structure, Tertiary; Protozoan Proteins; Trypanocidal Agents | 2012 |
Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.
Topics: Adolescent; Adult; Antiprotozoal Agents; Artificial Gene Fusion; Cell Survival; Cells, Cultured; Female; Gene Expression Profiling; Genes, Reporter; Humans; Immunologic Factors; Leishmania donovani; Luciferases; Macrophages; Male; NF-kappa B; Nitric Oxide; Paromomycin; Phosphorylcholine; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Young Adult | 2012 |
Giardia lamblia: a new target for miltefosine.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Female; Giardia lamblia; Giardiasis; Intestines; Male; Mice; Microscopy, Electron; Parasitic Sensitivity Tests; Phosphorylcholine; Treatment Outcome | 2012 |
Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Humans; Immune Evasion; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, SCID; Phosphorylcholine; Treatment Outcome | 2012 |
Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier.
Topics: Acanthamoeba; Adult; Amebiasis; Animals; Encephalitis; Granuloma; Humans; Immunocompetence; Male; Military Personnel; Phosphorylcholine; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2012 |
Leishmania promastigotes lack phosphatidylserine but bind annexin V upon permeabilization or miltefosine treatment.
Topics: Annexin A5; Antiprotozoal Agents; Cell Membrane Permeability; Humans; Leishmania; Phagocytosis; Phosphatidylserines; Phosphorylcholine | 2012 |
Real-time PCR to quantify Leishmania donovani in hamsters.
Topics: Amidines; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; DNA, Kinetoplast; Dose-Response Relationship, Drug; Furans; Leishmania donovani; Leishmaniasis, Visceral; Liver; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Phosphorylcholine; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Sensitivity and Specificity | 2013 |
Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Cell Culture Techniques; Cell Survival; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasitic Sensitivity Tests; Peptidomimetics; Phosphorylcholine; Primaquine | 2012 |
Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Glioblastoma; Humans; Male; Nanostructures; Paclitaxel; Phosphorylcholine; Rats; Rats, Wistar | 2013 |
Leishmania mexicana metacaspase is a negative regulator of amastigote proliferation in mammalian cells.
Topics: Animals; Antiprotozoal Agents; Caspases; Female; Leishmania mexicana; Macrophages; Mice; Mice, Inbred BALB C; Phosphorylcholine | 2012 |
Effect of alkylphospholipids on Candida albicans biofilm formation and maturation.
Topics: Antifungal Agents; Biofilms; Candida albicans; Phospholipids; Phosphorylcholine; Plankton; Treatment Outcome | 2013 |
Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.
Topics: Animals; Antiprotozoal Agents; Communicable Disease Control; Health Services Accessibility; Humans; India; Insect Vectors; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; Psychodidae | 2012 |
Chemotherapy of leishmaniasis. Part IX: synthesis and bioevaluation of aryl substituted ketene dithioacetals as antileishmanial agents.
Topics: Acetals; Animals; Antiprotozoal Agents; Cricetinae; Ethylenes; Ketones; Leishmania donovani; Leishmaniasis; Models, Animal; Molecular Structure; Phosphorylcholine; Sulfhydryl Compounds | 2012 |
Molecular recognition of zwitterions: enhanced binding and selective recognition of miltefosine by a squaramide-based host.
Topics: Cyclobutanes; Ions; Magnetic Resonance Spectroscopy; Phosphorylcholine | 2013 |
Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Deoxycholic Acid; Drug Combinations; Fluconazole; Meningitis, Cryptococcal; Meningoencephalitis; Mice; Microbial Sensitivity Tests; Phosphorylcholine; Survival | 2013 |
Pathogens and Global Health counterfeit medicine photo campaign.
Topics: Antiprotozoal Agents; Bangladesh; Counterfeit Drugs; Humans; Phosphorylcholine; Photography | 2012 |
Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Clinical Trials, Phase III as Topic; Cohort Studies; Educational Status; Female; Humans; Leishmaniasis, Visceral; Male; Medication Adherence; Nepal; Phosphorylcholine; Prospective Studies; Sex Factors; Surveys and Questionnaires; Young Adult | 2013 |
Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.
Topics: Animals; Antiprotozoal Agents; Cell Line; Fluorometry; India; Leishmania donovani; Macrophages; Mice; Oxazines; Parasitic Sensitivity Tests; Phosphorylcholine; Staining and Labeling; Xanthenes | 2013 |
Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.
Topics: Antiprotozoal Agents; Humans; Leishmania mexicana; Leishmaniasis, Diffuse Cutaneous; Phosphorylcholine | 2013 |
A series of case reports of autochthonous visceral leishmaniasis, mostly in non-endemic hilly areas of Nepal.
Topics: Adolescent; Adult; Aged; Amphotericin B; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Leishmania; Leishmaniasis, Visceral; Male; Middle Aged; Nepal; Phosphorylcholine; Young Adult | 2013 |
Apoptotic marker expression in the absence of cell death in staurosporine-treated Leishmania donovani.
Topics: Amino Acid Sequence; Amphotericin B; Annexin A5; Antiprotozoal Agents; Apoptosis; Benzamides; Biomarkers; Casein Kinase I; Cell Cycle Checkpoints; Humans; Imidazoles; Leishmania donovani; Molecular Sequence Data; Phosphorylcholine; Phosphotransferases; Protein Biosynthesis; Protein Kinase Inhibitors; Protozoan Proteins; Staurosporine; Substrate Specificity | 2013 |
Recurring extracorporeal circuit clotting during continuous renal replacement therapy in fungal sepsis: successful treatment with argatroban.
Topics: Antifungal Agents; Antithrombins; Arginine; Blood Coagulation; Coronary Artery Bypass; Humans; Male; Mediastinitis; Middle Aged; Mycoses; Phosphorylcholine; Pipecolic Acids; Postoperative Complications; Renal Replacement Therapy; Scedosporium; Sepsis; Sulfonamides | 2013 |
Imidazolium ionic liquids as solvents of pharmaceuticals: influence on HSA binding and partition coefficient of nimesulide.
Topics: Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Ionic Liquids; Membrane Lipids; Membrane Proteins; Models, Biological; Phosphorylcholine; Protein Binding; Serum Albumin; Solubility; Solvents; Spectrometry, Fluorescence; Sulfonamides | 2013 |
Synthesis of perspicamide A and related diverse analogues: their bioevaluation as potent antileishmanial agents.
Topics: Antiprotozoal Agents; Carboxylic Acids; Leishmania donovani; Molecular Structure; Phosphorylcholine; Quinolines | 2013 |
Miltefosine-induced acute interstitial pneumonitis in a patient with renal dysfunction.
Topics: Aged; Antiprotozoal Agents; Humans; Lung Diseases, Interstitial; Male; Phosphorylcholine; Renal Insufficiency, Chronic | 2013 |
Lipid efflux mediated by alkylphospholipids in HepG2 cells.
Topics: Antineoplastic Agents; Biological Transport; Cell Membrane; Cholesterol; Endoplasmic Reticulum; Extracellular Space; Hep G2 Cells; Humans; Kinetics; Phospholipids; Phosphorylcholine; Sphingomyelin Phosphodiesterase | 2013 |
What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?
Topics: Antiprotozoal Agents; Clinical Protocols; Communicable Disease Control; Drug Resistance, Microbial; HIV Infections; Humans; India; Leishmaniasis, Visceral; Medication Adherence; Phosphorylcholine | 2013 |
Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines.
Topics: Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans; Neoplasms; Phospholipid Ethers; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2013 |
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; Kaplan-Meier Estimate; Leishmania donovani; Leishmaniasis, Visceral; Male; Nepal; Parasite Load; Patient Compliance; Phosphorylcholine; Prospective Studies; Recurrence; Treatment Failure | 2013 |
Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Ethiopia; Humans; Inhibitory Concentration 50; Leishmania; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Mice; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine | 2013 |
Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleates.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Leishmania; Nanostructures; Phosphorylcholine | 2013 |
Interaction of miltefosine with the lipid and protein components of the erythrocyte membrane.
Topics: Antineoplastic Agents; Antiprotozoal Agents; Erythrocyte Membrane; Hemolysis; Humans; Membrane Lipids; Membrane Microdomains; Membrane Proteins; Phosphorylcholine | 2013 |
Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project.
Topics: Amphotericin B; Antiprotozoal Agents; Cohort Studies; Data Collection; Female; Humans; India; Leishmaniasis, Visceral; Male; Nepal; Phosphorylcholine; Pilot Projects; Primary Health Care; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept study.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Clindamycin; DNA Fragmentation; Humans; Hydrogen Peroxide; In Situ Nick-End Labeling; Male; Mice; Phosphorylcholine; Staurosporine; Toxoplasma | 2013 |
HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Calcium; Cell Line; Cell Line, Tumor; Cells, Cultured; Chlorocebus aethiops; Epithelial Cells; Female; Glycoproteins; Herpesvirus 2, Human; Host-Pathogen Interactions; Humans; Keratinocytes; Microscopy, Confocal; Mutation; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA Interference; Vero Cells; Viral Proteins; Virus Internalization | 2013 |
Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers.
Topics: Adult; Aged; Amphotericin B; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; South America; Travel; Young Adult | 2013 |
Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Antiprotozoal Agents; Biguanides; Cell Line; Cell Proliferation; Disease Models, Animal; Disinfectants; Drug Therapy, Combination; Fibroblasts; Male; Phosphorylcholine; Rats; Rats, Wistar | 2014 |
Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients.
Topics: Adolescent; Adult; Cells, Cultured; Child; Enzyme-Linked Immunosorbent Assay; Female; Fluorometry; Gene Expression Profiling; Glutathione Peroxidase; Heme Oxygenase-1; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Repressor Proteins; Superoxide Dismutase; Young Adult | 2013 |
Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.
Topics: Antineoplastic Agents; Humans; Jurkat Cells; Liposomes; Membrane Microdomains; Phospholipid Ethers; Phosphorylcholine | 2013 |
In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Deoxycholic Acid; Disease Reservoirs; Dog Diseases; Dogs; Drug Combinations; Humans; Immunocompetence; Immunocompromised Host; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Phosphorylcholine | 2013 |
Drug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Leishmania donovani; Meglumine; Meglumine Antimoniate; Membrane Proteins; Organometallic Compounds; Phosphorylcholine; Protozoan Proteins; Rhodamine 123 | 2013 |
Effect of miltefosine on erythrocytes.
Topics: Anti-Infective Agents; Antineoplastic Agents; Cell Death; Cell Size; Cells, Cultured; Erythrocytes; Hemolysis; Humans; Phosphatidylserines; Phosphorylcholine | 2013 |
Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cytokines; Disease Models, Animal; Humans; Immunoenzyme Techniques; Inflammation; Inflammatory Bowel Diseases; Mice; Mice, Inbred BALB C; Mice, SCID; Phosphorylcholine; T-Lymphocytes | 2013 |
Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Infant; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Retrospective Studies; Species Specificity; Switzerland; Travel; Treatment Outcome; Young Adult | 2013 |
In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
Topics: Antifungal Agents; Drug Synergism; Fungi; Humans; Microbial Sensitivity Tests; Mycoses; Phosphorylcholine; Pyrimidines; Triazoles; Voriconazole | 2013 |
Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
Topics: Administration, Oral; Aged; Antiprotozoal Agents; Histocytochemistry; Humans; Immunocompromised Host; Immunologic Deficiency Syndromes; Leishmania infantum; Leishmaniasis, Mucocutaneous; Male; Mouth Mucosa; Phosphorylcholine; Recurrence; Treatment Outcome | 2013 |
Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species.
Topics: Calcium; Drug Resistance; Flow Cytometry; Leishmania donovani; Membrane Potential, Mitochondrial; Phosphorylcholine; Protozoan Proteins; Reactive Oxygen Species | 2013 |
Synthesis and antifungal activities of miltefosine analogs.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candida; Candidiasis; Cell Line; Cryptococcosis; Cryptococcus neoformans; Fungi; Humans; Mice; Mycoses; Phosphorylcholine | 2013 |
Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
Topics: Adult; Antiprotozoal Agents; Bangladesh; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Mouth Mucosa; Phosphorylcholine; Treatment Outcome | 2013 |
One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India.
Topics: Antiprotozoal Agents; Child; Follow-Up Studies; Humans; India; Leishmaniasis, Visceral; Male; Phosphorylcholine; Recurrence; Treatment Outcome | 2013 |
Investigational drug available directly from CDC for the treatment of infections with free-living amebae.
Topics: Acanthamoeba; Amebiasis; Animals; Antiprotozoal Agents; Balamuthia mandrillaris; Centers for Disease Control and Prevention, U.S.; Central Nervous System Protozoal Infections; Drugs, Investigational; Encephalitis; Humans; Naegleria fowleri; Phosphorylcholine; Treatment Outcome; United States | 2013 |
Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Topics: Adenosine Triphosphate; Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Cytochromes c; Dose-Response Relationship, Drug; Drug Resistance; Gene Expression Profiling; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Membrane Potential, Mitochondrial; Mice; Oxidative Stress; Phosphorylcholine; Sirtuins; Superoxide Dismutase | 2013 |
In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine | 2013 |
Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
Topics: Amphotericin B; Antiprotozoal Agents; DNA, Protozoan; Drug Therapy, Combination; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Parasite Load; Phosphorylcholine; Young Adult | 2014 |
Functional characterization of the hexose transporter Hxt13p: an efflux pump that mediates resistance to miltefosine in yeast.
Topics: Antifungal Agents; Drug Resistance, Fungal; Gene Expression; Microbial Viability; Monosaccharide Transport Proteins; Phosphorylcholine; Saccharomyces cerevisiae | 2013 |
Translating immune cell cross-talk into a treatment opportunity for visceral leishmaniasis.
Topics: Animals; Cell Communication; Humans; Immunity, Cellular; Immunotherapy; Interferon-gamma; Interleukin-10; Leishmaniasis, Visceral; Lymphocyte Cooperation; Phosphorylcholine; Th1-Th2 Balance; Translational Research, Biomedical | 2013 |
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Topics: Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; Recurrence; Virulence | 2013 |
Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily G; ATP-Binding Cassette Transporters; Child; Drug Resistance; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Phosphorylcholine; Prospective Studies; Treatment Failure; Young Adult | 2014 |
In brief: miltefosine for amebic meningeoencephalitis available from CDC.
Topics: Centers for Disease Control and Prevention, U.S.; Central Nervous System Protozoal Infections; Drugs, Investigational; Humans; Phosphorylcholine; United States | 2013 |
Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Caspases; Cell Line, Tumor; Cell Survival; Curcumin; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; Lymphoma, T-Cell, Cutaneous; Microtubule-Associated Proteins; Organophosphates; Phosphorylation; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quaternary Ammonium Compounds; Skin Neoplasms | 2014 |
Combination therapy with nitazoxanide and amphotericin B, Glucantime®, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes.
Topics: Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Combinations; Leishmania infantum; Leishmaniasis, Visceral; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice; Nitro Compounds; Organometallic Compounds; Parasitic Sensitivity Tests; Phosphorylcholine; Thiazoles | 2014 |
Evaluation of the effect of miltefosine on Trichomonas vaginalis.
Topics: Antiprotozoal Agents; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Phosphorylcholine; Trichomonas vaginalis | 2014 |
Cytotoxic amphiphiles and phosphoinositides bind to two discrete sites on the Akt1 PH domain.
Topics: Antineoplastic Agents; Binding Sites; Humans; Micelles; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Phosphatidylinositols; Phosphorylcholine; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Spin Labels | 2014 |
Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Blood Chemical Analysis; Child; Child, Preschool; Chromatography, Liquid; Humans; Infant; Leishmaniasis, Visceral; Male; Middle Aged; Nepal; Phosphorylcholine; Tandem Mass Spectrometry; Treatment Failure; Young Adult | 2014 |
A BODIPY-embedding miltefosine analog linked to cell-penetrating Tat(48-60) peptide favors intracellular delivery and visualization of the antiparasitic drug.
Topics: Anthelmintics; Boron Compounds; Cell Line; Cell-Penetrating Peptides; Drug Design; Humans; Leishmania; Leishmaniasis; Macrophages, Peritoneal; Molecular Structure; Phosphorylcholine; tat Gene Products, Human Immunodeficiency Virus | 2014 |
Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani.
Topics: Antiprotozoal Agents; Drug Resistance; Gene Expression Profiling; Leishmania donovani; Oligonucleotide Array Sequence Analysis; Phosphorylcholine; RNA, Protozoan | 2014 |
Alkyl galactofuranosides strongly interact with Leishmania donovani membrane and provide antileishmanial activity.
Topics: Antiprotozoal Agents; Cell Line; Electron Spin Resonance Spectroscopy; Humans; Leishmania donovani; Magnetic Resonance Spectroscopy; Microscopy, Electron, Transmission; Phosphorylcholine; Reactive Oxygen Species | 2014 |
Miltefosine increases lipid and protein dynamics in Leishmania amazonensis membranes at concentrations similar to those needed for cytotoxicity activity.
Topics: Antineoplastic Agents; Cell Membrane; Cell Survival; Electron Spin Resonance Spectroscopy; Humans; Hydrophobic and Hydrophilic Interactions; Leishmania mexicana; Membrane Lipids; Membrane Proteins; Micelles; Molecular Dynamics Simulation; Phosphorylcholine; Protein Conformation; Spin Labels | 2014 |
Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.
Topics: Animals; Antimony; Antiprotozoal Agents; Drug Resistance; Female; Humans; Leishmania donovani; Macrophages; Mice; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine | 2014 |
Antileishmanial activity of semisynthetic lupane triterpenoids betulin and betulinic acid derivatives: synergistic effects with miltefosine.
Topics: Animals; Antiprotozoal Agents; Betulinic Acid; Cell Line; Cell Survival; Drug Synergism; Imidazoles; Inhibitory Concentration 50; Leishmania infantum; Life Cycle Stages; Macrophages; Mice; Pentacyclic Triterpenes; Phosphorylcholine; Structure-Activity Relationship; Triterpenes | 2014 |
In vitro inhibitory effect of miltefosine against strains of Histoplasma capsulatum var. capsulatum and Sporothrix spp.
Topics: Antifungal Agents; Histoplasma; Microbial Sensitivity Tests; Microbial Viability; Phosphorylcholine; Sporothrix | 2014 |
Multi-analytical platform metabolomic approach to study miltefosine mechanism of action and resistance in Leishmania.
Topics: Arginine; Carbon; Chromatography, Gas; Chromatography, Liquid; Drug Resistance; Electrophoresis, Capillary; Gas Chromatography-Mass Spectrometry; Glutathione; Hydrodynamics; Leishmania donovani; Mass Spectrometry; Metabolomics; Phosphorylcholine; Quality Control; Reactive Oxygen Species; Spermidine | 2014 |
Functional disruption of yeast metacaspase, Mca1, leads to miltefosine resistance and inability to mediate miltefosine-induced apoptotic effects.
Topics: Antifungal Agents; Apoptosis; Caspases; Drug Resistance, Fungal; Mutation; Phosphorylcholine; Reactive Oxygen Species; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2014 |
Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Enzyme-Linked Immunosorbent Assay; Immunity, Cellular; Immunoglobulin G; Immunologic Factors; Leishmaniasis, Visceral; Liposomes; Mesocricetus; Mice; Mice, Inbred BALB C; Nitric Oxide; Oligodeoxyribonucleotides; Phosphorylcholine; RNA, Messenger; T-Lymphocytes | 2014 |
Novel organic salts based on fluoroquinolone drugs: synthesis, bioavailability and toxicological profiles.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Biological Availability; Caco-2 Cells; Cell Survival; Chemistry, Pharmaceutical; Ciprofloxacin; Gluconates; Glycolates; Humans; Intestinal Absorption; Intestinal Mucosa; Mesylates; Micelles; Norfloxacin; Phosphorylcholine; Solubility; Solvents; Technology, Pharmaceutical; Water | 2014 |
Repurposing miltefosine for the treatment of immune-mediated disease?
Topics: Adaptive Immunity; Adjuvants, Immunologic; Drug Discovery; Humans; Immune System Diseases; Immunity, Innate; Leishmaniasis; Phosphorylcholine | 2014 |
Affinity of alkylphosphocholines to biological membrane of prostate cancer: studies in natural and model systems.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Humans; Male; Models, Biological; Phosphorylcholine; Prostatic Neoplasms | 2014 |
Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
Topics: Adolescent; Adult; Aged; Antimony; Child; Child, Preschool; Cohort Studies; Colombia; Drug Resistance; Humans; Infant; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Randomized Controlled Trials as Topic; Young Adult | 2014 |
Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1.
Topics: Amidines; Animals; Antiprotozoal Agents; Axenic Culture; Blotting, Western; Cricetinae; Drug Combinations; Drug Resistance; Drug Synergism; Furans; Gene Expression Regulation; Ketoconazole; Leishmania donovani; Life Cycle Stages; Mice; Phosphorylcholine; Protozoan Proteins; Sterol 14-Demethylase; Triazoles | 2014 |
Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Coinfection; HIV Infections; Humans; India; Leishmaniasis, Visceral; Male; Phosphorylcholine; Recurrence; Treatment Outcome | 2014 |
Evaluation of the inhibitory effects of miltefosine on the growth of Babesia and Theileria parasites.
Topics: Animals; Antiparasitic Agents; Babesia; Babesiosis; Choline-Phosphate Cytidylyltransferase; Female; Mice; Mice, Inbred BALB C; Parasitemia; Phosphorylcholine; Protozoan Proteins; Real-Time Polymerase Chain Reaction; Theileria; Theileriasis | 2014 |
Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Topics: Adolescent; Adult; Age Factors; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Male; Nepal; Parasitic Sensitivity Tests; Phosphorylcholine; Practice Guidelines as Topic; Prospective Studies; Recurrence; Risk Factors; Sex Factors; Treatment Failure | 2014 |
Development of antileishmanial lipid nanocomplexes.
Topics: Administration, Oral; Amphotericin B; Antiprotozoal Agents; Calcium; Cholesterol; Circular Dichroism; Drug Compounding; Drug Stability; Humans; Leishmaniasis, Visceral; Lipids; Liposomes; Microscopy, Electron, Transmission; Nanocomposites; Particle Size; Phosphatidylserines; Phosphorylcholine; Spectrophotometry | 2014 |
In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
Topics: Animals; Antiprotozoal Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Organometallic Compounds; Phosphorylcholine; Spleen | 2014 |
In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania; Leishmaniasis, Diffuse Cutaneous; Mice; Mice, Inbred BALB C; Phosphorylcholine | 2014 |
US incentive scheme for neglected diseases: a good idea gone wrong?
Topics: Antiprotozoal Agents; Drug Approval; Drug Industry; Health Policy; Humans; Neglected Diseases; Orphan Drug Production; Phosphorylcholine; United States | 2014 |
In vitro combination of voriconazole and miltefosine against clinically relevant molds.
Topics: Antifungal Agents; Aspergillosis; Aspergillus; Candida; Drug Resistance, Fungal; Drug Synergism; Drug Therapy, Combination; Fusariosis; Fusarium; Microbial Sensitivity Tests; Phosphorylcholine; Scedosporium; Voriconazole | 2014 |
Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Phosphatidylcholines; Phosphorylcholine | 2014 |
Miltefosine (Impavido) for leishmaniasis.
Topics: Antiprotozoal Agents; Drug Approval; Humans; Leishmaniasis; Phosphorylcholine; United States; United States Food and Drug Administration | 2014 |
Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Leishmaniasis, Cutaneous; Mice, Inbred C57BL; Pentoxifylline; Phosphorylcholine; Time Factors | 2014 |
In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine.
Topics: Animals; Antineoplastic Agents; Antiparasitic Agents; Apoptosis; Female; Mice; Phospholipid Ethers; Phosphorylcholine; Schistosoma mansoni; Schistosomiasis mansoni | 2014 |
Miltefosine and BODIPY-labeled alkylphosphocholine with leishmanicidal activity: Aggregation properties and interaction with model membranes.
Topics: Antiparasitic Agents; Azoles; Boron Compounds; Humans; Nitrobenzenes; Phosphorylcholine; Spectrometry, Fluorescence; Surface Tension; Unilamellar Liposomes | 2015 |
Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Survival; Cells, Cultured; Chlorocebus aethiops; Inhibitory Concentration 50; Ketones; Leishmania donovani; Leishmaniasis; Macrophages; Mice; Molecular Structure; Parasitic Sensitivity Tests; Phosphorylcholine; Retinoids; Structure-Activity Relationship; Vero Cells | 2015 |
Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caenorhabditis elegans; Cell Line, Tumor; Cholesterol; Drug Resistance; Embryo, Nonmammalian; Embryonic Development; Humans; Insulin-Like Growth Factor I; Larva; Membrane Microdomains; Phospholipid Ethers; Phosphorylcholine | 2014 |
The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Drug Resistance; Glutamate-Cysteine Ligase; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Membrane Transport Proteins; Mutation; Phosphorylcholine; Protozoan Proteins; Sulfhydryl Compounds | 2014 |
Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes.
Topics: Acyltransferases; Amphotericin B; Animals; Antiprotozoal Agents; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Leishmania donovani; Macrophages; Mice; Mice, Inbred BALB C; Phosphorylcholine | 2014 |
Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Aspergillus fumigatus; Azoles; Disease Models, Animal; Mice; Microbial Sensitivity Tests; Phosphorylcholine; Pyrimidines; Triazoles; Voriconazole | 2015 |
In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.
Topics: Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Mycoses; Phosphorylcholine; Scedosporium; Voriconazole | 2015 |
Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Topics: Animals; Antimony; Antiprotozoal Agents; Cricetinae; Humans; India; Leishmania infantum; Leishmaniasis, Visceral; Luciferases; Parasite Load; Phosphorylcholine; Recombinant Proteins | 2015 |
Miltefosine is active against Sporothrix brasiliensis isolates with in vitro low susceptibility to amphotericin B or itraconazole.
Topics: Amphotericin B; Animals; Antifungal Agents; Brazil; Cell Line; Cell Membrane; Cell Survival; Cell Wall; Cytoplasm; Drug Resistance, Fungal; Epithelial Cells; Humans; Itraconazole; Macaca mulatta; Microbial Sensitivity Tests; Microbial Viability; Microscopy, Electron, Transmission; Phosphorylcholine; Sporothrix; Sporotrichosis | 2015 |
Synthesis of structural analogues of hexadecylphosphocholine and their antineoplastic, antimicrobial and amoebicidal activity.
Topics: Amebicides; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Humans; Phosphorylcholine; Structure-Activity Relationship | 2015 |
Understanding Miltefosine-Membrane Interactions Using Molecular Dynamics Simulations.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Cholesterol; Kinetics; Lipid Bilayers; Membrane Microdomains; Molecular Dynamics Simulation; Phosphatidylcholines; Phosphorylcholine; Thermodynamics; Water | 2015 |
Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.
Topics: Antiprotozoal Agents; Drug Design; Hep G2 Cells; Humans; Leishmania donovani; Leishmania infantum; Life Cycle Stages; Macrophages; Nitroquinolines; Parasitic Sensitivity Tests; Pentamidine; Phosphorylcholine; Structure-Activity Relationship | 2015 |
Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum.
Topics: Antiprotozoal Agents; Drug Evaluation, Preclinical; Drug Resistance; Humans; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine | 2015 |
[Cutaneous leishmaniasis in a patient with ulcerative colitis under treatment with infliximab].
Topics: Antiprotozoal Agents; Azathioprine; Colitis, Ulcerative; Diagnosis, Differential; Humans; Immunocompromised Host; Immunosuppressive Agents; Infliximab; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphorylcholine; Pyoderma Gangrenosum | 2015 |
Chemical and bioassay techniques to authenticate quality of the anti-leishmanial drug miltefosine.
Topics: Animals; Antiprotozoal Agents; Biological Assay; Capsules; Counterfeit Drugs; Leishmania donovani; Macrophages, Peritoneal; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Phosphorylcholine; Quality Control | 2015 |
Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
Topics: Animals; Antibodies, Monoclonal; Antigens, Protozoan; Antiprotozoal Agents; CD4-Positive T-Lymphocytes; Gene Knockout Techniques; Interferon-gamma; Leishmania donovani; Leishmaniasis, Visceral; Ligands; Macrophages; Mice; Models, Molecular; Molecular Conformation; Phosphorylcholine; Platelet Membrane Glycoproteins; Protein Binding; Receptors, G-Protein-Coupled | 2015 |
In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Resistance; Female; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine | 2015 |
Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Topics: Adolescent; Animals; Antiprotozoal Agents; Female; Humans; Immunologic Factors; Interferon-alpha; Interleukin-10; Interleukin-13; Leishmania; Leishmaniasis; Leukocytes, Mononuclear; Macrophages; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Tumor Necrosis Factor-alpha; Young Adult | 2015 |
Caruncular Leishmaniasis--An Unusual Case.
Topics: Antiprotozoal Agents; Diagnosis, Differential; Eye Diseases; Humans; Leishmaniasis; Male; Middle Aged; Phosphorylcholine | 2015 |
Could miltefosine be used as a therapy for toxoplasmosis?
Topics: Animals; Antiprotozoal Agents; Brain; Disease Models, Animal; Infectious Encephalitis; Liver; Mice; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Phosphorylcholine; Spleen; Survival Rate; Toxoplasma; Toxoplasmosis, Animal | 2015 |
Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Cytokines; Leishmaniasis, Visceral; Leptin; Macrophages; Mice; Nitric Oxide; Phosphorylcholine | 2015 |
Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Amphotericin B; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; India; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Recurrence; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Leishmania is not prone to develop resistance to tamoxifen.
Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Leishmania; Leishmaniasis; Mice; Mice, Inbred BALB C; Phosphorylcholine; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antiprotozoal Agents; Chromatography, High Pressure Liquid; Humans; Leukocytes, Mononuclear; Phosphorylcholine; Tandem Mass Spectrometry | 2015 |
In vitro antifungal activity of miltefosine and levamisole: their impact on ergosterol biosynthesis and cell permeability of dimorphic fungi.
Topics: Antifungal Agents; Cell Membrane Permeability; Coccidioides; Ergosterol; Histoplasma; Levamisole; Microbial Sensitivity Tests; Phosphorylcholine | 2015 |
Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Female; Gene Expression Regulation; Genetic Fitness; Leishmania major; Mice; Mice, Inbred BALB C; Phlebotomus; Phosphorylcholine; Virulence | 2015 |
Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmania donovani; Leishmaniasis, Visceral; Nepal; Parasitic Sensitivity Tests; Phosphorylcholine; Recurrence; Treatment Outcome | 2015 |
Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Doxorubicin; Drug Delivery Systems; Drug Synergism; Drug Therapy, Combination; Female; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Phosphorylcholine; Polyethylene Glycols | 2015 |
Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice.
Topics: Animals; Antifungal Agents; Female; Indoles; Leishmania; Leishmaniasis, Cutaneous; Liposomes; Mice; Mice, Inbred C57BL; Organometallic Compounds; Phosphorylcholine; Photochemotherapy; Photosensitizing Agents; Treatment Outcome | 2016 |
Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain.
Topics: Amebiasis; Amebicides; Balamuthia mandrillaris; Blood-Brain Barrier; Brain; Child; Encephalitis; Fatal Outcome; Humans; Male; Phosphorylcholine | 2015 |
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Schedules; Disease Models, Animal; Drug Therapy, Combination; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome | 2015 |
Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
Topics: Antiprotozoal Agents; Benzoates; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Humans; Leishmania donovani; Macrophages; Parasitic Sensitivity Tests; Phosphorylcholine | 2015 |
Miltefosine is effective against Candida albicans and Fusarium oxysporum nail biofilms in vitro.
Topics: Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Fusariosis; Fusarium; Humans; Nail Diseases; Nails; Phosphorylcholine | 2015 |
Experience With the Priority Review Voucher Program for Drug Development.
Topics: Antibodies, Monoclonal; Antimalarials; Antineoplastic Agents; Antiprotozoal Agents; Antitubercular Agents; Artemether, Lumefantrine Drug Combination; Artemisinins; Cholic Acid; Chondroitinsulfatases; Diarylquinolines; Drug Approval; Drug Combinations; Drug Industry; Ethanolamines; Fluorenes; Humans; Neglected Diseases; Phosphorylcholine; Program Development; Rare Diseases; United States; United States Food and Drug Administration | 2015 |
In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis.
Topics: Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis, Oral; Cytochrome P-450 Enzyme System; Drug Resistance, Fungal; Fluconazole; Gene Expression; Mice; Microbial Sensitivity Tests; Mutation; Phosphorylcholine; Plankton; Transcription Factors; Treatment Outcome | 2015 |
PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Disease Transmission, Infectious; Epidemiological Monitoring; Female; Humans; India; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Polymerase Chain Reaction; Prevalence; Recurrence; Rural Population; Young Adult | 2015 |
Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Topics: Adult; Antiprotozoal Agents; Child; Female; Histocytochemistry; Humans; India; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Parasite Load; Phosphorylcholine; Real-Time Polymerase Chain Reaction; Recurrence; Treatment Outcome; Young Adult | 2015 |
A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Topics: Adolescent; Adult; Amphotericin B; Antibodies, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agents; Disease Progression; Female; Humans; Immunoglobulin G; India; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Neglected Diseases; Phosphorylcholine; Sex Factors; Testosterone; Young Adult | 2016 |
Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Drug Evaluation, Preclinical; Hemolysis; Liver; Male; Mice; Nanocapsules; Phosphorylcholine; Rats, Sprague-Dawley; Schistosoma mansoni; Schistosomiasis mansoni; Tissue Distribution | 2015 |
Development of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis.
Topics: Animals; Cricetinae; Drug Delivery Systems; Lactic Acid; Leishmania donovani; Leishmaniasis, Visceral; Nanoparticles; Phosphorylcholine; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2016 |
Two cases of cutaneous leishmaniasis in Dutch military personnel treated with oral miltefosine.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Military Personnel; Phosphorylcholine | 2017 |
Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case.
Topics: Antiprotozoal Agents; Central Nervous System Protozoal Infections; Child; Fatal Outcome; Humans; Male; Naegleria fowleri; Phosphorylcholine; Treatment Outcome | 2016 |
In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
Topics: Animals; Antimony; Antiprotozoal Agents; Drug Resistance; Female; Leishmania donovani; Leishmaniasis, Visceral; Lipid Metabolism; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Mutation; Nepal; Parasitic Sensitivity Tests; Phosphorylcholine | 2016 |
15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Cricetulus; Disease Models, Animal; Drug Administration Schedule; Female; Interleukin-10; Leishmania donovani; Leishmaniasis, Visceral; Life Cycle Stages; Liver; Macrophages; Male; Mice; Mice, Inbred BALB C; Mitochondria; Phosphorylcholine; Prostaglandin D2; Reactive Oxygen Species; Spleen; Transforming Growth Factor beta; Treatment Outcome | 2016 |
Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Leishmania; Leishmaniasis, Cutaneous; Mice, Inbred BALB C; Parasite Load; Phosphorylcholine; Tamoxifen; Treatment Outcome | 2016 |
Treatment of visceral leishmaniasis: options and choice.
Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2016 |
Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.
Topics: ATP-Binding Cassette Transporters; Biological Transport, Active; Cell Line, Tumor; Gene Knockdown Techniques; Humans; Leishmania; Leishmaniasis; Macrophages; Phosphorylcholine | 2016 |
LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma.
Topics: Administration, Oral; Adult; Animals; Antiprotozoal Agents; Chromatography, High Pressure Liquid; Cricetinae; Half-Life; Humans; Leishmaniasis; Limit of Detection; Male; Phosphorylcholine; Reference Standards; Spectrometry, Mass, Electrospray Ionization | 2016 |
Hemolytic potential of miltefosine is dependent on cell concentration: Implications for in vitro cell cytotoxicity assays and pharmacokinetic data.
Topics: Erythrocyte Membrane; Hemolysis; Humans; In Vitro Techniques; Phosphorylcholine | 2016 |
Naegleria fowleri That Induces Primary Amoebic Meningoencephalitis: Rapid Diagnosis and Rare Case of Survival in a 12-Year-Old Caucasian Girl.
Topics: Amebiasis; Amphotericin B; Antiprotozoal Agents; Azithromycin; Central Nervous System Protozoal Infections; Cerebrospinal Fluid; Cerebrospinal Fluid Shunts; Child; Early Diagnosis; Female; Fluconazole; Humans; Hypothermia, Induced; Meningoencephalitis; Naegleria fowleri; Phosphorylcholine; Rifampin | 2016 |
A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Humans; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice; Mice, Inbred BALB C; Parasitic Sensitivity Tests; Phosphorylcholine | 2016 |
Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Repositioning; Granuloma; Liver; Mice; Nanocapsules; Nanotechnology; Phosphorylcholine; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2016 |
Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania infantum; Leishmaniasis, Visceral; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Selection, Genetic; Virulence | 2016 |
Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Female; Genomics; Leishmania donovani; Phosphorylcholine; Protozoan Proteins; Psychodidae | 2016 |
Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.
Topics: Antiprotozoal Agents; Biological Transport; Carrier Proteins; Drug Resistance; Gene Expression Regulation; Genetic Complementation Test; Genome, Protozoan; Genotype; High-Throughput Nucleotide Sequencing; Leishmania infantum; Life Cycle Stages; Mutation; Parasitic Sensitivity Tests; Phenotype; Phosphorylcholine; Protozoan Proteins; Selection, Genetic | 2016 |
A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.
Topics: Amphotericin B; Animals; Antifungal Agents; Antiprotozoal Agents; Cricetinae; Deoxycholic Acid; Drug Combinations; Female; Gene Expression Regulation, Enzymologic; Leishmania braziliensis; Leishmaniasis, Cutaneous; Luciferases; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Organisms, Genetically Modified; Phosphorylcholine; Time Factors | 2016 |
Primary Amebic Meningoencephalitis as Cause of Headache and Fever.
Topics: Antiprotozoal Agents; Brain Edema; Centers for Disease Control and Prevention, U.S.; Central Nervous System Protozoal Infections; Disease Notification; Diving; Fever; Fresh Water; Headache; Humans; Naegleria fowleri; Nasal Lavage; Phosphorylcholine; Swimming; United States | 2016 |
Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: a
Topics: Adolescent; Antiprotozoal Agents; Arsenic; Bangladesh; Case-Control Studies; Child; Child, Preschool; Cross-Sectional Studies; Drinking Water; Environmental Exposure; Environmental Pollutants; Female; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Risk Factors; Vitamin E | 2016 |
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Topics: Administration, Topical; Animals; Cells, Cultured; Disease Models, Animal; Drug Compounding; Female; Leishmaniasis, Cutaneous; Mice; Parasitic Sensitivity Tests; Phosphorylcholine; Skin Absorption; Solubility; Solvents | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
A Telomeric Cluster of Antimony Resistance Genes on Chromosome 34 of Leishmania infantum.
Topics: Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Cadmium; Cloning, Molecular; Copper; Drosophila Proteins; Drug Resistance; Exosomes; Gene Expression; Heat-Shock Proteins; High-Throughput Nucleotide Sequencing; Leishmania infantum; Life Cycle Stages; Multigene Family; Phosphorylcholine; Protozoan Proteins; Telomere | 2016 |
Laryngeal leishmaniasis in a patient taking inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Antiemetics; Antiprotozoal Agents; Asthma; Bronchoscopy; Dysphonia; Hoarseness; Humans; Laryngeal Diseases; Leishmaniasis; Male; Phosphorylcholine; Prochlorperazine; Spain; Travel; Treatment Outcome; Vocal Cords | 2016 |
Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Topics: Antiprotozoal Agents; Coinfection; HIV Infections; Humans; Immunocompromised Host; Leishmania infantum; Leishmaniasis, Visceral; Pentamidine; Phosphorylcholine | 2016 |
Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Delivery Systems; Drug Liberation; Female; Liposomes; Mice; Mice, Inbred BALB C; Peptide Fragments; Phosphorylcholine; Polyethylene Glycols; tat Gene Products, Human Immunodeficiency Virus; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Immunoprotective effect of lentinan in combination with miltefosine on Leishmania-infected J-774A.1 macrophages.
Topics: Adjuvants, Immunologic; Animals; Antiprotozoal Agents; Cell Line; Cytokines; Immunologic Factors; Leishmania donovani; Lentinan; Macrophages; Mice; Nitric Oxide; Phosphorylcholine | 2016 |
The alkylphospholipid edelfosine shows activity against Strongyloides venezuelensis and induces apoptosis-like cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Female; Larva; Mice; Phospholipid Ethers; Phosphorylcholine; Strongyloides; Strongyloidiasis | 2016 |
Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
Topics: Animals; Cricetinae; Disease Models, Animal; Female; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Liver; Mesocricetus; Phosphorylcholine; Spleen | 2016 |
In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania; Leishmaniasis, Cutaneous; Mice; Phosphorylcholine | 2016 |
Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance.
Topics: Alleles; Animals; Antiprotozoal Agents; High-Throughput Nucleotide Sequencing; Humans; Leishmania infantum; Leishmaniasis; Membrane Transport Proteins; Phosphorylcholine; Point Mutation; Sequence Analysis, DNA | 2016 |
Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry.
Topics: Animals; Antiprotozoal Agents; Biological Availability; Chromatography, High Pressure Liquid; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2016 |
The antileishmanial drug miltefosine (Impavido(®)) causes oxidation of DNA bases, apoptosis, and necrosis in mammalian cells.
Topics: Adult; Animals; Antiprotozoal Agents; Apoptosis; Cell Survival; Cells, Cultured; Comet Assay; DNA Damage; Female; Humans; Leukocytes; Male; Mice; Micronucleus Tests; Oxidation-Reduction; Phosphorylcholine; Young Adult | 2016 |
Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages.
Topics: Animals; Antiprotozoal Agents; Cell Death; Cells, Cultured; Drug Carriers; Drug Stability; Erythrocytes; Gastrointestinal Diseases; Hemolysis; Humans; Lipids; Macrophages; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Phosphorylcholine; RAW 264.7 Cells | 2016 |
Synthesis of new quinazolin-2,4-diones as anti-Leishmania mexicana agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Inhibitory Concentration 50; Leishmania mexicana; Macrophages; Mice; Molecular Structure; Parasitic Sensitivity Tests; Phosphorylcholine; Quinazolinones | 2016 |
The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
Topics: Animals; Antifungal Agents; Antiprotozoal Agents; Benzylamines; Drug Repositioning; Female; Leishmania braziliensis; Leishmaniasis, Diffuse Cutaneous; Leishmaniasis, Mucocutaneous; Macrophages; Mice; Mice, Inbred BALB C; Naphthalenes; Parasitic Sensitivity Tests; Phosphorylcholine | 2016 |
Adamantylidene-substituted alkylphosphocholine TCAN26 is more active against Sporothrix schenckii than miltefosine.
Topics: Adamantane; Antifungal Agents; Cell Membrane; Drug Substitution; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Phosphorylcholine; Sporothrix | 2016 |
Biocompatible silver nanoparticles reduced from Anethum graveolens leaf extract augments the antileishmanial efficacy of miltefosine.
Topics: Anethum graveolens; Animals; Antiprotozoal Agents; Biocompatible Materials; Cell Line, Tumor; DNA Breaks; Humans; Inhibitory Concentration 50; Leishmania; Macrophages; Metal Nanoparticles; Mice; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Phosphorylcholine; Plant Extracts; Plant Leaves; Silver; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2016 |
Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiprotozoal Agents; Aspartate Aminotransferases; Child; Cohort Studies; Coinfection; Diarrhea; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Pancreatitis; Patient Compliance; Pharmacovigilance; Phosphorylcholine; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2016 |
Miltefosine inhibits Candida albicans and non-albicans Candida spp. biofilms and impairs the dispersion of infectious cells.
Topics: Antifungal Agents; Biofilms; Candida; Candidiasis; Female; Humans; Inhibitory Concentration 50; Male; Microbial Viability; Phosphorylcholine | 2016 |
Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; DNA, Protozoan; Female; Humans; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Polymerase Chain Reaction | 2016 |
Nodular granulomatous glossitis as the sole clinical sign in canine leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Fluorescent Antibody Technique, Indirect; Glossitis; Immunohistochemistry; Leishmania infantum; Leishmaniasis, Visceral; Male; Phosphorylcholine; Tongue | 2016 |
Torn from the Headlines: Surviving the "Brain Eating Amoeba".
Topics: Adolescent; Antiprotozoal Agents; Centers for Disease Control and Prevention, U.S.; Central Nervous System Protozoal Infections; Communications Media; Drug Industry; Health Services Accessibility; Humans; Molecular Structure; Naegleria fowleri; Phosphorylcholine; United States | 2016 |
Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
Topics: Adult; Aged; Amphotericin B; Antiprotozoal Agents; Humans; Immunocompromised Host; Incidence; Kidney Transplantation; Leishmania infantum; Leishmaniasis, Visceral; Lung Transplantation; Male; Middle Aged; Phosphorylcholine; Retrospective Studies; Salvage Therapy; Secondary Prevention; Spain; Treatment Outcome | 2017 |
The cytotoxic activity of miltefosine against Leishmania and macrophages is associated with dynamic changes in plasma membrane proteins.
Topics: Animals; Antiprotozoal Agents; Cell Membrane; Cell Survival; Electron Spin Resonance Spectroscopy; Inhibitory Concentration 50; Leishmania mexicana; Life Cycle Stages; Macrophages, Peritoneal; Membrane Proteins; Mice; Mice, Inbred BALB C; Phosphorylcholine; Primary Cell Culture; Protozoan Proteins; Spin Labels | 2017 |
A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.
Topics: Antiprotozoal Agents; DNA Mutational Analysis; Drug Resistance; Electrophoresis, Gel, Two-Dimensional; HSP70 Heat-Shock Proteins; Leishmania donovani; Mitochondrial Proteins; Phosphorylcholine; Proteome; Protozoan Proteins | 2016 |
Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania infantum; Leishmaniasis; Mutation; Phosphorylcholine; Proton-Translocating ATPases; Protozoan Proteins | 2016 |
Leishmania recombinant antigen modulates macrophage effector function facilitating early clearance of intracellular parasites.
Topics: Animals; Antigens, Protozoan; Cricetinae; Disease Models, Animal; Leishmania; Leishmaniasis; Macrophage Activation; Macrophages; Mesocricetus; Nitric Oxide; Phagocytosis; Phosphorylcholine; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2016 |
Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Curcumin; Disease Models, Animal; Drug Carriers; Drug Combinations; Drug Resistance; Drug Synergism; Humans; Leishmania donovani; Leishmaniasis, Visceral; Lymphocytes; Male; Medicine, Ayurvedic; Nanoparticles; Phagocytosis; Phosphorylcholine; Reactive Nitrogen Species; Reactive Oxygen Species | 2017 |
Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.
Topics: Antiprotozoal Agents; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Phosphorylcholine; Specimen Handling; Tandem Mass Spectrometry | 2017 |
In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruzi.
Topics: Animals; Animals, Wild; Australia; Cell Line; Drug Discovery; High-Throughput Screening Assays; Inhibitory Concentration 50; Melarsoprol; Nitroimidazoles; Phosphorylcholine; Potoroidae; Pyrimidines; Triazoles; Trypanocidal Agents; Trypanosoma; Trypanosoma cruzi | 2017 |
Antileishmanial Activity of Pyrazolopyridine Derivatives and Their Potential as an Adjunct Therapy with Miltefosine.
Topics: Animals; Antiprotozoal Agents; Leishmania; Mice; Mice, Inbred BALB C; Phosphorylcholine; Pyrazoles; Pyridines | 2017 |
A P4-ATPase subunit of the Cdc50 family plays a role in iron acquisition and virulence in Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Bacteriocins; Brefeldin A; Cell Division; Cell Membrane; Cryptococcosis; Cryptococcus neoformans; Curcumin; Endoplasmic Reticulum; Female; Fluconazole; Fungal Polysaccharides; Fungal Proteins; Iron; Macrophages; Mice; Mice, Inbred BALB C; P-type ATPases; Peptides, Cyclic; Phospholipid Transfer Proteins; Phosphorylcholine; Virulence; Virulence Factors | 2017 |
Susceptibility to Miltefosine in Brazilian Clinical Isolates of
Topics: Adolescent; Adult; Aged; Brazil; Child, Preschool; Drug Resistance; Humans; Inhibitory Concentration 50; Leishmania braziliensis; Middle Aged; Phosphorylcholine; Young Adult | 2017 |
Study of antileishmanial activity of 2-aminobenzoyl amino acid hydrazides and their quinazoline derivatives.
Topics: Amino Acids; Amphotericin B; Antiprotozoal Agents; Deoxycholic Acid; Drug Combinations; Inhibitory Concentration 50; Isomerism; Leishmania; Magnetic Resonance Spectroscopy; Molecular Conformation; Phosphorylcholine; Quinazolines; Structure-Activity Relationship | 2017 |
Perifosine Mechanisms of Action in Leishmania Species.
Topics: Adenosine Triphosphate; Antiprotozoal Agents; Apoptosis; Gene Expression; Inhibitory Concentration 50; Leishmania donovani; Leishmania mexicana; Membrane Potential, Mitochondrial; Mitochondria; Phosphatidylserines; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Protozoan Proteins | 2017 |
Elimination of Kala-Azar from the Southeast Asia Region.
Topics: Animals; Antiprotozoal Agents; Bangladesh; Humans; India; Insect Control; Insect Vectors; Insecticides; Internationality; Leishmaniasis, Visceral; Nepal; Phosphorylcholine; Preventive Health Services | 2017 |
Antileishmanial activity of meroditerpenoids from the macroalgae Cystoseira baccata.
Topics: Animals; Antiprotozoal Agents; Biomass; Diterpenes; DNA Fragmentation; DNA, Protozoan; Inhibitory Concentration 50; Leishmania infantum; Macrophages, Peritoneal; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Mitochondria; Nitric Oxide; Phaeophyceae; Phosphorylcholine; Portugal; Spectrophotometry | 2017 |
Methionine aminopeptidase 2 is a key regulator of apoptotic like cell death in Leishmania donovani.
Topics: Aminopeptidases; Antiprotozoal Agents; Cell Death; Cloning, Molecular; Cyclohexanes; DNA Fragmentation; Gene Expression Regulation; Leishmania donovani; Metalloendopeptidases; O-(Chloroacetylcarbamoyl)fumagillol; Phosphorylcholine; Protozoan Proteins; Sesquiterpenes | 2017 |
Miltefosine is fungicidal to Paracoccidioides spp. yeast cells but subinhibitory concentrations induce melanisation.
Topics: Animals; Antifungal Agents; Cell Membrane; Dogs; Drug Synergism; Humans; Melanins; Microbial Sensitivity Tests; Microbial Viability; Organelles; Paracoccidioides; Phosphorylcholine | 2017 |
Biochemical and inhibition studies of glutamine synthetase from Leishmania donovani.
Topics: Antibodies, Protozoan; Base Sequence; DNA, Protozoan; Enzyme Activation; Enzyme Inhibitors; Escherichia coli; Gene Expression Regulation; Genes, Protozoan; Genome, Protozoan; Glutamate-Ammonia Ligase; Hydrogen-Ion Concentration; Kinetics; Leishmania donovani; Leishmaniasis; Metals; Molecular Weight; Phosphorylcholine; Protozoan Proteins; Recombinant Proteins; Sequence Analysis; Sequence Homology, Amino Acid; Temperature | 2017 |
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Risk Factors; Treatment Failure; Young Adult | 2017 |
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Caregivers; Child; Child, Preschool; Cost-Benefit Analysis; Directly Observed Therapy; Drug Costs; Female; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Monte Carlo Method; Organometallic Compounds; Phosphorylcholine; Sensitivity and Specificity; Treatment Outcome; United States | 2017 |
Effect of 1,2,3-triazole salts, non-classical bioisosteres of miltefosine, on Leishmania amazonensis.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Erythrocytes; Humans; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages; Mice; Phosphorylcholine; Reactive Oxygen Species; Triazoles | 2017 |
Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Leishmania infantum; Leishmaniasis, Visceral; Mice; Paromomycin; Phosphorylcholine | 2017 |
Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine.
Topics: Amphotericin B; Antiprotozoal Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Phosphorylcholine | 2017 |
Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Fluorometry; Humans; Leishmania donovani; Leishmaniasis, Visceral; Linear Models; Macrophages; Mice; Mice, Inbred BALB C; Oxidative Stress; Parasitic Sensitivity Tests; Phosphorylcholine; Recurrence | 2017 |
Risk Factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India.
Topics: Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Female; Health Facilities; Humans; India; Leishmaniasis, Visceral; Male; National Health Programs; Patient Satisfaction; Phosphorylcholine; Primary Health Care; Private Sector; Public Sector; Specialization; Young Adult | 2017 |
Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Chloroquine; Disease Models, Animal; Drug Combinations; Female; Leishmania major; Leishmania mexicana; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Parasite Load; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine | 2017 |
Crossregulation between the insertion of Hexadecylphosphocholine (miltefosine) into lipid membranes and their rheology and lateral structure.
Topics: Cell Membrane; Cholesterol; Ergosterol; Lipid Bilayers; Membrane Lipids; Membranes, Artificial; Phospholipids; Phosphorylcholine; Rheology; Sterols | 2017 |
Attenuating Staphylococcus aureus Virulence by Targeting Flotillin Protein Scaffold Activity.
Topics: Animals; Bacterial Proteins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Endoribonucleases; Female; Membrane Microdomains; Membrane Proteins; Mice; Mice, Inbred BALB C; Phosphorylcholine; Protein Multimerization; RNA, Bacterial; RNA, Ribosomal, 5S; Small Molecule Libraries; Staphylococcal Infections; Staphylococcus aureus; Survival Rate; Two-Hybrid System Techniques; Virulence | 2017 |
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Topics: Amphotericin B; Antiprotozoal Agents; Biopsy; Female; Humans; Immunocompromised Host; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Middle Aged; Paromomycin; Phosphorylcholine; Polymerase Chain Reaction; Recurrence | 2017 |
Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line; Chitosan; Drug Carriers; Drug Stability; Leishmania donovani; Macrophages; Nanoparticles; Phosphorylcholine; Rats; Rats, Wistar; Tissue Distribution | 2017 |
Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans.
Topics: Animals; Antifungal Agents; Biofilms; Candida albicans; Catheters; Cell Membrane; Fungal Proteins; Gene Deletion; Membrane Proteins; Phosphatidylcholines; Phosphorylcholine; Rats | 2017 |
Epidemiology of Cutaneous Leishmaniasis in a Colombian Municipality.
Topics: Adolescent; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Colombia; Female; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Prevalence; Retrospective Studies; Socioeconomic Factors; Urban Population; Young Adult | 2017 |
Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens.
Topics: Animals; Anthelmintics; Antigens, Helminth; Antigens, Surface; Blotting, Western; Fluorescent Antibody Technique, Indirect; Mass Spectrometry; Phosphorylcholine; Rabbits; Schistosoma mansoni | 2017 |
Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.
Topics: Antiprotozoal Agents; Biomarkers; Cytokines; Drug Resistance; Gene Expression Regulation; Genes, Helminth; Humans; Leishmania donovani; Leishmaniasis, Visceral; Membrane Potential, Mitochondrial; Nitric Oxide; Parasite Load; Parasitic Sensitivity Tests; Phenotype; Phosphorylcholine; Polymorphism, Restriction Fragment Length; Reactive Oxygen Species; RNA, Messenger; T-Lymphocyte Subsets | 2017 |
Development and characterization of miltefosine-loaded polymeric micelles for cancer treatment.
Topics: Cell Line, Tumor; Humans; Micelles; Phosphorylcholine; Poloxamer; Polymers | 2017 |
Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Asymptomatic Infections; Biopsy; DNA, Intergenic; DNA, Protozoan; Female; Humans; India; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Parasite Load; Phosphorylcholine; Polymerase Chain Reaction; Skin; Young Adult | 2018 |
Synthesis, modeling and biological evaluation of hybrids from pyrazolo[1,5c]pyrimidine as antileishmanial agents.
Topics: Amphotericin B; Antiprotozoal Agents; Binding Sites; Deoxycholic Acid; Drug Combinations; Drug Design; Humans; Leishmania major; Molecular Docking Simulation; Molecular Structure; Phosphorylcholine; Protein Binding; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2017 |
Case Report: Old World Mucosal Leishmaniasis: Report of Five Imported Cases to the Hospital for Tropical Diseases, London, United Kingdom.
Topics: Aged; Antiprotozoal Agents; Female; Humans; Immunosuppressive Agents; Leishmania infantum; Leishmaniasis, Visceral; London; Male; Mediterranean Region; Middle Aged; Phosphorylcholine; Travel | 2017 |
Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca
Topics: Animals; Antiprotozoal Agents; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Membrane; Homeostasis; Leishmania donovani; Membrane Potential, Mitochondrial; Nifedipine; Organelles; Phosphorylcholine; Sphingosine | 2018 |
Functional Involvement of Leishmania donovani Tryparedoxin Peroxidases during Infection and Drug Treatment.
Topics: Animals; Antimony Potassium Tartrate; Cytosol; Drug Resistance; Female; Host-Parasite Interactions; Leishmania donovani; Leishmaniasis, Visceral; Macrophages, Peritoneal; Male; Mice, Inbred BALB C; Mitochondrial Proteins; Oxidative Stress; Peroxidases; Phosphorylcholine; Protozoan Proteins; Reactive Oxygen Species; Trypanocidal Agents | 2018 |
Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.
Topics: Antiprotozoal Agents; Apoptosis; Benzoates; Cell Line, Tumor; Humans; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; U937 Cells | 2018 |
Miltefosine-based regimen as salvage therapy in Lomentospora prolificans bone and joint infection.
Topics: Aged; Antifungal Agents; Arthritis, Infectious; Humans; Male; Mycoses; Osteomyelitis; Phosphorylcholine; Salvage Therapy; Scedosporium | 2018 |
Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania infantum; Leishmaniasis, Visceral; Membrane Transport Proteins; Mutant Proteins; Parasitic Sensitivity Tests; Phosphorylcholine; Protozoan Proteins | 2018 |
In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Topics: Amino Acid Sequence; Amphotericin B; Animals; Antiprotozoal Agents; Arginase; Benzimidazoles; Cell Line; Inhibitory Concentration 50; Leishmania braziliensis; Leishmania donovani; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Leishmaniasis, Visceral; Macrophages; Mice; Molecular Docking Simulation; Phosphorylcholine; Sequence Alignment | 2018 |
Perichondritis of the ear in an Afghan immigrant.
Topics: Adult; Afghanistan; Animals; Biopsy; Cartilage Diseases; Diagnosis, Differential; Ear Diseases; Ear, External; Emigrants and Immigrants; Germany; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Skin; Zoonoses | 2018 |
Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis.
Topics: Antiprotozoal Agents; Biomarkers; Biopsy, Needle; Calpain; Humans; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; Real-Time Polymerase Chain Reaction; Recurrence; Spleen | 2018 |
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bridged Bicyclo Compounds, Heterocyclic; Clarithromycin; Diterpenes; Humans; Josamycin; Linezolid; Macrolides; Oomycetes; Oxazolidinones; Phosphorylcholine; Pleuromutilins; Polycyclic Compounds; Pythiosis; Pythium | 2018 |
Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl.
Topics: Amphotericin B; Antiprotozoal Agents; Child; Female; Humans; Iran; Leishmaniasis, Cutaneous; Phosphorylcholine; Skin; Treatment Outcome | 2018 |
Complex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine.
Topics: Antiprotozoal Agents; Ergosterol; Humans; Leishmania donovani; Leishmania major; Leishmaniasis, Visceral; Membrane Lipids; Metabolome; Phospholipids; Phosphorylcholine; Serine C-Palmitoyltransferase; Sphingolipids; Sterols | 2018 |
Ultraestructural study of effects of alkylphospholipid analogs against nematodes.
Topics: Animals; Antinematodal Agents; Caenorhabditis elegans; Feces; Larva; Male; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Phospholipids; Phosphorylcholine; Rats; Rats, Wistar; Strongyloides | 2018 |
Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.
Topics: Amphotericin B; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Cells, Cultured; Female; Leishmania donovani; Macrophages; Mice, Inbred BALB C; Models, Theoretical; Phosphorylcholine | 2018 |
Effects of nanoemulsions prepared with essential oils of copaiba- and andiroba against Leishmania infantum and Leishmania amazonensis infections.
Topics: Animals; Antiprotozoal Agents; Emulsions; Fabaceae; Female; Gas Chromatography-Mass Spectrometry; Inhibitory Concentration 50; Intestines; Kidney; Leishmania infantum; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Nanoparticles; Oils, Volatile; Phosphorylcholine; Stomach | 2018 |
First report of Leishmania infantum infection in the endangered orangutan (Pongo pygmaeus pygmaeus) in Madrid, Spain.
Topics: Allopurinol; Animals; Diagnosis, Differential; Disease Outbreaks; Endangered Species; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Phosphorylcholine; Pongo pygmaeus; Psychodidae; Spain | 2018 |
High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms.
Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Cosmids; CRISPR-Cas Systems; Drug Resistance; Gene Library; High-Throughput Nucleotide Sequencing; Leishmania infantum; Leishmaniasis; Life Cycle Stages; Macrophages; Phosphorylcholine | 2018 |
In vitro 4-Aryloxy-7-chloroquinoline derivatives are effective in mono- and combined therapy against Leishmania donovani and induce mitocondrial membrane potential disruption.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line; Drug Therapy, Combination; Leishmania donovani; Macrophages; Membrane Potential, Mitochondrial; Mice; Phosphorylcholine; Quinolines | 2018 |
Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.
Topics: Antimony; Antiprotozoal Agents; Drug Resistance, Multiple; Genomics; Leishmania donovani; Leishmania infantum; Leishmania major; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Paromomycin; Phenotype; Phosphorylcholine; Transcriptome | 2018 |
Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes.
Topics: Animals; Antiprotozoal Agents; Ketoconazole; Leishmania major; Leishmaniasis, Cutaneous; Nanostructures; Phosphorylcholine | 2018 |
Lactoferrin-modified Betulinic Acid-loaded PLGA nanoparticles are strong anti-leishmanials.
Topics: Amphotericin B; Animals; Anti-Inflammatory Agents; Antiparasitic Agents; Betulinic Acid; Cytokines; Lactoferrin; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice; Mice, Inbred BALB C; Nanoparticles; Pentacyclic Triterpenes; Phosphorylcholine; Polylactic Acid-Polyglycolic Acid Copolymer; Triterpenes | 2018 |
The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts.
Topics: Amphotericin B; Antifungal Agents; Apoptosis; Biofilms; Cell Membrane; Cell Membrane Permeability; Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans; DNA Fragmentation; Ergosterol; Fungal Capsules; Humans; Membrane Potential, Mitochondrial; Microbial Sensitivity Tests; Opportunistic Infections; Phosphorylcholine; Plankton; Reactive Oxygen Species | 2018 |
Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Female; Leishmania infantum; Leishmaniasis, Visceral; Male; Mice; Phosphorylcholine | 2018 |
Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Survival; Disease Models, Animal; Drug Synergism; Humans; Leishmania infantum; Leishmaniasis, Visceral; Liver; Male; Mice, Inbred BALB C; Nelfinavir; Parasite Load; Phosphorylcholine; Spleen; Treatment Outcome | 2018 |
Effect of Anti-Leishmania Drugs on the Structural and Elastic Properties of Ultradeformable Lipid Membranes.
Topics: Amphotericin B; Antiprotozoal Agents; Imiquimod; Indoles; Liposomes; Phosphatidylcholines; Phosphorylcholine; Sodium Cholate; X-Ray Diffraction | 2018 |
Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections.
Topics: Animals; Antiprotozoal Agents; Gene Knockdown Techniques; Green Fluorescent Proteins; Intracellular Membranes; Leishmania; Leishmaniasis; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Phosphatidylinositols; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RAW 264.7 Cells; Reactive Oxygen Species; Transfection; Vacuoles | 2018 |
Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chalcones; Female; Leishmania; Leishmania infantum; Leishmaniasis; Mice; Mice, Inbred BALB C; Phosphorylcholine | 2018 |
Importance of secondary screening with clinical isolates for anti-leishmania drug discovery.
Topics: Antiprotozoal Agents; Drug Discovery; Drug Resistance; Humans; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Phosphorylcholine; THP-1 Cells | 2018 |
Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Apigenin; Biomarkers; Drug Combinations; Female; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages; Mice; Mice, Inbred BALB C; Molecular Structure; Parasite Load; Phosphorylcholine | 2018 |
Novel organic salts based on quinoline derivatives: The in vitro activity trigger apoptosis inhibiting autophagy in Leishmania spp.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Autophagy; Female; Leishmania; Leishmaniasis; Macrophages; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Oxidative Stress; Phosphatidylserines; Phosphorylcholine; Quinolines; Reactive Oxygen Species; Salts | 2018 |
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Bangladesh; Female; Humans; Leishmania donovani; Leishmania tropica; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Myocardial Infarction; Paromomycin; Patient Safety; Pharmacovigilance; Phosphorylcholine; Quality of Life; Recurrence; Survival Analysis | 2018 |
Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility.
Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Cells, Cultured; Drug Resistance; Female; Interleukin-6; Leishmania infantum; Leishmaniasis; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nitric Oxide; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Reactive Oxygen Species; Tumor Necrosis Factor-alpha | 2018 |
Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment.
Topics: Adolescent; Adult; Antiprotozoal Agents; Bangladesh; Humans; Keratitis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine | 2018 |
A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.
Topics: Antiprotozoal Agents; Brazil; Computational Biology; DNA Copy Number Variations; Genetic Markers; Genome, Protozoan; Genomics; Geography; Humans; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine; Quantitative Trait Loci; Treatment Failure; Treatment Outcome | 2018 |
Case Report: Squamous Cell Carcinoma Referred for Mohs Surgery Found to be Cutaneous Leishmaniasis.
Topics: Antibodies, Protozoan; Antiprotozoal Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Female; Humans; Leishmania guyanensis; Leishmaniasis, Cutaneous; Middle Aged; Mohs Surgery; Phosphorylcholine; Skin Neoplasms; Treatment Outcome | 2018 |
New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
Topics: Antiprotozoal Agents; Brazil; Drug Resistance; Genes, Protozoan; Humans; Leishmania infantum; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Phosphorylcholine; Treatment Outcome | 2018 |
In vitro effects of the antitumor drug miltefosine on human erythrocytes and molecular models of its membrane.
Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Dimyristoylphosphatidylcholine; Erythrocyte Membrane; Erythrocytes; Hemolysis; Humans; Lipid Bilayers; Microscopy, Electron, Scanning; Models, Molecular; Phosphatidylethanolamines; Phospholipids; Phosphorylcholine; Spectrometry, Fluorescence; Thermodynamics; X-Ray Diffraction | 2019 |
Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice.
Topics: Animals; Antiprotozoal Agents; Azithromycin; Immunocompromised Host; Mice; Phosphorylcholine; Pythiosis; Pythium | 2019 |
Miltefosine Reduces the Cytolytic Activity and Virulence of
Topics: A549 Cells; Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Cell Line; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Moths; Phosphorylcholine; Type C Phospholipases; Virulence | 2019 |
Miltefosine enhances the fitness of a non-virulent drug-resistant Leishmania infantum strain.
Topics: Animals; Female; Genetic Fitness; Immunosuppression Therapy; Leishmania infantum; Leishmaniasis, Visceral; Luciferases; Luminescent Measurements; Macrophages; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mutation; Parasitic Sensitivity Tests; Phosphorylcholine; Virulence | 2019 |
Potassium iodide and miltefosine inhibit biofilms of Sporothrix schenckii species complex in yeast and filamentous forms.
Topics: Antifungal Agents; Biofilms; Fungi; Kinetics; Microbial Sensitivity Tests; Microbial Viability; Microscopy, Electron, Scanning; Phosphorylcholine; Potassium Iodide; Sporothrix; Sporotrichosis | 2019 |
Case Reports: Late Emergence of Cutaneous Leishmaniasis in an Immunocompromised Patient in a Non-Endemic Setting.
Topics: Adult; Afghanistan; Antiprotozoal Agents; Australia; Biopsy; DNA, Ribosomal Spacer; Humans; Immunocompromised Host; Immunosuppression Therapy; Leishmania major; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Skin; Treatment Outcome | 2019 |
[Refractory cutaneous leishmaniasis: Benefit of miltefosine].
Topics: Aged; Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholine | 2019 |
Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.
Topics: Animals; Antiprotozoal Agents; CD4-Positive T-Lymphocytes; Cricetinae; Cyclophosphamide; Drug Resistance; Female; Immunocompromised Host; Immunosuppressive Agents; Leishmania donovani; Leishmaniasis, Visceral; Mesocricetus; Mice; Parasitic Sensitivity Tests; Phosphorylcholine; Recurrence | 2019 |
Efficacy of Topical Miltefosine in Patients with Acanthamoeba Keratitis: A Pilot Study.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Animals; Antiprotozoal Agents; Cornea; Eye Infections, Parasitic; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Phosphorylcholine; Pilot Projects | 2019 |
Ascorbic acid reduces the genetic damage caused by miltefosine (hexadecylphosphocholine) in animals infected by Leishmania (Leishamnia) infantum without decreasing its antileishmanial activity.
Topics: Animals; Antiprotozoal Agents; Ascorbic Acid; DNA Damage; Injections, Intraperitoneal; Leishmania infantum; Leishmaniasis; Male; Mice; Mice, Inbred BALB C; Parasite Load; Phosphorylcholine; Reactive Oxygen Species; Superoxide Dismutase | 2019 |
In silico studies and evaluation of antiparasitic role of a novel pyruvate phosphate dikinase inhibitor in Leishmania donovani infected macrophages.
Topics: Animals; Antiparasitic Agents; Cells, Cultured; Drug Design; Humans; Leishmania donovani; Macrophages; Mice; Molecular Dynamics Simulation; Phosphorylcholine; Pyruvate, Orthophosphate Dikinase | 2019 |
Resistance of
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Drug Resistance; Extracellular Traps; Humans; Leishmania guyanensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mice; Mice, Inbred C57BL; Neutrophils; Parasitic Sensitivity Tests; Phosphorylcholine; Primary Cell Culture; Reactive Oxygen Species | 2018 |
Eliminating visceral leishmaniasis in South Asia: the road ahead.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Bangladesh; Disease Vectors; Drug Therapy, Combination; Epidemiological Monitoring; Humans; India; International Cooperation; Leishmaniasis, Visceral; Neglected Diseases; Nepal; Paromomycin; Phosphorylcholine; Program Development; Program Evaluation | 2019 |
Anti-leishmanial effect of spiro dihydroquinoline-oxindoles on volume regulation decrease and sterol biosynthesis of Leishmania braziliensis.
Topics: Animals; Antiprotozoal Agents; Inhibitory Concentration 50; Leishmania braziliensis; Leishmaniasis, Cutaneous; Macrophages; Mice; Mice, Inbred BALB C; Oxindoles; Phosphorylcholine; Quinolines; Spiro Compounds | 2019 |
Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Insect Vectors; Leishmania infantum; Leishmaniasis, Visceral; Male; Parasite Load; Phosphorylcholine; Psychodidae; Real-Time Polymerase Chain Reaction; Skin; Treatment Outcome; Xenodiagnosis | 2019 |
A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Discovery; Female; Leishmania infantum; Leishmaniasis, Visceral; Luminescent Measurements; Luminescent Proteins; Mice; Mice, Inbred BALB C; Phosphorylcholine; Spleen | 2019 |
Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Ethiopia; HIV Infections; Humans; Leishmania donovani; Leishmaniasis, Cutaneous; Male; Phosphorylcholine | 2019 |
Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Biopsy; Disease Models, Animal; Drug Stability; Female; Gels; Leishmania; Leishmaniasis, Cutaneous; Mice; Parasitic Sensitivity Tests; Phosphorylcholine | 2019 |
Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Meglumine Antimoniate; Phosphorylcholine | 2019 |
Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake.
Topics: Biological Transport; Drug Resistance; Gene Expression Profiling; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Parasitic Sensitivity Tests; Phosphorylcholine; Protozoan Proteins; Sequence Analysis, RNA | 2019 |
Visceral leishmaniasis in a patient with systemic lupus erythematosus from Colombia, Latin America.
Topics: Adult; Antiprotozoal Agents; Colombia; Humans; Leishmaniasis, Visceral; Lupus Erythematosus, Systemic; Male; Pentamidine; Phosphorylcholine | 2019 |
Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis.
Topics: Analysis of Variance; Animals; Antiprotozoal Agents; Caspases; Cell Cycle; Cell Line; Cell Membrane; Cell Membrane Permeability; Female; Flow Cytometry; Inhibitory Concentration 50; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Pentamidine; Phospholipids; Phosphorylcholine; Semicarbazones | 2019 |
(De)glutamylation and cell death in Leishmania parasites.
Topics: Actins; Apoptosis; Cell Survival; Curcumin; Cytoskeleton; Fluorescent Antibody Technique; Leishmania; Microtubules; Peptide Synthases; Phosphorylcholine; Protein Processing, Post-Translational | 2019 |
Interactions of miltefosine with erythrocyte membrane proteins compared to those of ionic surfactants.
Topics: Animals; Antiprotozoal Agents; Bis-Trimethylammonium Compounds; Cattle; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Hemolysis; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Membrane Proteins; Micelles; Phosphorylcholine; Quaternary Ammonium Compounds; Serum Albumin, Bovine; Sodium Dodecyl Sulfate; Spin Labels; Static Electricity | 2019 |
Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh.
Topics: Adolescent; Antiprotozoal Agents; Bangladesh; Fertility; Humans; Infertility, Male; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosphorylcholine; Treatment Outcome | 2019 |
Iron superoxide dismutase contributes to miltefosine resistance in Leishmania donovani.
Topics: Antiprotozoal Agents; Drug Resistance; Leishmania donovani; Mutation; Phosphorylcholine; Protozoan Proteins; Superoxide Dismutase | 2019 |
Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Leishmania major; Leishmaniasis, Cutaneous; Liposomes; Mice; Mice, Inbred BALB C; Phosphorylcholine; Skin; Spleen | 2019 |
A potential acetyltransferase involved in Leishmania major metacaspase-dependent cell death.
Topics: Acetyltransferases; Apoptosis; Caspases; Curcumin; Leishmania major; Leishmaniasis; Phosphorylcholine; Protozoan Proteins | 2019 |
Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei.
Topics: Adenosine Triphosphatases; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Leishmania; Paromomycin; Phosphorylcholine; R-SNARE Proteins; Trypanosoma brucei brucei | 2019 |
Oral Miltefosine as Adjunctive Treatment for Recalcitrant Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Administration, Oral; Adult; Antiprotozoal Agents; Chemotherapy, Adjuvant; Contact Lenses, Hydrophilic; Female; Humans; Keratoplasty, Penetrating; Phosphorylcholine; Treatment Outcome | 2019 |
Dimethylsphingosine and miltefosine induce apoptosis in lung adenocarcinoma A549 cells in a synergistic manner.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Humans; Lysophospholipids; Phosphorylcholine; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Sphingosine | 2019 |
Flavonoid-alkylphospholipid conjugates elicit dual inhibition of cancer cell growth and lipid accumulation.
Topics: Anti-Obesity Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lipid Droplets; Liver X Receptors; Phospholipid Ethers; Phosphorylcholine; Poly(ADP-ribose) Polymerases; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Quercetin; Signal Transduction | 2019 |
Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1β release.
Topics: Animals; Autophagy; Cell Line; Cholesterol; HEK293 Cells; Humans; Inflammasomes; Interleukin-1beta; Macrophages; Mice; Mitochondria; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphorylation; Phosphorylcholine; RAW 264.7 Cells; Reactive Oxygen Species; Signal Transduction | 2019 |
Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis.
Topics: Alginates; Animals; Antifungal Agents; Candida albicans; Candidiasis; Cryptococcosis; Drug Delivery Systems; Drug Liberation; Larva; Microbial Sensitivity Tests; Nanoparticles; Phosphorylcholine; Sheep | 2019 |
Identifying miltefosine-resistant key genes in protein-protein interactions network and experimental verification in Iranian Leishmania major.
Topics: Computational Biology; Computer Simulation; Drug Resistance; Drug Resistance, Fungal; Gene Ontology; Iran; Leishmania major; Phosphorylcholine; Protein Interaction Maps | 2019 |
Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Female; Leishmania mexicana; Leishmaniasis, Cutaneous; Mice, Inbred BALB C; Nanoparticles; Phosphorylcholine | 2019 |
Miltefosine treatment reduces visceral hypersensitivity in a rat model for irritable bowel syndrome via multiple mechanisms.
Topics: Abdominal Pain; Animals; Antifungal Agents; Female; Fungi; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; Male; Maternal Deprivation; Mycobiome; Phosphorylcholine; Rats; TRPV Cation Channels | 2019 |
Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Synergism; Drug Therapy, Combination; Host-Parasite Interactions; Humans; Leishmania donovani; Leishmaniasis, Visceral; Life Cycle Stages; Mice; Mice, Inbred BALB C; Phosphorylcholine; Pyrazoles; Sulfonamides | 2019 |
In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against Trypanosoma cruzi: Antiproliferative and ultrastructural effects.
Topics: Adamantane; Animals; Antiprotozoal Agents; Autophagy; Cell Membrane; Chagas Disease; Dose-Response Relationship, Drug; Flow Cytometry; Golgi Apparatus; Inhibitory Concentration 50; Lethal Dose 50; Macrophages, Peritoneal; Mice; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Microscopy, Immunoelectron; Mitochondria; Phosphorylcholine; Trypanocidal Agents; Trypanosoma cruzi | 2019 |
Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis.
Topics: Analysis of Variance; Animals; Antiprotozoal Agents; Drug Resistance; Female; Inhibitory Concentration 50; Insect Vectors; Leishmania infantum; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Phlebotomus; Phosphorylcholine; Psychodidae; Rabbits | 2019 |
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Drug Evaluation, Preclinical; Drug Resistance; Flavonols; Genomics; Humans; Leishmania; Leishmaniasis; Phosphorylcholine; Thiophenes | 2019 |
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Topics: Adolescent; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; India; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Recurrence; Treatment Outcome | 2019 |
Antileishmanial activity and ultrastructural changes of related tetrahydrofuran dineolignans isolated from Saururus cernuus L. (Saururaceae).
Topics: Animals; Antiprotozoal Agents; Furans; Leishmania; Leishmaniasis; Lignans; Mice; Mice, Inbred BALB C; Microscopy, Electron; Phosphorylcholine; Plant Leaves; Saururaceae | 2019 |
Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India.
Topics: Adult; Antiprotozoal Agents; Child; Eye Diseases; Female; Humans; India; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Treatment Outcome; Young Adult | 2020 |
Novel functionalized 1,2,3-triazole derivatives exhibit antileishmanial activity, increase in total and mitochondrial-ROS and depolarization of mitochondrial membrane potential of Leishmania amazonensis.
Topics: Animals; Antiprotozoal Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mitochondria; Phosphorylcholine; Reactive Oxygen Species; Triazoles | 2020 |
Structure based designing of benzimidazole/benzoxazole derivatives as anti-leishmanial agents.
Topics: Antiprotozoal Agents; Benzimidazoles; Benzoxazoles; Drug Discovery; Inhibitory Concentration 50; Leishmania donovani; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Phosphorylcholine; Protozoan Proteins; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2019 |
Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Topics: Administration, Cutaneous; Amphotericin B; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Combinations; Drug Compounding; Elasticity; Female; Humans; Inhibitory Concentration 50; Leishmania; Leishmaniasis, Cutaneous; Liposomes; Mice; Nanoparticles; Parasite Load; Particle Size; Permeability; Phosphorylcholine; Skin | 2020 |
Cutaneous leishmaniasis with secondary mucosal disease in a traveller due to Leishmania (Viannia) braziliensis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Communicable Diseases, Imported; Ear; Humans; Leishmania braziliensis; Leishmaniasis, Mucocutaneous; Male; Middle Aged; Phosphorylcholine; Travel | 2020 |
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Phosphorylcholine | 2020 |
Coupling chemical mutagenesis to next generation sequencing for the identification of drug resistance mutations in Leishmania.
Topics: Drug Resistance; High-Throughput Nucleotide Sequencing; Leishmania; Mutagenesis; Mutation; Paromomycin; Phosphorylation; Phosphorylcholine | 2019 |
Resolution of
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Oral; Adult; Antiprotozoal Agents; Cornea; DNA, Protozoan; Eye Infections, Parasitic; Female; Humans; Male; Microscopy, Confocal; Phosphorylcholine; Slit Lamp Microscopy; Visual Acuity | 2021 |
Use of miltefosine in a patient with mucosal leishmaniasis and HIV-coinfection: a challenge in long-term management.
Topics: Coinfection; HIV Infections; Humans; Leishmaniasis, Mucocutaneous; Male; Middle Aged; Phosphorylcholine; Time Factors | 2019 |
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; DNA, Protozoan; Drug Therapy, Combination; Female; Humans; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Liposomes; Longitudinal Studies; Male; Middle Aged; Parasite Load; Phosphorylcholine; Real-Time Polymerase Chain Reaction; Recurrence; Treatment Outcome; Young Adult | 2020 |
Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits.
Topics: Animals; Antifungal Agents; Dermatomycoses; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Microbial Sensitivity Tests; Phosphorylcholine; Pythiosis; Pythium; Rabbits; Subcutaneous Tissue; Treatment Outcome | 2020 |
An effective reagent to functionalize alcohols with phosphocholine.
Topics: Alcohols; Antiprotozoal Agents; Indicators and Reagents; Models, Chemical; Oxidation-Reduction; Phosphorylcholine | 2020 |
Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against
Topics: Animals; Antiprotozoal Agents; Leishmania donovani; Leishmaniasis; Mice; Phosphorylcholine; Tetraoxanes | 2020 |
Structural characterization by scattering and spectroscopic methods and biological evaluation of polymeric micelles of poloxamines and TPGS as nanocarriers for miltefosine delivery.
Topics: Animals; Antiprotozoal Agents; Drug Carriers; Dynamic Light Scattering; Ethylenediamines; Leishmania major; Macrophages; Mice; Micelles; Molecular Structure; Nanoparticles; Phosphorylcholine; Spectrum Analysis; Vitamin E | 2020 |
Biological risk assessment of miltefosine in concomitant infection with opportunistic toxoplasmosis.
Topics: Animal Structures; Animals; Disease Models, Animal; Female; Immunologic Factors; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Parasite Load; Phosphorylcholine; Toxoplasma; Toxoplasmosis, Animal | 2019 |
Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
Topics: Acclimatization; Animals; Antiprotozoal Agents; Drug Resistance; Humans; Insect Vectors; Leishmania donovani; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Phenotype; Phosphorylcholine; Psychodidae; Virulence | 2020 |
Advanced case of PKDL due to delayed treatment: A rare case report.
Topics: Antiprotozoal Agents; Humans; India; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine; Skin | 2020 |
Comparison of
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Female; Genotyping Techniques; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Paromomycin; Phosphorylcholine; Real-Time Polymerase Chain Reaction; Turkey | 2020 |
Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dietary Supplements; Disease Models, Animal; Female; Glutamine; Humans; Immunologic Factors; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred C57BL; Parasite Load; Phosphorylcholine; T-Lymphocyte Subsets; Treatment Outcome | 2020 |
Case Report: Mucosal Leishmaniasis in New York City.
Topics: Aged; Amphotericin B; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis, Mucocutaneous; Male; Middle Aged; New York City; Phosphorylcholine | 2020 |
Case Report: Cutaneous Leishmaniasis due to
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Biopsy; Central America; Female; Humans; Leishmania guyanensis; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Polymerase Chain Reaction; Skin; Travel | 2020 |
Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma.
Topics: Aged; Antiprotozoal Agents; Combined Modality Therapy; Drug Substitution; Endemic Diseases; Humans; Immunocompromised Host; Immunomodulation; Leishmania donovani; Leishmaniasis, Visceral; Lenalidomide; Male; Mediterranean Region; Multiple Myeloma; Pancytopenia; Phosphorylcholine; Recurrence; Renal Dialysis; Travel-Related Illness | 2020 |
Comparative evaluation of nucleic acid stabilizing reagents for RNA- and DNA-based Leishmania detection in blood as proxy for visceral burdens.
Topics: Animals; Cricetinae; Disease Models, Animal; DNA; DNA, Kinetoplast; Female; Humans; Indicators and Reagents; Leishmania; Leishmaniasis, Visceral; Nucleic Acids; Phosphorylcholine; Real-Time Polymerase Chain Reaction; RNA | 2020 |
Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Genes, Protozoan; Insect Vectors; Leishmania infantum; Leishmaniasis, Visceral; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Phlebotomus; Phosphorylcholine; Psychodidae | 2020 |
Computationally designed synthetic peptides for transporter proteins imparts allostericity in Miltefosine resistant L. major.
Topics: Allosteric Regulation; Animals; Antiprotozoal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cell Line; Computational Biology; Drug Resistance; Leishmania major; Leishmaniasis, Cutaneous; Machine Learning; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Peptide Library; Peptides; Phosphorylcholine | 2020 |
LEISHMANICIDAL ACTIVITY in vivo OF A MILTEFOSINE DERIVATIVE IN Mesocricetus auratus.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cytokines; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate; Mesocricetus; Phosphorylcholine; Spleen | 2020 |
Synthesis and Evaluation of Antitumor Alkylphospholipid Prodrugs.
Topics: Administration, Intravenous; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Stability; Hemolysis; Humans; Maximum Tolerated Dose; Neoplasms; Organophosphates; Phosphorylcholine; Prodrugs; Quaternary Ammonium Compounds | 2020 |
Case Report: Successful Treatment with Miltefosine of Severe New World Mucosal Leishmaniasis Caused by
Topics: Aged, 80 and over; Antiprotozoal Agents; Cytochromes b; Dysphonia; Humans; Leishmania guyanensis; Leishmaniasis, Mucocutaneous; Male; Nasal Septal Perforation; Nose Diseases; Pharyngeal Diseases; Phosphorylcholine; Severity of Illness Index | 2020 |
Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris.
Topics: Animals; Antifungal Agents; Biofilms; Candida; Drug Resistance, Fungal; Larva; Microbial Sensitivity Tests; Models, Animal; Moths; Nanoparticles; Phosphorylcholine | 2020 |
Miltefosine inhibits the membrane remodeling caused by phospholipase action by changing membrane physical properties.
Topics: Cell Membrane; Lipid Metabolism; Phosphorylcholine; Signal Transduction; Sphingomyelin Phosphodiesterase; Type C Phospholipases | 2020 |
Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Cytokines; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2020 |
Sesquiterpenoids and flavonoids from Inula viscosa induce programmed cell death in kinetoplastids.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Flavonoids; Inula; Leishmania; Macrophages; Oxidative Stress; Phosphorylcholine; Plant Extracts; Sesquiterpenes; Structure-Activity Relationship; Trypanosoma | 2020 |
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line; Emulsions; Leishmania donovani; Leishmaniasis, Visceral; Lipids; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Paromomycin; Particle Size; Phosphorylcholine | 2020 |
Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.
Topics: Adult; Africa, Eastern; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2020 |
Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis.
Topics: Administration, Topical; Antiprotozoal Agents; Cytokines; Cytotoxicity, Immunologic; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Host-Pathogen Interactions; Humans; Immunomodulation; Leishmania; Leishmaniasis, Cutaneous; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocytes; Male; Phosphorylcholine; Respiratory Burst | 2020 |
Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
Topics: Albania; Amphotericin B; Antiprotozoal Agents; Fatal Outcome; Humans; Leishmania infantum; Leishmaniasis, Visceral; Male; Phosphorylcholine; Recurrence; Skin Diseases, Parasitic; Turkey; Young Adult | 2021 |
Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Combinations; Drug Compounding; Female; Humans; Male; Mice; Nanocapsules; Phosphorylcholine; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2020 |
Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni.
Topics: Animals; Anthelmintics; Disease Models, Animal; Drug Carriers; Drug Combinations; Granuloma; Lipids; Liver; Male; Mice; Nanocapsules; Nanotechnology; Phosphorylcholine; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni | 2020 |
Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Female; Glucocorticoids; Humans; Keratitis; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphorylcholine; Retrospective Studies; Young Adult | 2021 |
The drug resistance mechanisms in Leishmania donovani are independent of immunosuppression.
Topics: Amphotericin B; Animals; Antimony; Cytokines; Drug Resistance; Immunosuppression Therapy; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice; Mice, Inbred BALB C; Phosphorylcholine; Protozoan Proteins | 2021 |
Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Mice; Phosphorylcholine | 2021 |
Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Biguanides; Female; Humans; Keratoplasty, Penetrating; Male; Middle Aged; Phosphorylcholine; Retrospective Studies; Salvage Therapy; Treatment Outcome; Visual Acuity; Young Adult | 2021 |
Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.
Topics: Adolescent; Antiprotozoal Agents; Child; Child, Preschool; Humans; Israel; Leishmaniasis, Cutaneous; Phosphorylcholine; Retrospective Studies | 2020 |
New phenalenone analogues with improved activity against Leishmania species.
Topics: Antiprotozoal Agents; Apoptosis; Leishmania; Membrane Potential, Mitochondrial; Phenalenes; Phosphorylcholine | 2020 |
Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmania infantum; Leishmaniasis, Cutaneous; Phosphorylcholine | 2021 |
Miltefosine Treatment of Cutaneous Leishmaniasis.
Topics: Humans; Leishmaniasis, Cutaneous; Phosphorylcholine | 2021 |
Cutaneous leishmaniasis successfully treated with miltefosine.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Male; Middle Aged; Phosphorylcholine; Treatment Outcome | 2020 |
Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.
Topics: Adolescent; Antiprotozoal Agents; Child; Child, Preschool; Humans; Israel; Leishmaniasis, Cutaneous; Phosphorylcholine; Retrospective Studies | 2020 |
Case Report: Erysipeloid Cutaneous Leishmaniasis Treated with Oral Miltefosine.
Topics: Administration, Oral; Aged; Antibodies, Protozoan; Antiprotozoal Agents; Erysipeloid; Humans; Leishmaniasis, Cutaneous; Male; Phosphorylcholine | 2020 |
Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis.
Topics: Drug Carriers; Humans; Leishmaniasis, Cutaneous; Lipids; Nanostructures; Particle Size; Phosphorylcholine | 2021 |
Vernonia brasiliana (L.) Druce induces ultrastructural changes and apoptosis-like death of Leishmania infantum promastigotes.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Dogs; Drug Interactions; Leishmania infantum; Membrane Potential, Mitochondrial; Mitochondria; Oils, Volatile; Phosphorylcholine; Plant Oils; Polycyclic Sesquiterpenes; Reactive Oxygen Species; Vernonia | 2021 |
Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine; Uveitis | 2020 |
Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020).
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Combinations; Drug Therapy; Humans; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral; Phosphorylcholine; Publications | 2021 |
Redox-Responsive Nanocapsules for the Spatiotemporal Release of Miltefosine in Lysosome: Protection against
Topics: Animals; Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis; Lysosomes; Mice; Nanocapsules; Oxidation-Reduction; Phosphorylcholine; RAW 264.7 Cells | 2021 |
The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice.
Topics: Animals; Eosinophils; Humans; Inflammation; Mice; Ovalbumin; Parasites; Pharmaceutical Preparations; Phosphorylcholine | 2021 |
Efficacy of topical Miltefosine formulations in an experimental model of cutaneous leishmaniasis.
Topics: Animals; Leishmania; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Models, Theoretical; Phosphorylcholine | 2022 |
Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy-A retrospective analysis.
Topics: Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Child; Female; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Middle Aged; Patient Outcome Assessment; Phosphorylcholine; Retrospective Studies; Treatment Failure; Young Adult | 2021 |
Severe Inflammatory Response in a Patient on Oral Miltefosine for Acanthamoeba Keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Humans; Phosphorylcholine | 2022 |
Macrophage targeting with the novel carbopol-based miltefosine-loaded transfersomal gel for the treatment of cutaneous leishmaniasis:
Topics: Acrylic Resins; Animals; Leishmaniasis, Cutaneous; Macrophages; Mice; Mice, Inbred BALB C; Phosphorylcholine | 2021 |
Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Homeodomain Proteins; Humans; Leishmaniasis, Visceral; Liver; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Parasite Load; Phosphorylcholine; Protein Binding | 2021 |
Case Report: COVID-19 Misdiagnosed as a Drug Reaction to Miltefosine.
Topics: COVID-19; Diagnostic Errors; Humans; Male; Middle Aged; Phosphorylcholine; SARS-CoV-2; Young Adult | 2021 |
Ros3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in
Topics: Drug Resistance; Gene Dosage; Leishmania braziliensis; Leishmania major; Phosphorylcholine | 2021 |
Leishmania donovani chaperonin TCP1γ subunit protects miltefosine induced oxidative damage.
Topics: Animals; Cell Line; Chaperonins; Drug Resistance; Interleukin-10; Leishmania donovani; Macrophages; Mice; Mutation; Oxidative Stress; Peroxidases; Phosphorylcholine; Protozoan Proteins; Reactive Oxygen Species; Sulfhydryl Compounds; Tumor Necrosis Factor-alpha; Up-Regulation | 2020 |
The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Phosphorylcholine; Young Adult | 2021 |
Investigating the Aggregation of Imported Cutaneous Leishmaniasis in Henan, Central China.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; China; Communicable Diseases, Imported; DNA, Kinetoplast; Humans; Leishmaniasis, Cutaneous; Phosphorylcholine; Psychodidae | 2021 |
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
Topics: Acarbose; Animals; Antiprotozoal Agents; Drug Repositioning; Female; Immunity; Leishmania infantum; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Micelles; Parasite Load; Phosphorylcholine; Reactive Oxygen Species; Treatment Outcome | 2021 |
Comparative EPR spectroscopy analysis of amphotericin B and miltefosine interactions with Leishmania, erythrocyte and macrophage membranes.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Electron Spin Resonance Spectroscopy; Erythrocytes; Humans; Leishmania; Macrophages; Mice; Phosphorylcholine | 2021 |
Enhancing the
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutical; Drug Carriers; Drug Combinations; Drug Liberation; Female; Hedgehog Proteins; Humans; Itraconazole; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanocapsules; Neovascularization, Pathologic; Particle Size; Phosphorylcholine; Random Allocation | 2021 |
Case Report: An Atypical Erysipeloid Presentation of Cutaneous Leishmaniasis from the Hilly Region of Nepal.
Topics: Antifungal Agents; Antiprotozoal Agents; Fluconazole; Humans; Leishmaniasis, Cutaneous; Male; Middle Aged; Nepal; Phosphorylcholine | 2021 |
Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis.
Topics: Antiprotozoal Agents; Female; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Peru; Phosphorylcholine; Treatment Failure; Young Adult | 2021 |
Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Drug Carriers; Humans; Lipids; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanostructures; Particle Size; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2021 |
Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Cohort Studies; Ethiopia; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Phosphorylcholine; Pilot Projects; Treatment Adherence and Compliance; Treatment Outcome | 2021 |
Diagnosis and clinical management of canine leishmaniosis by general veterinary practitioners: a questionnaire-based survey in Portugal.
Topics: Adult; Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Humans; Knowledge; Leishmania infantum; Leishmaniasis; Male; Middle Aged; Phosphorylcholine; Portugal; Practice Guidelines as Topic; Surveys and Questionnaires; Veterinarians | 2021 |
Comment on "Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis".
Topics: Acanthamoeba; Acanthamoeba Keratitis; Humans; Phosphorylcholine; Salvage Therapy | 2021 |
Case Report: Progressive Dysphonia and Dysphagia due to Laryngeal Leishmaniasis.
Topics: Aged; Amphotericin B; Antiprotozoal Agents; Deglutition Disorders; Diagnosis, Differential; Dysphonia; Humans; Laryngeal Neoplasms; Larynx; Leishmaniasis; Male; Phosphorylcholine | 2021 |
Oral combination of eugenol oleate and miltefosine induce immune response during experimental visceral leishmaniasis through nitric oxide generation with advanced cytokine demand.
Topics: Administration, Oral; Animals; Cell Death; Cell Proliferation; Cytokines; Drug Interactions; Drug Therapy, Combination; Eugenol; Female; Immunity; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis, Visceral; Life Cycle Stages; Macrophages; Male; Mice, Inbred BALB C; Nitric Oxide; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Parasites; Phosphorylation; Phosphorylcholine; T-Lymphocytes | 2021 |
Relapsing leishmanial arthritis: report of a tricky localization and evidence of miltefosine diffusion in synovial fluid.
Topics: Arthritis; Humans; Leishmania; Phosphorylcholine; Synovial Fluid | 2021 |
Reply to Comment on "Oral Miltefosine as Salvage Therapy for Recalcitrant Acanthamoeba Keratitis".
Topics: Acanthamoeba; Acanthamoeba Keratitis; Humans; Phosphorylcholine; Salvage Therapy | 2021 |
Downregulation of FeSOD-A expression in Leishmania infantum alters trivalent antimony and miltefosine susceptibility.
Topics: Antimony; Antiprotozoal Agents; Down-Regulation; Leishmania infantum; Mutation; Oxidative Stress; Phosphorylcholine; Superoxide Dismutase | 2021 |
Evaluation of release and pharmacokinetics of hexadecylphosphocholine (miltefosine) in phosphatidyldiglycerol-based thermosensitive liposomes.
Topics: Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Chromatography, Liquid; Hemolysis; Humans; Liposomes; Male; Phosphatidylglycerols; Phosphorylcholine; Rats; Tandem Mass Spectrometry; Temperature | 2021 |
Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Gene Expression Regulation; Interferon-gamma; Killer Cells, Natural; Leishmania infantum; Leishmaniasis, Visceral; Liver; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Natural Killer T-Cells; Neutrophils; Parasitic Sensitivity Tests; Phosphorylcholine; Spleen | 2021 |
Screening of Chemical Libraries for New Antifungal Drugs against Aspergillus fumigatus Reveals Sphingolipids Are Involved in the Mechanism of Action of Miltefosine.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Drug Resistance, Fungal; Fungal Proteins; High-Throughput Screening Assays; Larva; Microbial Sensitivity Tests; Moths; Phenotype; Phosphorylcholine; Small Molecule Libraries; Sphingolipids; Virulence | 2021 |
Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Imines; MCF-7 Cells; Neoplasms; Phosphorylcholine; Pyridines | 2021 |
Corneal Manifestations of Miltefosine Toxicity in Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Anti-Allergic Agents; Antiprotozoal Agents; Corneal Stroma; Drug Substitution; Humans; Keratitis; Loteprednol Etabonate; Microscopy, Confocal; Phosphorylcholine | 2021 |
Clinical leishmaniosis in a domestic ferret (Mustela putorius furo) treated with miltefosine plus allopurinol: Serological and clinical follow-up.
Topics: Allopurinol; Animals; Ferrets; Follow-Up Studies; Leishmania infantum; Phosphorylcholine | 2021 |
Anterior Scleral and Limbal Inflammatory Necrosis After Adjuvant Miltefosine for Recalcitrant Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Adjuvants, Immunologic; Adult; Humans; Inflammation; Necrosis; Phosphorylcholine; Retrospective Studies; Sclera | 2022 |
Topics: Alginates; Antifungal Agents; Aspergillus flavus; Aspergillus fumigatus; Drug Carriers; Drug Synergism; Nanoparticles; Phosphorylcholine; Voriconazole | 2021 |
Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.
Topics: Antiprotozoal Agents; Chromatography, High Pressure Liquid; Humans; Leishmania; Pharmaceutical Preparations; Phosphorylcholine; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
Topics: Antiprotozoal Agents; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine | 2022 |
Multi-Step Synthesis of Miltefosine: Integration of Flow Chemistry with Continuous Mechanochemistry.
Topics: Chemistry Techniques, Synthetic; Humans; Phosphorylcholine | 2021 |
Successful treatment of cutaneous Acanthamoeba castellanii infection with miltefosine in a patient with chronic lymphocytic leukaemia on ibrutinib.
Topics: Acanthamoeba castellanii; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylcholine; Piperidines | 2022 |
Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Membrane Microdomains; Mice; Phosphorylcholine | 2021 |
Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Female; Leishmania infantum; Leishmaniasis, Visceral; Meglumine Antimoniate; Phosphorylcholine | 2021 |
Mycobacterium abscessus cell wall and plasma membrane characterization by EPR spectroscopy and effects of amphotericin B, miltefosine and nerolidol.
Topics: Amphotericin B; Anti-Bacterial Agents; Cell Membrane; Cell Wall; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Microbial Sensitivity Tests; Mycobacterium abscessus; Phosphatidylcholines; Phosphorylcholine; Sesquiterpenes; Spin Labels; Stearic Acids | 2022 |
Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model.
Topics: Animals; Antigens, Protozoan; Cricetinae; Dogs; Immunity; Leishmania infantum; Leishmaniasis Vaccines; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Phosphorylcholine; Spleen | 2022 |
Evolutionary aspect of Miltefosine transporter proteins in Leishmania major.
Topics: Animals; Bayes Theorem; Leishmania major; Phosphorylcholine; Phylogeny | 2022 |
Successful Treatment of Primary Amoebic Meningoencephalitis Using a Novel Therapeutic Regimen Including Miltefosine and Voriconazole.
Topics: Amebiasis; Central Nervous System Protozoal Infections; Child; Humans; Naegleria; Naegleria fowleri; Phosphorylcholine; Voriconazole | 2022 |
Miltefosine and Benznidazole Combination Improve Anti-
Topics: Animals; Chagas Disease; Mice; Nitroimidazoles; Parasitemia; Phosphorylcholine; Trypanocidal Agents; Trypanosoma cruzi | 2022 |
Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, Visceral; Phosphorylcholine | 2022 |
Leishmania amazonensis from distinct clinical forms/hosts has polymorphisms in Lipophosphoglycans, displays variations in immunomodulatory properties and, susceptibility to antileishmanial drugs.
Topics: Amphotericin B; Animals; Dogs; Glycosphingolipids; Interleukin-6; Leishmania; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Phosphorylcholine; Tumor Necrosis Factor-alpha | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydrogels; Mice; Nanoparticles; Phosphorylcholine; Polymers; Temozolomide; Transferrin; Xenograft Model Antitumor Assays | 2022 |
Miltefosine to Treat Childhood Cutaneous Leishmaniasis.
Topics: Antiprotozoal Agents; Child; Humans; Leishmaniasis, Cutaneous; Phosphorylcholine | 2022 |
Direct In Vitro Comparison of the Anti-Leishmanial Activity of Different Olive Oil Total Polyphenolic Fractions and Assessment of Their Combined Effects with Miltefosine.
Topics: Aldehydes; Antiprotozoal Agents; Cyclopentane Monoterpenes; Iridoids; Leishmania major; Olive Oil; Phenols; Phosphorylcholine; Reactive Oxygen Species | 2022 |
Anti-leishmanial physalins-Phytochemical investigation, in vitro evaluation against clinical and MIL-resistant L. tropica strains and in silico studies.
Topics: Antiprotozoal Agents; Humans; Leishmania major; Leishmaniasis, Cutaneous; Molecular Docking Simulation; Pentamidine; Phosphorylcholine; Phytochemicals | 2022 |
Spiro heterocycles bearing piperidine moiety as potential scaffold for antileishmanial activity: synthesis, biological evaluation, and
Topics: Animals; Antiprotozoal Agents; Chlorocebus aethiops; Phosphorylcholine; Piperidines; Vero Cells | 2023 |
3'Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine.
Topics: Antiprotozoal Agents; Leishmania infantum; Nucleotidases; Phosphorylcholine | 2022 |
In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Brazil; Humans; Leishmania; Leishmaniasis; Leishmaniasis, Cutaneous; Phosphorylcholine | 2023 |
Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of
Topics: Animals; Antiprotozoal Agents; Female; Leishmania donovani; Leishmaniasis, Visceral; Mice; Nifuratel; Phosphorylcholine | 2023 |
A case of canine visceral leishmaniasis of unknown origin in Curitiba (state of Paraná, Brazil) treated successfully with miltefosine.
Topics: Animals; Brazil; Dog Diseases; Dogs; Female; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2023 |
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Phosphorylcholine | 2023 |
In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis.
Topics: Amphotericin B; Antiprotozoal Agents; Chronic Disease; Humans; Leishmania; Leishmaniasis; Leishmaniasis, Visceral; Phosphorylcholine; Recurrence | 2023 |